{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:06Z","timestamp":1794893586523,"version":"4.9.1"},"reference-count":985,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The year 2024 marks the 60th anniversary of the discovery of the Epstein-Barr virus (EBV), the first virus confirmed to cause human cancer. Viral infections significantly contribute to the global cancer burden, with seven known Group 1 oncogenic viruses, including hepatitis B virus (HBV), human papillomavirus (HPV), EBV, Kaposi sarcoma-associated herpesvirus (KSHV), hepatitis C virus (HCV), human T-cell leukemia virus type 1 (HTLV-1), and human immunodeficiency virus (HIV). These oncogenic viruses induce cellular transformation and cancer development by altering various biological processes within host cells, particularly under immunosuppression or co-carcinogenic exposures. These viruses are primarily associated with hepatocellular carcinoma, gastric cancer, cervical cancer, nasopharyngeal carcinoma, Kaposi sarcoma, lymphoma, and adult T-cell leukemia\/lymphoma. Understanding the mechanisms of viral oncogenesis is crucial for identifying and characterizing the early biological processes of virus-related cancers, providing new targets and strategies for treatment or prevention. This review first outlines the global epidemiology of virus-related tumors, milestone events in research, and the process by which oncogenic viruses infect target cells. It then focuses on the molecular mechanisms by which these viruses induce tumors directly or indirectly, including the regulation of oncogenes or tumor suppressor genes, induction of genomic instability, disruption of regular life cycle of cells, immune suppression, chronic inflammation, and inducing angiogenesis. Finally, current therapeutic strategies for virus-related tumors and recent advances in preclinical and clinical research are discussed.<\/jats:p>","DOI":"10.1038\/s41392-025-02197-9","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T19:01:50Z","timestamp":1746990110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Viral oncogenesis in cancer: from mechanisms to therapeutics"],"prefix":"10.1038","volume":"10","author":[{"given":"Qing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanxiu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyue","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2197_CR1","doi-asserted-by":"publisher","unstructured":"Contreras, A., Sanchez, S. A., Rodriguez-Medina, C. & Botero, J. E. The role and impact of viruses on cancer development. Periodontology 2000. https:\/\/doi.org\/10.1111\/prd.12566 (2024).","DOI":"10.1111\/prd.12566"},{"key":"2197_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2018.09.003","volume":"32","author":"MM Gaglia","year":"2018","unstructured":"Gaglia, M. M. & Munger, K. More than just oncogenes: mechanisms of tumorigenesis by human viruses. Curr. Opin. Virol. 32, 48\u201359 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cr.2016.153","volume":"27","author":"H Tashiro","year":"2017","unstructured":"Tashiro, H. & Brenner, M. K. Immunotherapy against cancer-related viruses. Cell Res. 27, 59\u201373 (2017).","journal-title":"Cell Res."},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/cancers6042155","volume":"6","author":"Y Chen","year":"2014","unstructured":"Chen, Y. et al. Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers 6, 2155\u20132186 (2014).","journal-title":"Cancers"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"188960","DOI":"10.1016\/j.bbcan.2023.188960","volume":"1878","author":"K Ahmed","year":"2023","unstructured":"Ahmed, K. & Jha, S. Oncoviruses: How do they hijack their host and current treatment regimes. Biochim. Biophys. Acta Rev. Cancer 1878, 188960 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","volume":"16","author":"NA Krump","year":"2018","unstructured":"Krump, N. A. & You, J. Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol. 16, 684\u2013698 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"2197_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11, 97\u2013107 (2004).","journal-title":"J. Viral Hepat."},{"key":"2197_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie, S. J. et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J. Natl. Cancer Inst. 96, 604\u2013615 (2004).","journal-title":"J. Natl. Cancer Inst."},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","volume":"217","author":"JT Schiller","year":"2021","unstructured":"Schiller, J. T. & Lowy, D. R. An introduction to virus infections and human cancer. Recent Results Cancer Res. 217, 1\u201311 (2021).","journal-title":"Recent Results Cancer Res."},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609\u2013e616 (2016).","journal-title":"Lancet Glob. Health"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel, C. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180\u2013e190 (2020).","journal-title":"Lancet Glob. Health"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y. C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20, 524\u2013537 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts, C. J. et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol. Hepatol. 7, 724\u2013735 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2197_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1053\/j.gastro.2020.11.057","volume":"160","author":"JM Paik","year":"2021","unstructured":"Paik, J. M. et al. Recent trends in the global burden of Hepatitis B virus: 2007\u20132017. Gastroenterology 160, 1845\u20131846.e1843 (2021).","journal-title":"Gastroenterology"},{"key":"2197_CR15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/liv.14821","volume":"41","author":"C Li","year":"2021","unstructured":"Li, C. & He, W. Q. The impact of universal hepatitis B vaccine on the trend of liver cancer from the global burden of disease study 2017. Liver Int. 41, 1762\u20131774 (2021).","journal-title":"Liver Int."},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns, M. P. & Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19, 533\u2013550 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2197_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","volume":"34","author":"DQ Huang","year":"2022","unstructured":"Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest-growing cause of liver cancer. Cell Metab. 34, 969\u2013977.e962 (2022).","journal-title":"Cell Metab."},{"key":"2197_CR18","unstructured":"GBD 2019 Europe Hepatitis B & C Collaborators Hepatitis B and C in Europe: an update from the global burden of disease study 2019. Lancet Public Health. 8, e701\u2013e716 (2023)."},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000508568","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin, L. et al. The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the global burden of disease study 2017. Liver Cancer 9, 563\u2013582 (2020).","journal-title":"Liver Cancer"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 141, 664\u2013670 (2017).","journal-title":"Int. J. Cancer"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/488S2a","volume":"488","author":"JM Crow","year":"2012","unstructured":"Crow, J. M. HPV: The global burden. Nature 488, S2\u2013S3 (2012).","journal-title":"Nature"},{"key":"2197_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","volume":"21","author":"T Malag\u00f3n","year":"2024","unstructured":"Malag\u00f3n, T., Franco, E. L., Tejada, R. & Vaccarella, S. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nat. Rev. Clin. Oncol. 21, 522\u2013538 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ypmed.2016.12.029","volume":"98","author":"M Maza","year":"2017","unstructured":"Maza, M. & Gage, J. C. Considerations for HPV primary screening in lower-middle income countries. Prev. Med. 98, 39\u201341 (2017).","journal-title":"Prev. Med."},{"key":"2197_CR24","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2468-2667(21)00046-3","volume":"6","author":"M Bonjour","year":"2021","unstructured":"Bonjour, M. et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health 6, e510\u2013e521 (2021).","journal-title":"Lancet Public Health"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S2214-109X(20)30073-5","volume":"8","author":"J Luttjeboer","year":"2020","unstructured":"Luttjeboer, J., Wondimu, A., Van der Schans, J. & Postma, M. J. Maximising the potential of HPV vaccines. Lancet Glob. Health 8, e460\u2013e461 (2020).","journal-title":"Lancet Glob. Health"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ygyno.2021.10.075","volume":"163","author":"WQ He","year":"2021","unstructured":"He, W. Q. & Li, C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol. Oncol. 163, 583\u2013592 (2021).","journal-title":"Gynecol. Oncol."},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young, L. S., Yap, L. F. & Murray, P. G. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer. 16, 789\u2013802 (2016).","journal-title":"Nat. Rev. Cancer."},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/aje\/kwu176","volume":"180","author":"AE Coghill","year":"2014","unstructured":"Coghill, A. E. & Hildesheim, A. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am. J. Epidemiol. 180, 687\u2013695 (2014).","journal-title":"Am. J. Epidemiol."},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","volume":"148","author":"Y Wong","year":"2022","unstructured":"Wong, Y. et al. Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res. Clin. Oncol. 148, 31\u201346 (2022).","journal-title":"J Cancer Res. Clin. Oncol."},{"key":"2197_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-38","volume":"9","author":"G Khan","year":"2014","unstructured":"Khan, G. & Hashim, M. J. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990\u20132010. Infect. Agent. Cancer. 9, 38 (2014).","journal-title":"Infect. Agent. Cancer."},{"key":"2197_CR31","doi-asserted-by":"publisher","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","volume":"10","author":"G Khan","year":"2020","unstructured":"Khan, G., Fitzmaurice, C., Naghavi, M. & Ahmed, L. A. Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017. BMJ Open 10, e037505 (2020).","journal-title":"BMJ Open"},{"key":"2197_CR32","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/ijc.30885","volume":"141","author":"AR Mawson","year":"2017","unstructured":"Mawson, A. R. & Majumdar, S. Malaria, Epstein-Barr virus infection and the pathogenesis of Burkitt\u2019s lymphoma. Int. J. Cancer. 141, 1849\u20131855 (2017).","journal-title":"Int. J. Cancer."},{"key":"2197_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe, C. & Rickinson, A. The global landscape of EBV-associated tumors. Front. Oncol. 9, 713 (2019).","journal-title":"Front. Oncol."},{"key":"2197_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.cgh.2022.07.042","volume":"21","author":"M Hirabayashi","year":"2023","unstructured":"Hirabayashi, M., Georges, D., Clifford, G. M. & de Martel, C. Estimating the global burden of Epstein-Barr virus-associated gastric cancer: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 922\u2013930 e921 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2197_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07013-x","volume":"20","author":"A Tavakoli","year":"2020","unstructured":"Tavakoli, A. et al. Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer 20, 493 (2020).","journal-title":"BMC Cancer"},{"key":"2197_CR36","doi-asserted-by":"publisher","first-page":"677027","DOI":"10.3389\/fimmu.2021.677027","volume":"12","author":"C Sun","year":"2021","unstructured":"Sun, C., Chen, X. C., Kang, Y. F. & Zeng, M. S. The status and prospects of epstein-barr virus prophylactic vaccine development. Front. Immunol. 12, 677027 (2021).","journal-title":"Front. Immunol."},{"key":"2197_CR37","doi-asserted-by":"publisher","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","volume":"1","author":"CR Bangham","year":"2015","unstructured":"Bangham, C. R., Araujo, A., Yamano, Y. & Taylor, G. P. HTLV-1-associated myelopathy\/tropical spastic paraparesis. Nat. Rev. Dis. Primers 1, 15012 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2197_CR38","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciac925","volume":"76","author":"Y Ruffieux","year":"2023","unstructured":"Ruffieux, Y. et al. Age and cancer incidence in 5.2 million people with human immunodeficiency virus (HIV): the South African HIV cancer match study. Clin. Infect. Dis. 76, 1440\u20131448 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2197_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28891","volume":"95","author":"Z Wan","year":"2023","unstructured":"Wan, Z. et al. Global and regional estimates of cervical cancer burden associated with human immunodeficiency virus infection from 1990 to 2019. J. Med. Virol. 95, e28891 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR40","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","volume":"9","author":"D Stelzle","year":"2021","unstructured":"Stelzle, D. et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 9, e161\u2013e169 (2021).","journal-title":"Lancet Glob Health"},{"key":"2197_CR41","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood.2020005469","volume":"139","author":"A Carbone","year":"2022","unstructured":"Carbone, A., Vaccher, E. & Gloghini, A. Hematologic cancers in individuals infected by HIV. Blood 139, 995\u20131012 (2022).","journal-title":"Blood"},{"key":"2197_CR42","doi-asserted-by":"publisher","first-page":"e2224897","DOI":"10.1001\/jamanetworkopen.2022.24897","volume":"5","author":"B Park","year":"2022","unstructured":"Park, B. et al. Cancer incidence among adults with HIV in a population-based cohort in Korea. Jama Netw. Open 5, e2224897 (2022).","journal-title":"Jama Netw. Open"},{"key":"2197_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/nrc2961","volume":"10","author":"PS Moore","year":"2010","unstructured":"Moore, P. S. & Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 10, 878\u2013889 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2197_CR44","first-page":"526","volume":"37","author":"P Rous","year":"1973","unstructured":"Rous, P. Transmission of a malignant new growth by means of a cell-free filtrate. Conn. Med. 37, 526 (1973).","journal-title":"Conn. Med."},{"key":"2197_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1084\/jem.12.5.696","volume":"12","author":"P Rous","year":"1910","unstructured":"Rous, P. A transmissible avian neoplasm. (sarcoma of the common fowl.). J. Exp. Med. 12, 696\u2013705 (1910).","journal-title":"J. Exp. Med."},{"key":"2197_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1084\/jem.13.4.397","volume":"13","author":"P Rous","year":"1911","unstructured":"Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397\u2013411 (1911).","journal-title":"J. Exp. Med."},{"key":"2197_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.58.5.607","volume":"58","author":"RE Shope","year":"1933","unstructured":"Shope, R. E. & Hurst, E. W. Infectious papillomatosis of rabbits: with a note on the histopathology. J. Exp. Med. 58, 607\u2013624 (1933).","journal-title":"J. Exp. Med."},{"key":"2197_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3181\/00379727-76-18379","volume":"76","author":"L Gross","year":"1951","unstructured":"Gross, L. \u201cSpontaneous\u201d leukemia developing in C3H mice following inoculation in infancy, with AK-leukemic extracts, or AK-embrvos. Proc. Soc. Exp. Biol. Med. 76, 27\u201332 (1951).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"2197_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0042-6822(62)90082-X","volume":"17","author":"BE Eddy","year":"1962","unstructured":"Eddy, B. E., Borman, G. S., Grubbs, G. E. & Young, R. D. Identification of the oncogenic substance in rhesus monkey kidney cell culture as simian virus 40. Virology 17, 65\u201375 (1962).","journal-title":"Virology"},{"key":"2197_CR50","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1, 702\u2013703 (1964).","journal-title":"Lancet"},{"key":"2197_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","volume":"3","author":"J Chen","year":"2018","unstructured":"Chen, J. et al. Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. Nat. Microbiol. 3, 172\u2013180 (2018).","journal-title":"Nat. Microbiol."},{"key":"2197_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/310207a0","volume":"310","author":"R Baer","year":"1984","unstructured":"Baer, R. et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207\u2013211 (1984).","journal-title":"Nature"},{"key":"2197_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","volume":"191","author":"BS Blumberg","year":"1965","unstructured":"Blumberg, B. S., Alter, H. J. & Visnich, S. A \u201cNew\u201d antigen in leukemia sera. JAMA 191, 541\u2013546 (1965).","journal-title":"JAMA"},{"key":"2197_CR54","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(81)90585-7","volume":"2","author":"RP Beasley","year":"1981","unstructured":"Beasley, R. P., Hwang, L. Y., Lin, C. C. & Chien, C. S. Hepatocellular carcinoma and hepatitis B virus. a prospective study of 22,707 men in Taiwan. Lancet 2, 1129\u20131133 (1981).","journal-title":"Lancet"},{"key":"2197_CR55","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/2261211a0","volume":"226","author":"HM Temin","year":"1970","unstructured":"Temin, H. M. & Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226, 1211\u20131213 (1970).","journal-title":"Nature"},{"key":"2197_CR56","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/2261209a0","volume":"226","author":"D Baltimore","year":"1970","unstructured":"Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226, 1209\u20131211 (1970).","journal-title":"Nature"},{"key":"2197_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/260170a0","volume":"260","author":"D Stehelin","year":"1976","unstructured":"Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170\u2013173 (1976).","journal-title":"Nature"},{"key":"2197_CR58","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3181\/00379727-84-20714","volume":"84","author":"WP Rowe","year":"1953","unstructured":"Rowe, W. P. et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570\u2013573 (1953).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"2197_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0092-8674(79)90293-9","volume":"17","author":"DI Linzer","year":"1979","unstructured":"Linzer, D. I. & Levine, A. J. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43\u201352 (1979).","journal-title":"Cell"},{"key":"2197_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/278261a0","volume":"278","author":"DP Lane","year":"1979","unstructured":"Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261\u2013263 (1979).","journal-title":"Nature"},{"key":"2197_CR61","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz, B. J. et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci\/USA 77, 7415\u20137419 (1980).","journal-title":"Proc. Natl. Acad. Sci\/USA"},{"key":"2197_CR62","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","volume":"78","author":"Y Hinuma","year":"1981","unstructured":"Hinuma, Y. et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78, 6476\u20136480 (1981).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR63","first-page":"794","volume":"36","author":"H zur Hausen","year":"1976","unstructured":"zur Hausen, H. Condylomata acuminata and human genital cancer. Cancer Res. 36, 794 (1976).","journal-title":"Cancer Res."},{"key":"2197_CR64","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"M Durst","year":"1983","unstructured":"Durst, M., Gissmann, L., Ikenberg, H. & zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA 80, 3812\u20133815 (1983).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR65","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.6189183","volume":"220","author":"F Barre-Sinoussi","year":"1983","unstructured":"Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868\u2013871 (1983).","journal-title":"Science"},{"key":"2197_CR66","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM198911303212202","volume":"321","author":"HJ Alter","year":"1989","unstructured":"Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494\u20131500 (1989).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.1840140227","volume":"14","author":"M Houghton","year":"1991","unstructured":"Houghton, M. et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14, 381\u2013388 (1991).","journal-title":"Hepatology"},{"key":"2197_CR68","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 266, 1865\u20131869 (1994).","journal-title":"Science"},{"key":"2197_CR69","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","volume":"332","author":"E Cesarman","year":"1995","unstructured":"Cesarman, E. et al. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186\u20131191 (1995).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR70","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.1152586","volume":"319","author":"H Feng","year":"2008","unstructured":"Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096\u20131100 (2008).","journal-title":"Science"},{"key":"2197_CR71","doi-asserted-by":"publisher","first-page":"e2076","DOI":"10.1002\/rmv.2076","volume":"29","author":"F Taheri","year":"2019","unstructured":"Taheri, F., Goudarzi, H. & Faghihloo, E. Aneuploidy and oncoviruses. Rev. Med. Virol. 29, e2076 (2019).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR72","doi-asserted-by":"publisher","DOI":"10.1128\/mmbr.00035-22","volume":"87","author":"S Liu","year":"2023","unstructured":"Liu, S., Han, Y., Li, W. X. & Ding, S. W. Infection Defects of RNA and DNA Viruses Induced by Antiviral RNA Interference. Microbiol. Mol. Biol. Rev. 87, e0003522 (2023).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2197_CR73","doi-asserted-by":"publisher","first-page":"e2343","DOI":"10.1002\/rmv.2343","volume":"32","author":"YM Fan","year":"2022","unstructured":"Fan, Y. M., Zhang, Y. L., Luo, H. & Mohamud, Y. Crosstalk between RNA viruses and DNA sensors: role of the cGAS-STING signalling pathway. Rev. Med. Virol. 32, e2343 (2022).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman, E. et al. Kaposi sarcoma. Nat. Rev. Dis. Primers 5, 9 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2197_CR75","doi-asserted-by":"crossref","unstructured":"Nguyen, M. H. et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin. Microbiol. Rev. 33, (2020).","DOI":"10.1128\/CMR.00046-19"},{"key":"2197_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2197_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.14683","volume":"48","author":"CL Lin","year":"2018","unstructured":"Lin, C. L. & Kao, J. H. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment. Pharmacol. Ther. 48, 5\u201314 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2197_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/v9050125","volume":"9","author":"S Schreiner","year":"2017","unstructured":"Schreiner, S. & Nassal, M. A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond? Viruses 9, 125 (2017).","journal-title":"Viruses"},{"key":"2197_CR79","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/CM9.0000000000002111","volume":"136","author":"H Song","year":"2023","unstructured":"Song, H. et al. TRIM25 inhibits HBV replication by promoting HBx degradation and the RIG-I-mediated pgRNA recognition. Chin. Med. J. 136, 799\u2013806 (2023).","journal-title":"Chin. Med. J."},{"key":"2197_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-023-01573-7","volume":"8","author":"T Zhang","year":"2023","unstructured":"Zhang, T. et al. RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation. Signal Transduct. Target. Ther. 8, 346 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2197_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40225-w","volume":"14","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Molecular insights into Spindlin1-HBx interplay and its impact on HBV transcription from cccDNA minichromosome. Nat. Commun. 14, 4663 (2023).","journal-title":"Nat. Commun."},{"key":"2197_CR82","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3748\/wjg.v24.i14.1507","volume":"24","author":"BF Chen","year":"2018","unstructured":"Chen, B. F. Hepatitis B virus pre-S\/S variants in liver diseases. World J. Gastroenterol. 24, 1507\u20131520 (2018).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR83","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pathol.2021.07.003","volume":"54","author":"N Assarzadegan","year":"2022","unstructured":"Assarzadegan, N., Brooks, E. & Voltaggio, L. HPV-driven anal neoplasia: review and recent developments. Pathology 54, 184\u2013194 (2022).","journal-title":"Pathology"},{"key":"2197_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2537","volume":"34","author":"J Wolf","year":"2024","unstructured":"Wolf, J. et al. Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev. Med. Virol. 34, e2537 (2024).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR85","doi-asserted-by":"publisher","first-page":"7616","DOI":"10.3390\/ijms25147616","volume":"25","author":"B Mlynarczyk-Bonikowska","year":"2024","unstructured":"Mlynarczyk-Bonikowska, B. & Rudnicka, L. HPV infections-classification, pathogenesis, and potential new therapies. Int. J. Mol. Sci. 25, 7616 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012289","volume":"20","author":"K Speckhart","year":"2024","unstructured":"Speckhart, K., Choi, J., DiMaio, D. & Tsai, B. The BICD2 dynein cargo adaptor binds to the HPV16 L2 capsid protein and promotes HPV infection. PLoS Pathog. 20, e1012289 (2024).","journal-title":"PLoS Pathog."},{"key":"2197_CR87","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/pathogens12121380","volume":"12","author":"M Jain","year":"2023","unstructured":"Jain, M. et al. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for HPV-associated carcinogenesis. Pathogens 12, 1380 (2023).","journal-title":"Pathogens"},{"key":"2197_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.10.015","volume":"231","author":"S DiGiuseppe","year":"2017","unstructured":"DiGiuseppe, S., Bienkowska-Haba, M., Guion, L. G. & Sapp, M. Cruising the cellular highways: How human papillomavirus travels from the surface to the nucleus. Virus Res. 231, 1\u20139 (2017).","journal-title":"Virus Res."},{"key":"2197_CR89","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/v9120370","volume":"9","author":"SK Campos","year":"2017","unstructured":"Campos, S. K. Subcellular trafficking of the papillomavirus genome during initial infection: the remarkable abilities of minor capsid protein L2. Viruses 9, 370 (2017).","journal-title":"Viruses"},{"key":"2197_CR90","doi-asserted-by":"publisher","first-page":"e1007755","DOI":"10.1371\/journal.ppat.1007755","volume":"15","author":"I Murakami","year":"2019","unstructured":"Murakami, I. et al. Roles for E1-independent replication and E6-mediated p53 degradation during low-risk and high-risk human papillomavirus genome maintenance. PLoS Pathog. 15, e1007755 (2019).","journal-title":"PLoS Pathog."},{"key":"2197_CR91","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/ijc.31883","volume":"144","author":"FL Sand","year":"2019","unstructured":"Sand, F. L. et al. Risk of CIN3 or worse with the persistence of 13 individual oncogenic HPV types. Int. J. Cancer. 144, 1975\u20131982 (2019).","journal-title":"Int. J. Cancer."},{"key":"2197_CR92","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/cancers16050991","volume":"16","author":"AS Torne","year":"2024","unstructured":"Torne, A. S. & Robertson, E. S. Epigenetic mechanisms in latent Epstein-Barr virus infection and associated cancers. Cancers 16, 991 (2024).","journal-title":"Cancers"},{"key":"2197_CR93","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/v13091849","volume":"13","author":"N Jambunathan","year":"2021","unstructured":"Jambunathan, N. et al. Two sides to every story: herpes simplex type-1 viral glycoproteins gB, gD, gH\/gL, gK, and cellular receptors function as key players in membrane fusion. Viruses 13, 1849 (2021).","journal-title":"Viruses"},{"key":"2197_CR94","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1073\/pnas.232381299","volume":"99","author":"B Neuhierl","year":"2002","unstructured":"Neuhierl, B., Feederle, R., Hammerschmidt, W. & Delecluse, H. J. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc. Natl. Acad. Sci. USA 99, 15036\u201315041 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR95","doi-asserted-by":"publisher","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui, X. & Snapper, C. M. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front. Immunol. 12, 734471 (2021).","journal-title":"Front. Immunol."},{"key":"2197_CR96","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41564-024-01659-0","volume":"9","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein-Barr virus entry into epithelial cells. Nat. Microbiol. 9, 1256\u20131270 (2024).","journal-title":"Nat. Microbiol."},{"key":"2197_CR97","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02243-21","volume":"12","author":"D Westhoff Smith","year":"2021","unstructured":"Westhoff Smith, D. et al. The Epstein-Barr virus oncogene EBNA1 suppresses natural killer cell responses and apoptosis early after infection of peripheral B cells. mBio 12, e0224321 (2021).","journal-title":"mBio"},{"key":"2197_CR98","doi-asserted-by":"publisher","first-page":"e1011040","DOI":"10.1371\/journal.ppat.1011040","volume":"19","author":"IR Hayman","year":"2023","unstructured":"Hayman, I. R. et al. New insight into Epstein-Barr virus infection using models of stratified epithelium. PLoS Pathog. 19, e1011040 (2023).","journal-title":"PLoS Pathog."},{"key":"2197_CR99","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","volume":"19","author":"SA Connolly","year":"2021","unstructured":"Connolly, S. A., Jardetzky, T. S. & Longnecker, R. The structural basis of herpesvirus entry. Nat. Rev. Microbiol. 19, 110\u2013121 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"2197_CR100","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12985-023-02187-9","volume":"20","author":"W Huang","year":"2023","unstructured":"Huang, W., Bai, L. & Tang, H. Epstein-Barr virus infection: the micro and macro worlds. Virol. J. 20, 220 (2023).","journal-title":"Virol. J."},{"key":"2197_CR101","doi-asserted-by":"publisher","first-page":"152286","DOI":"10.1016\/j.anndiagpath.2024.152286","volume":"70","author":"AK Volaric","year":"2024","unstructured":"Volaric, A. K. et al. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: diagnostic implications. Ann. Diagn. Pathol. 70, 152286 (2024).","journal-title":"Ann. Diagn. Pathol."},{"key":"2197_CR102","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C Munz","year":"2019","unstructured":"Munz, C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat. Rev. Microbiol. 17, 691\u2013700 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"2197_CR103","doi-asserted-by":"crossref","unstructured":"Murata, T. et al. Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation. Viruses. 13, 2344 (2021).","DOI":"10.3390\/v13122344"},{"key":"2197_CR104","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/labinvest.2015.69","volume":"95","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. Epstein-Barr virus BZLF1 protein impairs accumulation of host DNA damage proteins at damage sites in response to DNA damage. Lab. Investig. 95, 937\u2013950 (2015).","journal-title":"Lab. Investig."},{"key":"2197_CR105","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.2020005470","volume":"139","author":"E Cesarman","year":"2022","unstructured":"Cesarman, E., Chadburn, A. & Rubinstein, P. G. KSHV\/HHV8-mediated hematologic diseases. Blood 139, 1013\u20131025 (2022).","journal-title":"Blood"},{"key":"2197_CR106","doi-asserted-by":"publisher","first-page":"e1002479","DOI":"10.1371\/journal.ppat.1002479","volume":"8","author":"J Lu","year":"2012","unstructured":"Lu, J. et al. The RBP-Jkappa binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog. 8, e1002479 (2012).","journal-title":"PLoS Pathog."},{"key":"2197_CR107","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/v8110305","volume":"8","author":"B Kumar","year":"2016","unstructured":"Kumar, B. & Chandran, B. KSHV entry and trafficking in target cells-hijacking of cell signal pathways, actin and membrane dynamics. Viruses 8, 305 (2016).","journal-title":"Viruses"},{"key":"2197_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008968","volume":"16","author":"F Aalam","year":"2020","unstructured":"Aalam, F., Nabiee, R., Castano, J. R. & Totonchy, J. Analysis of KSHV B lymphocyte lineage tropism in human tonsil reveals efficient infection of CD138+ plasma cells. PLoS Pathog. 16, e1008968 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2160","volume":"31","author":"MJ Blumenthal","year":"2021","unstructured":"Blumenthal, M. J. et al. Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. Rev. Med. Virol. 31, e2160 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR110","doi-asserted-by":"publisher","first-page":"e1009231","DOI":"10.1371\/journal.ppat.1009231","volume":"17","author":"O Vladimirova","year":"2021","unstructured":"Vladimirova, O. et al. Phase separation and DAXX redistribution contribute to LANA nuclear body and KSHV genome dynamics during latency and reactivation. PLoS Pathog. 17, e1009231 (2021).","journal-title":"PLoS Pathog."},{"key":"2197_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010744","volume":"18","author":"C Han","year":"2022","unstructured":"Han, C. et al. KSHV RTA antagonizes SMC5\/6 complex-induced viral chromatin compaction by hijacking the ubiquitin-proteasome system. PLoS Pathog. 18, e1010744 (2022).","journal-title":"PLoS Pathog."},{"key":"2197_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07314-7","volume":"9","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection. Nat. Commun. 9, 4841 (2018).","journal-title":"Nat. Commun."},{"key":"2197_CR113","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.abn9884","volume":"378","author":"A Torrents de la Pena","year":"2022","unstructured":"Torrents de la Pena, A. et al. Structure of the hepatitis C virus E1E2 glycoprotein complex. Science 378, 263\u2013269 (2022).","journal-title":"Science"},{"key":"2197_CR114","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41594-022-00901-9","volume":"29","author":"KH Wrighton","year":"2022","unstructured":"Wrighton, K. H. Structure of the HCV glycoprotein. Nat. Struct. Mol. Biol. 29, 1147 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2197_CR115","doi-asserted-by":"publisher","first-page":"a036822","DOI":"10.1101\/cshperspect.a036822","volume":"10","author":"AD Dearborn","year":"2020","unstructured":"Dearborn, A. D. & Marcotrigiano, J. Hepatitis C virus structure: defined by what it is not. Cold Spring Harb. Perspect. Med. 10, a036822 (2020).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2197_CR116","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","volume":"598","author":"A Kumar","year":"2021","unstructured":"Kumar, A. et al. Structural insights into hepatitis C virus receptor binding and entry. Nature 598, 521\u2013525 (2021).","journal-title":"Nature"},{"key":"2197_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2197","volume":"31","author":"E Laugel","year":"2021","unstructured":"Laugel, E. et al. Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses. Rev. Med. Virol. 31, e2197 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR118","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/ijms21072328","volume":"21","author":"M Niepmann","year":"2020","unstructured":"Niepmann, M. & Gerresheim, G. K. Hepatitis C virus translation regulation. Int. J. Mol. Sci. 21, 2328 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR119","doi-asserted-by":"publisher","first-page":"a036814","DOI":"10.1101\/cshperspect.a036814","volume":"11","author":"K Shimotohno","year":"2021","unstructured":"Shimotohno, K. HCV assembly and egress via modifications in host lipid metabolic systems. Cold Spring Harb. Perspect. Med. 11, a036814 (2021).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2197_CR120","doi-asserted-by":"publisher","first-page":"114595","DOI":"10.1016\/j.ejmech.2022.114595","volume":"240","author":"Z Zhou","year":"2022","unstructured":"Zhou, Z. et al. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: a medicinal chemistry perspective. Eur. J. Med. Chem. 240, 114595 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2197_CR121","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41586-023-06301-3","volume":"619","author":"AV Sherwood","year":"2023","unstructured":"Sherwood, A. V. et al. Hepatitis C virus RNA is 5\u2019-capped with flavin adenine dinucleotide. Nature 619, 811\u2013818 (2023).","journal-title":"Nature"},{"key":"2197_CR122","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2023.12.004","volume":"57","author":"N Frumento","year":"2024","unstructured":"Frumento, N. et al. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. Immunity 57, 40\u201351.e45 (2024).","journal-title":"Immunity"},{"key":"2197_CR123","doi-asserted-by":"publisher","first-page":"a037101","DOI":"10.1101\/cshperspect.a037101","volume":"10","author":"HR Rosen","year":"2020","unstructured":"Rosen, H. R. & Golden-Mason, L. Control of HCV infection by natural killer cells and macrophages. Cold Spring Harb. Perspect. Med. 10, a037101 (2020).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2197_CR124","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jhep.2020.02.009","volume":"73","author":"JW Han","year":"2020","unstructured":"Han, J. W. et al. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. J. Hepatol. 73, 72\u201383 (2020).","journal-title":"J. Hepatol."},{"key":"2197_CR125","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41590-020-00817-w","volume":"22","author":"N Hensel","year":"2021","unstructured":"Hensel, N. et al. Memory-like HCV-specific CD8(+) T cells retain a molecular scar after cure of chronic HCV infection. Nat. Immunol. 22, 229\u2013239 (2021).","journal-title":"Nat. Immunol."},{"key":"2197_CR126","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41590-021-00982-6","volume":"22","author":"P Tonnerre","year":"2021","unstructured":"Tonnerre, P. et al. Differentiation of exhausted CD8(+) T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. Nat. Immunol. 22, 1030\u20131041 (2021).","journal-title":"Nat. Immunol."},{"key":"2197_CR127","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41586-022-05556-6","volume":"614","author":"IC Clark","year":"2023","unstructured":"Clark, I. C. et al. HIV silencing and cell survival signatures in infected T cell reservoirs. Nature 614, 318\u2013325 (2023).","journal-title":"Nature"},{"key":"2197_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101472","volume":"51","author":"RT Veenhuis","year":"2021","unstructured":"Veenhuis, R. T. et al. HIV replication and latency in monocytes and macrophages. Semin. Immunol. 51, 101472 (2021).","journal-title":"Semin. Immunol."},{"key":"2197_CR129","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.chom.2019.07.007","volume":"26","author":"BJ Summers","year":"2019","unstructured":"Summers, B. J. et al. Modular HIV-1 capsid assemblies reveal diverse host-capsid recognition mechanisms. Cell Host Microbe 26, 203\u2013216.e206 (2019).","journal-title":"Cell Host Microbe"},{"key":"2197_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39146-5","volume":"14","author":"G Xue","year":"2023","unstructured":"Xue, G. et al. The HIV-1 capsid core is an opportunistic nuclear import receptor. Nat. Commun. 14, 3782 (2023).","journal-title":"Nat. Commun."},{"key":"2197_CR131","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.abe6821","volume":"373","author":"K Qu","year":"2021","unstructured":"Qu, K. et al. Maturation of the matrix and viral membrane of HIV-1. Science 373, 700\u2013704 (2021).","journal-title":"Science"},{"key":"2197_CR132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41579-021-00586-9","volume":"20","author":"GN Maertens","year":"2022","unstructured":"Maertens, G. N., Engelman, A. N. & Cherepanov, P. Structure and function of retroviral integrase. Nat. Rev. Microbiol. 20, 20\u201334 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"2197_CR133","doi-asserted-by":"publisher","first-page":"e0004822","DOI":"10.1128\/mmbr.00048-22","volume":"87","author":"S Jang","year":"2023","unstructured":"Jang, S. & Engelman, A. N. Capsid-host interactions for HIV-1 ingress. Microbiol. Mol. Biol. Rev. 87, e0004822 (2023).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2197_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22628-9","volume":"12","author":"B Ha","year":"2021","unstructured":"Ha, B. et al. High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs. Nat. Commun. 12, 2500 (2021).","journal-title":"Nat. Commun."},{"key":"2197_CR135","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-virology-020922-110929","volume":"9","author":"TG Muller","year":"2022","unstructured":"Muller, T. G., Zila, V., Muller, B. & Krausslich, H. G. Nuclear capsid uncoating and reverse transcription of HIV-1. Annu. Rev. Virol. 9, 261\u2013284 (2022).","journal-title":"Annu. Rev. Virol."},{"key":"2197_CR136","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41576-021-00378-0","volume":"22","author":"PJ McLaren","year":"2021","unstructured":"McLaren, P. J. & Fellay, J. HIV-1 and human genetic variation. Nat. Rev. Genet. 22, 645\u2013657 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"2197_CR137","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","volume":"585","author":"C Jiang","year":"2020","unstructured":"Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261\u2013267 (2020).","journal-title":"Nature"},{"key":"2197_CR138","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.chom.2021.07.006","volume":"29","author":"C Bou-Nader","year":"2021","unstructured":"Bou-Nader, C. et al. HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. Cell Host Microbe 29, 1421\u20131436.e1427 (2021).","journal-title":"Cell Host Microbe"},{"key":"2197_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115009","volume":"200","author":"M Ullah Nayan","year":"2023","unstructured":"Ullah Nayan, M. et al. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Adv. Drug Deliv. Rev. 200, 115009 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2197_CR140","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","volume":"27","author":"LB Cohn","year":"2020","unstructured":"Cohn, L. B., Chomont, N. & Deeks, S. G. The 33gy of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe 27, 519\u2013530 (2020).","journal-title":"Cell Host Microbe"},{"key":"2197_CR141","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/v15122435","volume":"15","author":"NN Duggan","year":"2023","unstructured":"Duggan, N. N., Dragic, T., Chanda, S. K. & Pache, L. Breaking the silence: regulation of HIV transcription and latency on the road to a cure. Viruses 15, 2435 (2023).","journal-title":"Viruses"},{"key":"2197_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2235","volume":"31","author":"S Ahmadi Ghezeldasht","year":"2021","unstructured":"Ahmadi Ghezeldasht, S. et al. HTLV-1 oncovirus-host interactions: from entry to the manifestation of associated diseases. Rev. Med. Virol. 31, e2235 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR143","first-page":"2299","volume":"141","author":"CRM Bangham","year":"2023","unstructured":"Bangham, C. R. M. HTLV-1 persistence and the oncogenesis of adult T-cell leukemia\/lymphoma. Blood 141, 2299\u20132306 (2023).","journal-title":"Blood"},{"key":"2197_CR144","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(20)30328-5","volume":"21","author":"A Hirons","year":"2021","unstructured":"Hirons, A., Khoury, G. & Purcell, D. F. J. Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent. Lancet Infect. Dis. 21, e2\u2013e10 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2197_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg1778","volume":"9","author":"ZZ Lu","year":"2023","unstructured":"Lu, Z. Z. et al. Neuropilin 1 is an entry receptor for KSHV infection of mesenchymal stem cell through TGFBR1\/2-mediated macropinocytosis. Sci. Adv. 9, eadg1778 (2023).","journal-title":"Sci. Adv."},{"key":"2197_CR146","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/pathogens13050349","volume":"13","author":"C Acchioni","year":"2024","unstructured":"Acchioni, C., Sandini, S., Acchioni, M. & Sgarbanti, M. Co-infections and superinfections between HIV-1 and other human viruses at the cellular level. Pathogens 13, 349 (2024).","journal-title":"Pathogens"},{"key":"2197_CR147","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.coviro.2017.07.013","volume":"26","author":"L Cook","year":"2017","unstructured":"Cook, L., Melamed, A., Yaguchi, H. & Bangham, C. R. The impact of HTLV-1 on the cellular genome. Curr. Opin. Virol. 26, 125\u2013131 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"2197_CR148","doi-asserted-by":"publisher","first-page":"959962","DOI":"10.3389\/fimmu.2022.959962","volume":"13","author":"K Nakano","year":"2022","unstructured":"Nakano, K. & Watanabe, T. Tuning Rex rules HTLV-1 pathogenesis. Front. Immunol. 13, 959962 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR149","doi-asserted-by":"publisher","first-page":"13740","DOI":"10.1073\/pnas.1922884117","volume":"117","author":"Y Higuchi","year":"2020","unstructured":"Higuchi, Y. et al. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc. Natl. Acad. Sci. USA 117, 13740\u201313749 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR150","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1158\/2643-3230.BCD-22-0139","volume":"4","author":"K Toyoda","year":"2023","unstructured":"Toyoda, K. et al. HTLV-1 bZIP factor-induced reprogramming of lactate metabolism and epigenetic status promote leukemic cell expansion. Blood Cancer Discov. 4, 374\u2013393 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2197_CR151","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150472","volume":"131","author":"BJ Tan","year":"2021","unstructured":"Tan, B. J. et al. HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia\/lymphoma. J. Clin. Investig. 131, e150472 (2021).","journal-title":"J. Clin. Investig."},{"key":"2197_CR152","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00078-21","volume":"35","author":"N Legrand","year":"2022","unstructured":"Legrand, N. et al. Clinical and public health implications of human T-lymphotropic virus type 1 infection. Clin. Microbiol. Rev. 35, e0007821 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"2197_CR153","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41588-019-0558-9","volume":"52","author":"M Zapatka","year":"2020","unstructured":"Zapatka, M. et al. The landscape of viral associations in human cancers. Nat. Genet. 52, 320\u2013330 (2020).","journal-title":"Nat. Genet."},{"key":"2197_CR154","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.7150\/jca.37282","volume":"11","author":"R Ayee","year":"2020","unstructured":"Ayee, R., Ofori, M. E. O., Wright, E. & Quaye, O. Epstein Barr virus-associated lymphomas and epithelia cancers in humans. J. Cancer. 11, 1737\u20131750 (2020).","journal-title":"J. Cancer."},{"key":"2197_CR155","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1128\/JVI.02601-13","volume":"88","author":"S Koganti","year":"2014","unstructured":"Koganti, S., de la Paz, A., Freeman, A. F. & Bhaduri-McIntosh, S. B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation. J. Virol. 88, 516\u2013524 (2014).","journal-title":"J. Virol."},{"key":"2197_CR156","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"2197_CR157","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"2197_CR158","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","volume":"49","author":"S Reuter","year":"2010","unstructured":"Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603\u20131616 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"2197_CR159","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444 (2008).","journal-title":"Nature"},{"key":"2197_CR160","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/ijms22031224","volume":"22","author":"E Digifico","year":"2021","unstructured":"Digifico, E., Balinzo, S. & Belgiovine, C. The dark side of the force: when the immune system is the fuel of tumor onset. Int. J. Mol. Sci. 22, 1224 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR161","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","volume":"36","author":"JA Eble","year":"2019","unstructured":"Eble, J. A. & Niland, S. The extracellular matrix in tumor progression and metastasis. Clin. Exp. Metastasis 36, 171\u2013198 (2019).","journal-title":"Clin. Exp. Metastasis"},{"key":"2197_CR162","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395\u2013406 (2012).","journal-title":"J. Cell Biol."},{"key":"2197_CR163","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"2197_CR164","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273\u2013286 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2197_CR165","doi-asserted-by":"crossref","unstructured":"Uzun, S. et al. Comprehensive analysis of VEGFR2 expression in HPV-Positive and -negative OPSCC reveals differing VEGFR2 expression patterns. Cancers 13, 5221 (2021).","DOI":"10.3390\/cancers13205221"},{"key":"2197_CR166","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"2197_CR167","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657\u2013669 (2017).","journal-title":"Cell"},{"key":"2197_CR168","doi-asserted-by":"publisher","first-page":"188646","DOI":"10.1016\/j.bbcan.2021.188646","volume":"1877","author":"K Sitarz","year":"2022","unstructured":"Sitarz, K., Czamara, K., Szostek, S. & Kaczor, A. The impact of HPV infection on human glycogen and lipid metabolism\u2014a review. Biochim. Biophys. Acta Rev. Cancer 1877, 188646 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2197_CR169","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"2197_CR170","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2197_CR171","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4254\/wjh.v14.i4.708","volume":"14","author":"R Kumar","year":"2022","unstructured":"Kumar, R. Review on hepatitis B virus precore\/core promoter mutations and their correlation with genotypes and liver disease severity. World J. Hepatol. 14, 708\u2013718 (2022).","journal-title":"World J. Hepatol."},{"key":"2197_CR172","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.7150\/thno.31683","volume":"9","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Evaluation of polymer nanoformulations in hepatoma therapy by established rodent models. Theranostics 9, 1426\u20131452 (2019).","journal-title":"Theranostics"},{"key":"2197_CR173","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","volume":"151","author":"WS Mason","year":"2016","unstructured":"Mason, W. S. et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151, 986\u2013998.e984 (2016).","journal-title":"Gastroenterology"},{"key":"2197_CR174","first-page":"1410","volume":"19","author":"P Ruan","year":"2019","unstructured":"Ruan, P. et al. Different types of viral\u2011host junction found in HBV integration breakpoints in HBV\u2011infected patients. Mol. Med. Rep. 19, 1410\u20131416 (2019).","journal-title":"Mol. Med. Rep."},{"key":"2197_CR175","doi-asserted-by":"crossref","unstructured":"Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 9, eaan0241 (2017).","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"2197_CR176","first-page":"467","volume":"26","author":"Z Peng","year":"2005","unstructured":"Peng, Z. et al. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int. J. Oncol. 26, 467\u2013473 (2005).","journal-title":"Int. J. Oncol."},{"key":"2197_CR177","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1038\/onc.2013.468","volume":"33","author":"H Ye","year":"2014","unstructured":"Ye, H. et al. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene 33, 5133\u20135138 (2014).","journal-title":"Oncogene"},{"key":"2197_CR178","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13046-022-02531-x","volume":"41","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-kappaBp65\/HK2 signalling. J. Exp. Clin. Cancer Res. 41, 329 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR179","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1440-1746.2000.02069.x","volume":"15","author":"P Arbuthnot","year":"2000","unstructured":"Arbuthnot, P., Capovilla, A. & Kew, M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK\/STAT pathways. J. Gastroenterol. Hepatol. 15, 357\u2013368 (2000).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2197_CR180","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.neo.2021.04.004","volume":"23","author":"N McBrearty","year":"2021","unstructured":"McBrearty, N. et al. Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia 23, 529\u2013538 (2021).","journal-title":"Neoplasia"},{"key":"2197_CR181","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.3748\/wjg.v20.i30.10238","volume":"20","author":"A Ali","year":"2014","unstructured":"Ali, A. et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J. Gastroenterol. 20, 10238\u201310248 (2014).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR182","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc2290","volume":"8","author":"M Welcker","year":"2008","unstructured":"Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83\u201393 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2197_CR183","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.3390\/ijms20225714","volume":"20","author":"H Tsuchiya","year":"2019","unstructured":"Tsuchiya, H. et al. HBx and c-MYC cooperate to induce URI1 expression in HBV-related hepatocellular carcinoma. Int. J. Mol. Sci. 20, 5714 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR184","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1080\/22221751.2022.2125344","volume":"11","author":"Y Fu","year":"2022","unstructured":"Fu, Y. et al. Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma. Emerg. Microbes Infect. 11, 2486\u20132501 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"2197_CR185","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41388-019-1107-9","volume":"39","author":"KS Dong","year":"2020","unstructured":"Dong, K. S. et al. TGF-beta1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p. Oncogene 39, 1807\u20131820 (2020).","journal-title":"Oncogene"},{"key":"2197_CR186","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcmgh.2022.09.003","volume":"15","author":"S Yuan","year":"2023","unstructured":"Yuan, S. et al. HBV X protein induces degradation of UBXN7, a novel negative regulator of NF-kappaB signaling, to promote HBV replication. Cell. Mol. Gastroenterol. Hepatol. 15, 179\u2013195 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2197_CR187","doi-asserted-by":"publisher","first-page":"906","DOI":"10.7150\/jca.33766","volume":"11","author":"GZ Zhu","year":"2020","unstructured":"Zhu, G. Z. et al. Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy. J. Cancer. 11, 906\u2013918 (2020).","journal-title":"J. Cancer."},{"key":"2197_CR188","doi-asserted-by":"crossref","unstructured":"Joerger, A. C., Stiewe, T. & Soussi, T. TP53: the unluckiest of genes? Cell Death Differ. 32, 219\u2013224 (2024).","DOI":"10.1038\/s41418-024-01391-6"},{"key":"2197_CR189","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","volume":"31","author":"AM Boutelle","year":"2021","unstructured":"Boutelle, A. M. & Attardi, L. D. p53 and tumor suppression: it takes a network. Trends Cell Biol. 31, 298\u2013310 (2021).","journal-title":"Trends Cell Biol."},{"key":"2197_CR190","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.2147\/OTT.S231630","volume":"12","author":"M Yang","year":"2019","unstructured":"Yang, M. & Wei, W. SNHG16: A novel long-non coding RNA in human cancers. Onco. Targets Ther. 12, 11679\u201311690 (2019).","journal-title":"Onco. Targets Ther."},{"key":"2197_CR191","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/hep.30098","volume":"68","author":"N Liu","year":"2018","unstructured":"Liu, N. et al. Hepatitis B virus-upregulated LNC-HUR1 promotes cell proliferation and tumorigenesis by blocking p53 activity. Hepatology 68, 2130\u20132144 (2018).","journal-title":"Hepatology"},{"key":"2197_CR192","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2017.08.013","volume":"67","author":"S Torrecilla","year":"2017","unstructured":"Torrecilla, S. et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J. Hepatol. 67, 1222\u20131231 (2017).","journal-title":"J. Hepatol."},{"key":"2197_CR193","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/v13020180","volume":"13","author":"T Tu","year":"2021","unstructured":"Tu, T., Zhang, H. & Urban, S. Hepatitis B virus DNA integration: in vitro models for investigating 2831 viral pathogenesis and persistence. Viruses 13, 180 (2021).","journal-title":"Viruses"},{"key":"2197_CR194","doi-asserted-by":"publisher","first-page":"9099","DOI":"10.1158\/0008-5472.CAN-06-1886","volume":"66","author":"R Fujii","year":"2006","unstructured":"Fujii, R. et al. HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res. 66, 9099\u20139107 (2006).","journal-title":"Cancer Res."},{"key":"2197_CR195","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2020.08.005","volume":"492","author":"SK Li","year":"2020","unstructured":"Li, S. K. et al. Centrosomal protein TAX1BP2 inhibits centrosome-microtubules aberrations induced by hepatitis B virus X oncoprotein. Cancer Lett. 492, 147\u2013161 (2020).","journal-title":"Cancer Lett."},{"key":"2197_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14011","volume":"8","author":"A Alt","year":"2017","unstructured":"Alt, A. et al. Specialized interfaces of Smc5\/6 control hinge stability and DNA association. Nat. Commun. 8, 14011 (2017).","journal-title":"Nat. Commun."},{"key":"2197_CR197","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","volume":"16","author":"CM Murphy","year":"2016","unstructured":"Murphy, C. M. et al. Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication. Cell Rep. 16, 2846\u20132854 (2016).","journal-title":"Cell Rep."},{"key":"2197_CR198","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2021.08.010","volume":"76","author":"K Sekiba","year":"2022","unstructured":"Sekiba, K. et al. HBx-induced degradation of Smc5\/6 complex impairs homologous recombination-mediated repair of damaged DNA. J. Hepatol. 76, 53\u201362 (2022).","journal-title":"J. Hepatol."},{"key":"2197_CR199","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/hep.30947","volume":"71","author":"W Gao","year":"2020","unstructured":"Gao, W. et al. HBx protein contributes to liver carcinogenesis by H3K4me3 modification through stabilizing Wd repeat domain 5 protein. Hepatology 71, 1678\u20131695 (2020).","journal-title":"Hepatology"},{"key":"2197_CR200","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","volume":"26","author":"S D\u2019Souza","year":"2020","unstructured":"D\u2019Souza, S., Lau, K. C., Coffin, C. S. & Patel, T. R. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J. Gastroenterol. 26, 5759\u20135783 (2020).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR201","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1053\/jhep.2001.28886","volume":"34","author":"L Qiao","year":"2001","unstructured":"Qiao, L. et al. Hepatitis B virus X protein increases expression of p21(Cip-1\/WAF1\/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology 34, 906\u2013917 (2001).","journal-title":"Hepatology"},{"key":"2197_CR202","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200999RR","volume":"37","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. HBx downregulated decorin and decorin-derived peptides inhibit the proliferation and tumorigenicity of hepatocellular carcinoma cells. FASEB J. 37, e22871 (2023).","journal-title":"FASEB J."},{"key":"2197_CR203","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13402-022-00683-8","volume":"45","author":"W Chaomin","year":"2022","unstructured":"Chaomin, W. et al. Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer. Cell Oncol. 45, 573\u2013589 (2022).","journal-title":"Cell Oncol."},{"key":"2197_CR204","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/hep.22765","volume":"49","author":"M Murata","year":"2009","unstructured":"Murata, M. et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49, 1203\u20131217 (2009).","journal-title":"Hepatology"},{"key":"2197_CR205","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/liv.15805","volume":"44","author":"P Rawal","year":"2024","unstructured":"Rawal, P. et al. Targeted HBx gene editing by CRISPR\/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells. Liver Int. 44, 614\u2013624 (2024).","journal-title":"Liver Int."},{"key":"2197_CR206","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/cr.2010.49","volume":"20","author":"C Shan","year":"2010","unstructured":"Shan, C. et al. Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1\/2. Cell Res. 20, 563\u2013575 (2010).","journal-title":"Cell Res."},{"key":"2197_CR207","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/hep.22542","volume":"48","author":"S Martin-Lluesma","year":"2008","unstructured":"Martin-Lluesma, S. et al. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology 48, 1467\u20131476 (2008).","journal-title":"Hepatology"},{"key":"2197_CR208","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29805","volume":"96","author":"Q Zeng","year":"2024","unstructured":"Zeng, Q. et al. The nuclear matrix protein HNRNPU restricts hepatitis B virus transcription by promoting OAS3-based activation of host innate immunity. J. Med. Virol. 96, e29805 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR209","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12072-021-10172-z","volume":"15","author":"F Cheng","year":"2021","unstructured":"Cheng, F. et al. HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2. Hepatol. Int. 15, 707\u2013719 (2021).","journal-title":"Hepatol. Int."},{"key":"2197_CR210","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/15384101.2024.2353553","volume":"23","author":"X Wang","year":"2024","unstructured":"Wang, X., Lu, H., Sprangers, G. & Hallstrom, T. C. UHRF2 accumulates in early G(1)-phase after serum stimulation or mitotic exit to extend G(1) and total cell cycle length. Cell Cycle 23, 613\u2013627 (2024).","journal-title":"Cell Cycle"},{"key":"2197_CR211","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10555-023-10160-9","volume":"43","author":"D Tong","year":"2024","unstructured":"Tong, D., Tang, Y. & Zhong, P. The emerging roles of histone demethylases in cancers. Cancer Metastasis Rev. 43, 795\u2013821 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2197_CR212","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1080\/15548627.2021.1917948","volume":"17","author":"Y Lei","year":"2021","unstructured":"Lei, Y. et al. HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G(1)\/S cycle. Autophagy 17, 4423\u20134441 (2021).","journal-title":"Autophagy"},{"key":"2197_CR213","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/infdis\/jiac044","volume":"227","author":"Y Suehiro","year":"2023","unstructured":"Suehiro, Y. et al. Hepatitis B virus (HBV) upregulates TRAIL-R3 expression in hepatocytes resulting in escape from both cell apoptosis and suppression of HBV replication by TRAIL. J. Infect. Dis. 227, 686\u2013695 (2023).","journal-title":"J. Infect. Dis."},{"key":"2197_CR214","first-page":"1667","volume":"81","author":"R Abe","year":"1990","unstructured":"Abe, R., Etori, K., Kato, T. & Sato, K. Experience with transurethral uretero-nephrolithotripsy using flexible nephro-ureteroscope. Nihon Hinyokika Gakkai Zasshi 81, 1667\u20131674 (1990).","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"2197_CR215","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/rmv.1864","volume":"26","author":"HH Niller","year":"2016","unstructured":"Niller, H. H. et al. Wild type HBx and truncated HBx: pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms. Rev. Med. Virol. 26, 57\u201373 (2016).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR216","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s13046-019-1444-0","volume":"38","author":"Y Xiao","year":"2019","unstructured":"Xiao, Y. et al. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J. Exp. Clin. Cancer Res. 38, 458 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR217","doi-asserted-by":"publisher","first-page":"906.e901","DOI":"10.1016\/j.cmi.2018.11.017","volume":"25","author":"R Salpini","year":"2019","unstructured":"Salpini, R. et al. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin. Microbiol. Infect. 25, 906.e901\u2013906.e907 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"2197_CR218","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin, Y. et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp. Hematol. Oncol. 13, 72 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2197_CR219","doi-asserted-by":"publisher","first-page":"G162","DOI":"10.1152\/ajpgi.00197.2019","volume":"318","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Hepatitis B virus-triggered PTEN\/beta-catenin\/c-Myc signaling enhances PD-L1 expression to promote immune evasion. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G162\u2013G173 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2197_CR220","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jhep.2023.02.035","volume":"79","author":"I Montali","year":"2023","unstructured":"Montali, I. et al. Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B. J. Hepatol. 79, 50\u201360 (2023).","journal-title":"J. Hepatol."},{"key":"2197_CR221","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","volume":"631","author":"M Bosch","year":"2024","unstructured":"Bosch, M. et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature 631, 867\u2013875 (2024).","journal-title":"Nature"},{"key":"2197_CR222","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1016\/j.cell.2024.05.038","volume":"187","author":"F Andreata","year":"2024","unstructured":"Andreata, F. et al. Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell 187, 4078\u20134094.e4021 (2024).","journal-title":"Cell"},{"key":"2197_CR223","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41423-018-0006-2","volume":"16","author":"F Xu","year":"2019","unstructured":"Xu, F. et al. Type III interferon-induced CBFbeta inhibits HBV replication by hijacking HBx. Cell. Mol. Immunol. 16, 357\u2013366 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"2197_CR224","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303807","volume":"10","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. Deubiquitylating enzymes in cancer and immunity. Adv. Sci. 10, e2303807 (2023).","journal-title":"Adv. Sci."},{"key":"2197_CR225","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/rmv.1836","volume":"25","author":"P Kumari","year":"2015","unstructured":"Kumari, P., Narayanan, S. & Kumar, H. Herpesviruses: interfering innate immunity by targeting viral sensing and interferon pathways. Rev. Med. Virol. 25, 187\u2013201 (2015).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06412-9","volume":"15","author":"S Ding","year":"2024","unstructured":"Ding, S. et al. Epigenetic addition of m(5)C to HBV transcripts promotes viral replication and evasion of innate antiviral responses. Cell Death Dis. 15, 39 (2024).","journal-title":"Cell Death Dis."},{"key":"2197_CR227","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3350\/cmh.2024.0060","volume":"30","author":"M Dezhbord","year":"2024","unstructured":"Dezhbord, M. et al. Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Clin. Mol. Hepatol 30, 539\u2013560 (2024).","journal-title":"Clin. Mol. Hepatol"},{"key":"2197_CR228","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.3748\/wjg.v20.i37.13477","volume":"20","author":"HX Fan","year":"2014","unstructured":"Fan, H. X. & Tang, H. Complex interactions between microRNAs and hepatitis B\/C viruses. World J. Gastroenterol. 20, 13477\u201313492 (2014).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR229","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.immuni.2016.04.008","volume":"44","author":"Y Tian","year":"2016","unstructured":"Tian, Y., Kuo, C. F., Akbari, O. & Ou, J. H. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 44, 1204\u20131214 (2016).","journal-title":"Immunity"},{"key":"2197_CR230","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","volume":"62","author":"OV Makarova-Rusher","year":"2015","unstructured":"Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G. & Greten, T. F. The yin and yang of evasion and immune activation in HCC. J. Hepatol. 62, 1420\u20131429 (2015).","journal-title":"J. Hepatol."},{"key":"2197_CR231","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-13-0179","volume":"2","author":"N Vandeven","year":"2014","unstructured":"Vandeven, N. & Nghiem, P. Pathogen-driven cancers and emerging immune therapeutic strategies. Cancer Immunol. Res. 2, 9\u201314 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2197_CR232","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux, C., Liu, S., Trachootham, D. & Huang, P. Targeting ROS in cancer: rationale and strategies. Nat. Rev. Drug Discov. 23, 583\u2013606 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2197_CR233","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/ijms24054964","volume":"24","author":"A Schollmeier","year":"2023","unstructured":"Schollmeier, A., Glitscher, M. & Hildt, E. Relevance of HBx for hepatitis B virus-associated pathogenesis. Int. J. Mol. Sci. 24, 4964 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109737","volume":"123","author":"T He","year":"2020","unstructured":"He, T. et al. GPR43 regulates HBV X protein (HBx)-induced inflammatory response in human LO(2) hepatocytes. Biomed. Pharmacother. 123, 109737 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2197_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118029","volume":"258","author":"ZG Hu","year":"2020","unstructured":"Hu, Z. G. et al. DTNA promotes HBV-induced hepatocellular carcinoma progression by activating STAT3 and regulating TGFbeta1 and P53 signaling. Life Sci. 258, 118029 (2020).","journal-title":"Life Sci."},{"key":"2197_CR236","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1099\/vir.0.070680-0","volume":"96","author":"I Quetier","year":"2015","unstructured":"Quetier, I. et al. C-terminal-truncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. J. Gen. Virol. 96, 614\u2013625 (2015).","journal-title":"J. Gen. Virol."},{"key":"2197_CR237","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","volume":"71","author":"C Peneau","year":"2022","unstructured":"Peneau, C. et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut 71, 616\u2013626 (2022).","journal-title":"Gut"},{"key":"2197_CR238","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-pathmechdis-051222-122724","volume":"19","author":"R Kanagal-Shamanna","year":"2024","unstructured":"Kanagal-Shamanna, R., Beck, D. B. & Calvo, K. R. Clonal hematopoiesis, inflammation, and hematologic malignancy. Annu. Rev. Pathol. 19, 479\u2013506 (2024).","journal-title":"Annu. Rev. Pathol."},{"key":"2197_CR239","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou, S. L. et al. Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 150, 1646\u20131658.e1617 (2016).","journal-title":"Gastroenterology"},{"key":"2197_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0048-z","volume":"2","author":"LX Yu","year":"2018","unstructured":"Yu, L. X., Ling, Y. & Wang, H. Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis. Oncol. 2, 6 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"2197_CR241","doi-asserted-by":"crossref","unstructured":"Gupta, H., Youn, G. S., Shin, M. J. & Suk, K. T. Role of gut microbiota in hepatocarcinogenesis. Microorganisms 7, (2019).","DOI":"10.20944\/preprints201903.0267.v1"},{"key":"2197_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-018-0281-6","volume":"11","author":"Q Liu","year":"2019","unstructured":"Liu, Q. et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus-related hepatocellular carcinoma. Gut Pathog. 11, 1 (2019).","journal-title":"Gut Pathog."},{"key":"2197_CR243","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta, K. et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247\u20131261 (2020).","journal-title":"Hepatology"},{"key":"2197_CR244","first-page":"479","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Elevated HMGB1 expression induced by hepatitis B virus X protein promotes epithelial-mesenchymal transition and angiogenesis through STAT3\/miR-34a\/NF-kappaB in primary liver cancer. Am. J. Cancer Res. 11, 479\u2013494 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"2197_CR245","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","volume":"7","author":"Z Luo","year":"2022","unstructured":"Luo, Z. et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct. Target Ther. 7, 218 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2197_CR246","doi-asserted-by":"publisher","first-page":"12100","DOI":"10.3390\/ijms232012100","volume":"23","author":"CY Hou","year":"2022","unstructured":"Hou, C. Y. et al. WNK1-OSR1 signaling regulates angiogenesis-mediated metastasis towards developing a combinatorial anti-cancer strategy. Int. J. Mol. Sci. 23, 12100 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR247","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"2197_CR248","first-page":"1","volume":"11","author":"LM Phan","year":"2014","unstructured":"Phan, L. M., Yeung, S. C. & Lee, M. H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 11, 1\u201319 (2014).","journal-title":"Cancer Biol. Med."},{"key":"2197_CR249","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41388-020-01593-5","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene 40, 1147\u20131161 (2021).","journal-title":"Oncogene"},{"key":"2197_CR250","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.568574","volume":"10","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Research progress of TXNIP as a tumor suppressor gene participating in the metabolic reprogramming and oxidative stress of cancer cells in various cancers. Front. Oncol. 10, 568574 (2020).","journal-title":"Front. Oncol."},{"key":"2197_CR251","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ijbiomac.2022.11.312","volume":"226","author":"H You","year":"2023","unstructured":"You, H. et al. Hepatitis B virus X protein increases LASP1 SUMOylation to stabilize HER2 and facilitate hepatocarcinogenesis. Int. J. Biol. Macromol. 226, 996\u20131009 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"2197_CR252","doi-asserted-by":"publisher","unstructured":"Zhou, P. et al. SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma. Cell. Oncol. https:\/\/doi.org\/10.1007\/s13402-024-00955-5 (2024).","DOI":"10.1007\/s13402-024-00955-5"},{"key":"2197_CR253","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/1535370220914252","volume":"245","author":"TT Zhang","year":"2020","unstructured":"Zhang, T. T., Ye, S. S., Liang, J. & Bai, L. Prognostic value of non-invasive fibrosis indices post-curative resection in hepatitis-B-associated hepatocellular carcinoma patients. Exp. Biol. Med. 245, 703\u2013710 (2020).","journal-title":"Exp. Biol. Med."},{"key":"2197_CR254","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/IDR.S353605","volume":"15","author":"TK Nguyen","year":"2022","unstructured":"Nguyen, T. K. & Van Le, D. Identification of NS5B resistance-associated mutations in hepatitis c virus circulating in treatment naive Vietnamese patients. Infect. Drug Resist. 15, 1547\u20131554 (2022).","journal-title":"Infect. Drug Resist."},{"key":"2197_CR255","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210408","volume":"218","author":"P Reuther","year":"2021","unstructured":"Reuther, P. et al. Persistent RNA virus infection is short-lived at the single-cell level but leaves transcriptomic footprints. J. Exp. Med. 218, e20210408 (2021).","journal-title":"J. Exp. Med."},{"key":"2197_CR256","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1338606","volume":"14","author":"M Bunz","year":"2024","unstructured":"Bunz, M. et al. CD81 suppresses NF-kappaB signaling and is downregulated in hepatitis C virus-expressing cells. Front. Cell Infect. Microbiol. 14, 1338606 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2197_CR257","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.07.009","volume":"20","author":"E Shirvani-Dastgerdi","year":"2016","unstructured":"Shirvani-Dastgerdi, E., Schwartz, R. E. & Ploss, A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr. Opin. Virol. 20, 1\u201310 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"2197_CR258","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.3748\/wjg.v20.i41.15018","volume":"20","author":"M Murata","year":"2014","unstructured":"Murata, M., Yoshida, K., Yamaguchi, T. & Matsuzaki, K. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma. World J. Gastroenterol. 20, 15018\u201315027 (2014).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR259","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44960-6","volume":"15","author":"Q Pan","year":"2024","unstructured":"Pan, Q. et al. EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses. Nat. Commun. 15, 652 (2024).","journal-title":"Nat. Commun."},{"key":"2197_CR260","doi-asserted-by":"publisher","first-page":"e00639","DOI":"10.1128\/JVI.00639-18","volume":"92","author":"C Matsui","year":"2018","unstructured":"Matsui, C. et al. Hepatitis C virus NS5A protein promotes the lysosomal degradation of hepatocyte nuclear factor 1alpha via chaperone-mediated autophagy. J. Virol. 92, e00639\u201300618 (2018).","journal-title":"J. Virol."},{"key":"2197_CR261","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-020-0342-4","volume":"18","author":"GK Michalopoulos","year":"2021","unstructured":"Michalopoulos, G. K. & Bhushan, B. Liver regeneration: biological and pathological mechanisms and implications. Nat. Rev. Gastroenterol. Hepatol. 18, 40\u201355 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2197_CR262","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/cancers16081505","volume":"16","author":"M Capasso","year":"2024","unstructured":"Capasso, M. et al. The role of hepatitis viruses as drivers of hepatocarcinogenesis. Cancers 16, 1505 (2024).","journal-title":"Cancers"},{"key":"2197_CR263","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jhep.2015.07.024","volume":"63","author":"A El-Shamy","year":"2015","unstructured":"El-Shamy, A. et al. A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J. Hepatol. 63, 1323\u20131333 (2015).","journal-title":"J. Hepatol."},{"key":"2197_CR264","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3390\/cancers13102485","volume":"13","author":"D Pascut","year":"2021","unstructured":"Pascut, D. et al. HCV proteins modulate the host cell miRNA expression contributing to hepatitis C pathogenesis and hepatocellular carcinoma development. Cancers 13, 2485 (2021).","journal-title":"Cancers"},{"key":"2197_CR265","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3390\/ijms24032619","volume":"24","author":"B Kitab","year":"2023","unstructured":"Kitab, B. & Tsukiyama-Kohara, K. Regulatory role of ribonucleotide reductase subunit M2 in hepatocyte growth and pathogenesis of hepatitis C virus. Int. J. Mol. Sci. 24, 2619 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR266","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.3390\/ijms242216100","volume":"24","author":"S Barik","year":"2023","unstructured":"Barik, S. Suppression of innate immunity by the hepatitis C virus (HCV): revisiting the specificity of host-virus interactive pathways. Int. J. Mol. Sci. 24, 16100 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR267","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2016.06.008","volume":"380","author":"J Kwak","year":"2016","unstructured":"Kwak, J., Shim, J. H., Tiwari, I. & Jang, K. L. Hepatitis C virus core protein inhibits E6AP expression via DNA methylation to escape from ubiquitin-dependent proteasomal degradation. Cancer Lett. 380, 59\u201368 (2016).","journal-title":"Cancer Lett."},{"key":"2197_CR268","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmb.2006.03.020","volume":"359","author":"KH Baek","year":"2006","unstructured":"Baek, K. H. et al. Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation. J. Mol. Biol. 359, 22\u201334 (2006).","journal-title":"J. Mol. Biol."},{"key":"2197_CR269","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"Cancer genome atlas research network. electronic address: wheeler@bcm.edu; cancer genome atlas research network.","year":"2017","unstructured":"Cancer genome atlas research network. electronic address: wheeler@bcm.edu; cancer genome atlas research network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 169, 1327\u20131341.e1323 (2017).","journal-title":"Cell."},{"key":"2197_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34249-x","volume":"13","author":"M Fujita","year":"2022","unstructured":"Fujita, M. et al. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat. Commun. 13, 6481 (2022).","journal-title":"Nat. Commun."},{"key":"2197_CR271","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcmgh.2023.03.004","volume":"16","author":"S Perez","year":"2023","unstructured":"Perez, S. et al. High-resolution genomic profiling of liver cancer links etiology with mutation and epigenetic signatures. Cell. Mol. Gastroenterol. Hepatol. 16, 63\u201381 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2197_CR272","doi-asserted-by":"publisher","first-page":"153099","DOI":"10.1016\/j.prp.2020.153099","volume":"216","author":"JL Peng","year":"2020","unstructured":"Peng, J. L. et al. Association of RASSF1A hypermethylation with risk of HBV\/HCV-induced hepatocellular carcinoma: a meta-analysis. Pathol. Res. Pract. 216, 153099 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"2197_CR273","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/sj.onc.1210344","volume":"26","author":"Y Endo","year":"2007","unstructured":"Endo, Y. et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26, 5587\u20135595 (2007).","journal-title":"Oncogene"},{"key":"2197_CR274","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12866-017-1032-4","volume":"17","author":"XH Jiang","year":"2017","unstructured":"Jiang, X. H. et al. Effects of hepatitis C virus core protein and nonstructural protein 4B on the Wnt\/beta-catenin pathway. BMC Microbiol. 17, 124 (2017).","journal-title":"BMC Microbiol."},{"key":"2197_CR275","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/onc.2010.594","volume":"30","author":"DR McGivern","year":"2011","unstructured":"McGivern, D. R. & Lemon, S. M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus-associated liver cancer. Oncogene 30, 1969\u20131983 (2011).","journal-title":"Oncogene"},{"key":"2197_CR276","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/onc.2012.484","volume":"32","author":"MR Higgs","year":"2013","unstructured":"Higgs, M. R., Lerat, H. & Pawlotsky, J. M. Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene 32, 4683\u20134693 (2013).","journal-title":"Oncogene"},{"key":"2197_CR277","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01318-23","volume":"14","author":"NL Meyers","year":"2023","unstructured":"Meyers, N. L. et al. Hepatitis C virus infects and perturbs liver stem cells. mBio 14, e0131823 (2023).","journal-title":"mBio"},{"key":"2197_CR278","doi-asserted-by":"publisher","first-page":"95","DOI":"10.14309\/ajg.0000000000001994","volume":"118","author":"W Sohn","year":"2023","unstructured":"Sohn, W. et al. Isolated hepatitis B core antibody positivity and long-term liver-related mortality in Korea: a cohort study. Am. J. Gastroenterol. 118, 95\u2013104 (2023).","journal-title":"Am. J. Gastroenterol."},{"key":"2197_CR279","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","volume":"1","author":"M Puigvehi","year":"2019","unstructured":"Puigvehi, M., Moctezuma-Velazquez, C., Villanueva, A. & Llovet, J. M. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep. 1, 120\u2013130 (2019).","journal-title":"JHEP Rep."},{"key":"2197_CR280","first-page":"683","volume":"118","author":"N Tanaka","year":"2008","unstructured":"Tanaka, N. et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 118, 683\u2013694 (2008).","journal-title":"J. Clin. Invest."},{"key":"2197_CR281","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.3390\/ijms23105475","volume":"23","author":"MEH Kayesh","year":"2022","unstructured":"Kayesh, M. E. H., Kohara, M. & Tsukiyama-Kohara, K. Toll-like receptor response to hepatitis C virus infection: a recent overview. Int. J. Mol. Sci. 23, 5475 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR282","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook, R. H. & Dusheiko, G. Natural history of hepatitis C. J. Hepatol. 61, S58\u2013S68 (2014).","journal-title":"J. Hepatol."},{"key":"2197_CR283","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/infdis\/jiy331","volume":"218","author":"A Lidofsky","year":"2018","unstructured":"Lidofsky, A. et al. Macrophage activation marker soluble CD163 is a dynamic marker of liver fibrogenesis in human immunodeficiency virus\/hepatitis C virus coinfection. J. Infect. Dis. 218, 1394\u20131403 (2018).","journal-title":"J. Infect. Dis."},{"key":"2197_CR284","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04685-9","volume":"9","author":"B Strunz","year":"2018","unstructured":"Strunz, B. et al. Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nat. Commun. 9, 2275 (2018).","journal-title":"Nat. Commun."},{"key":"2197_CR285","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41421-020-00214-5","volume":"6","author":"G Song","year":"2020","unstructured":"Song, G. et al. Global immune characterization of HBV\/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 6, 90 (2020).","journal-title":"Cell Discov."},{"key":"2197_CR286","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-beta signaling in health, disease, and therapeutics. Signal Transduct. Target Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2197_CR287","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/biology9110390","volume":"9","author":"EW Harhaj","year":"2020","unstructured":"Harhaj, E. W. & Shembade, N. Lymphotropic viruses: chronic inflammation and induction of cancers. Biology 9, 390 (2020).","journal-title":"Biology"},{"key":"2197_CR288","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/eji.201646447","volume":"46","author":"J Hengst","year":"2016","unstructured":"Hengst, J. et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur. J. Immunol. 46, 2204\u20132210 (2016).","journal-title":"Eur. J. Immunol."},{"key":"2197_CR289","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2197_CR290","doi-asserted-by":"crossref","unstructured":"Szilveszter, R. M., Muntean, M. & Florea, A. Molecular mechanisms in tumorigenesis of hepatocellular carcinoma and in target treatments-an overview. Biomolecules. 14, 656 (2024).","DOI":"10.3390\/biom14060656"},{"key":"2197_CR291","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/hep.20454","volume":"40","author":"R Cabrera","year":"2004","unstructured":"Cabrera, R. et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40, 1062\u20131071 (2004).","journal-title":"Hepatology"},{"key":"2197_CR292","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3109\/00365521.2016.1170875","volume":"51","author":"HJ Hartling","year":"2016","unstructured":"Hartling, H. J. et al. Immune regulation in chronic hepatitis C virus infection. Scand. J. Gastroenterol. 51, 1387\u20131397 (2016).","journal-title":"Scand. J. Gastroenterol."},{"key":"2197_CR293","doi-asserted-by":"publisher","first-page":"e84953","DOI":"10.1371\/journal.pone.0084953","volume":"9","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells. PLoS One 9, e84953 (2014).","journal-title":"PLoS One"},{"key":"2197_CR294","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","volume":"22","author":"V Appay","year":"2001","unstructured":"Appay, V. & Rowland-Jones, S. L. RANTES: a versatile and controversial chemokine. Trends Immunol. 22, 83\u201387 (2001).","journal-title":"Trends Immunol."},{"key":"2197_CR295","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2147\/JHC.S325959","volume":"8","author":"D De Battista","year":"2021","unstructured":"De Battista, D. et al. Molecular signature and immune landscape of HCV-associated hepatocellular carcinoma (HCC): differences and similarities with HBV-HCC. J. Hepatocell Carcinoma 8, 1399\u20131413 (2021).","journal-title":"J. Hepatocell Carcinoma"},{"key":"2197_CR296","doi-asserted-by":"crossref","unstructured":"El-Mowafy, M. et al. Changes of gut-microbiota-liver axis in hepatitis C virus infection. Biology 10, 55 (2021).","DOI":"10.3390\/biology10010055"},{"key":"2197_CR297","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/jcm7080213","volume":"7","author":"MY Wu","year":"2018","unstructured":"Wu, M. Y. et al. Molecular targets in hepatocarcinogenesis and implications for therapy. J. Clin. Med. 7, 213 (2018).","journal-title":"J. Clin. Med."},{"key":"2197_CR298","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2009.10.007","volume":"134","author":"G Castello","year":"2010","unstructured":"Castello, G. et al. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin. Immunol. 134, 237\u2013250 (2010).","journal-title":"Clin. Immunol."},{"key":"2197_CR299","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/cancers13092270","volume":"13","author":"E Reungoat","year":"2021","unstructured":"Reungoat, E., Grigorov, B., Zoulim, F. & Pecheur, E. I. Molecular crosstalk between the hepatitis C virus and the extracellular matrix in liver fibrogenesis and early carcinogenesis. Cancers 13, 2270 (2021).","journal-title":"Cancers"},{"key":"2197_CR300","doi-asserted-by":"publisher","first-page":"2606928","DOI":"10.1155\/2022\/2606928","volume":"2022","author":"W Yu","year":"2022","unstructured":"Yu, W. et al. Reactive oxygen species bridge the gap between chronic inflammation and tumor development. Oxid. Med. Cell. Longev. 2022, 2606928 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"2197_CR301","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01351-6","volume":"21","author":"L Kalantari","year":"2023","unstructured":"Kalantari, L. et al. A state-of-the-art review on the NRF2 in hepatitis virus-associated liver cancer. Cell Commun. Signal 21, 318 (2023).","journal-title":"Cell Commun. Signal"},{"key":"2197_CR302","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2019.10.006","volume":"50","author":"S Abouelasrar Salama","year":"2019","unstructured":"Abouelasrar Salama, S. et al. Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection. Cytokine Growth Factor Rev. 50, 29\u201342 (2019).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2197_CR303","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.niox.2022.07.006","volume":"128","author":"S Dios-Barbeito","year":"2022","unstructured":"Dios-Barbeito, S. et al. Impact of nitric oxide in liver cancer microenvironment. Nitric Oxide 128, 1\u201311 (2022).","journal-title":"Nitric Oxide"},{"key":"2197_CR304","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40265-020-01458-x","volume":"81","author":"D Sepulveda-Crespo","year":"2021","unstructured":"Sepulveda-Crespo, D., Resino, S. & Martinez, I. Strategies targeting the innate immune response for the treatment of hepatitis C virus-associated liver fibrosis. Drugs 81, 419\u2013443 (2021).","journal-title":"Drugs"},{"key":"2197_CR305","doi-asserted-by":"crossref","unstructured":"Ismail, M. et al. Dynamic role of exosomal long non-coding RNA in liver diseases: pathogenesis and diagnostic aspects. Hepatol. Int., 18, 1715\u20131730 (2024).","DOI":"10.1007\/s12072-024-10722-1"},{"key":"2197_CR306","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.04.003","volume":"157","author":"J Lupberger","year":"2019","unstructured":"Lupberger, J. et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus-infected cells and liver to identify pathways associated with disease development. Gastroenterology 157, 537\u2013551 (2019).","journal-title":"Gastroenterology"},{"key":"2197_CR307","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2015.04.015","volume":"63","author":"MS Hiet","year":"2015","unstructured":"Hiet, M. S. et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J. Hepatol. 63, 829\u2013837 (2015).","journal-title":"J. Hepatol."},{"key":"2197_CR308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033314","volume":"13","author":"O Diaz","year":"2022","unstructured":"Diaz, O. et al. What role for cellular metabolism in the control of hepatitis viruses? Front. Immunol. 13, 1033314 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR309","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","volume":"77","author":"J Leslie","year":"2022","unstructured":"Leslie, J. et al. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. J. Hepatol. 77, 219\u2013236 (2022).","journal-title":"J. Hepatol."},{"key":"2197_CR310","doi-asserted-by":"publisher","first-page":"1358511","DOI":"10.3389\/fimmu.2024.1358511","volume":"15","author":"MY Salnikov","year":"2024","unstructured":"Salnikov, M. Y., MacNeil, K. M. & Mymryk, J. S. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape. Front. Immunol. 15, 1358511 (2024).","journal-title":"Front. Immunol."},{"key":"2197_CR311","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.3390\/ijms24098104","volume":"24","author":"A Giammanco","year":"2023","unstructured":"Giammanco, A. et al. Helicobacter pylori and Epstein-Barr virus co-infection in gastric disease: what is the correlation with p53 mutation, genes methylation and microsatellite instability in a cohort of sicilian population? Int. J. Mol. Sci. 24, 8104 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR312","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.3748\/wjg.v20.i21.6448","volume":"20","author":"TO Yau","year":"2014","unstructured":"Yau, T. O., Tang, C. M. & Yu, J. Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments. World J. Gastroenterol. 20, 6448\u20136456 (2014).","journal-title":"World J. Gastroenterol."},{"key":"2197_CR313","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.28402","volume":"134","author":"MC Camargo","year":"2014","unstructured":"Camargo, M. C. et al. Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer. Int. J. Cancer. 134, 948\u2013953 (2014).","journal-title":"Int. J. Cancer."},{"key":"2197_CR314","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01776-23","volume":"98","author":"JY Kim","year":"2024","unstructured":"Kim, J. Y. et al. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma. J. Virol. 98, e0177623 (2024).","journal-title":"J. Virol."},{"key":"2197_CR315","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2017.07.010","volume":"404","author":"J Ribeiro","year":"2017","unstructured":"Ribeiro, J. et al. P53 deregulation in Epstein-Barr virus-associated gastric cancer. Cancer Lett 404, 37\u201343 (2017).","journal-title":"Cancer Lett"},{"key":"2197_CR316","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tim.2016.03.008","volume":"24","author":"D Elgui de Oliveira","year":"2016","unstructured":"Elgui de Oliveira, D., Muller-Coan, B. G. & Pagano, J. S. Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers. Trends Microbiol 24, 649\u2013664 (2016).","journal-title":"Trends Microbiol"},{"key":"2197_CR317","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3390\/ijms18081606","volume":"18","author":"J Nishikawa","year":"2017","unstructured":"Nishikawa, J. et al. The role of epigenetic regulation in Epstein-Barr virus-associated gastric cancer. Int. J. Mol. Sci. 18, 1606 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR318","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/sj.onc.1208319","volume":"24","author":"MT Liu","year":"2005","unstructured":"Liu, M. T. et al. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Oncogene 24, 2635\u20132646 (2005).","journal-title":"Oncogene"},{"key":"2197_CR319","doi-asserted-by":"publisher","first-page":"e00722","DOI":"10.1128\/JVI.00722-20","volume":"94","author":"RJ Kraus","year":"2020","unstructured":"Kraus, R. J. et al. Reactivation of Epstein-Barr virus by HIF-1alpha requires p53. J. Virol. 94, e00722\u201300720 (2020).","journal-title":"J. Virol."},{"key":"2197_CR320","doi-asserted-by":"publisher","first-page":"e1000530","DOI":"10.1371\/journal.ppat.1000530","volume":"5","author":"Y Sato","year":"2009","unstructured":"Sato, Y. et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog. 5, e1000530 (2009).","journal-title":"PLoS Pathog."},{"key":"2197_CR321","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-023-00606-1","volume":"23","author":"TC Felismino","year":"2023","unstructured":"Felismino, T. C. & Coimbra, F. J. F. Lessons in gastric adenocarcinoma from TCGA. Nat. Rev. Cancer. 23, 655 (2023).","journal-title":"Nat. Rev. Cancer."},{"key":"2197_CR322","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s10120-020-01059-3","volume":"23","author":"CJ Yoon","year":"2020","unstructured":"Yoon, C. J. et al. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3\/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas. Gastric Cancer 23, 780\u2013795 (2020).","journal-title":"Gastric Cancer"},{"key":"2197_CR323","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1074\/jbc.RA118.006853","volume":"294","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Epstein-Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. J. Biol. Chem. 294, 4854\u20134866 (2019).","journal-title":"J. Biol. Chem."},{"key":"2197_CR324","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S1097-2765(03)00180-1","volume":"11","author":"S Huang","year":"2003","unstructured":"Huang, S. et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53\/p21(Cip1). Mol. Cell. 11, 1491\u20131501 (2003).","journal-title":"Mol. Cell."},{"key":"2197_CR325","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00006-22","volume":"10","author":"J Li","year":"2022","unstructured":"Li, J. et al. LMP1 induces p53 protein expression via the H19\/miR-675-5p axis. Microbiol. Spectr. 10, e0000622 (2022).","journal-title":"Microbiol. Spectr."},{"key":"2197_CR326","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28725","volume":"95","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Downregulation of MUS81 expression inhibits cell migration and maintains EBV latent infection through miR-BART9-5p in EBV-associated gastric cancer. J. Med. Virol. 95, e28725 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR327","doi-asserted-by":"publisher","first-page":"e01022","DOI":"10.1128\/JVI.01022-18","volume":"92","author":"X Zheng","year":"2018","unstructured":"Zheng, X. et al. Epstein-Barr virus microRNA miR-BART5-3p inhibits p53 expression. J. Virol. 92, e01022\u201301018 (2018).","journal-title":"J. Virol."},{"key":"2197_CR328","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem, M. et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat. Rev. 66, 15\u201322 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"2197_CR329","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1349-7006.2011.02129.x","volume":"103","author":"HY Chen","year":"2012","unstructured":"Chen, H. Y. et al. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 103, 73\u201379 (2012).","journal-title":"Cancer Sci."},{"key":"2197_CR330","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.3390\/ijms21176451","volume":"21","author":"JWT Toh","year":"2020","unstructured":"Toh, J. W. T. & Wilson, R. B. Pathways of gastric carcinogenesis, helicobacter pylori virulence and interactions with antioxidant systems, vitamin C and phytochemicals. Int. J. Mol. Sci. 21, 6451 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR331","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research, N.","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"2197_CR332","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s13402-024-00932-y","volume":"47","author":"J Elizazu","year":"2024","unstructured":"Elizazu, J. et al. Identification of a novel gene signature related to prognosis and metastasis in gastric cancer. Cell. Oncol. (Dordr.). 47, 1355\u20131373 (2024).","journal-title":"Cell. Oncol. (Dordr.)."},{"key":"2197_CR333","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku, A., Kunita, A. & Fukayama, M. Update on Epstein-Barr virus and gastric cancer (review). Int. J. Oncol. 46, 1421\u20131434 (2015).","journal-title":"Int. J. Oncol."},{"key":"2197_CR334","doi-asserted-by":"publisher","unstructured":"Shi, D. et al. Research advances in the molecular classification of gastric cancer. Cell. Oncol. https:\/\/doi.org\/10.1007\/s13402-024-00951-9 (2024).","DOI":"10.1007\/s13402-024-00951-9"},{"key":"2197_CR335","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12272-017-0939-5","volume":"40","author":"SJ Choi","year":"2017","unstructured":"Choi, S. J. et al. DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma. Arch. Pharm. Res. 40, 894\u2013905 (2017).","journal-title":"Arch. Pharm. Res."},{"key":"2197_CR336","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7150\/ijbs.30099","volume":"15","author":"K Min","year":"2019","unstructured":"Min, K. & Lee, S. K. EBV miR-BART10-3p promotes cell proliferation and migration by targeting DKK1. Int. J. Biol. Sci. 15, 657\u2013667 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR337","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.dld.2021.06.004","volume":"54","author":"H Song","year":"2022","unstructured":"Song, H. et al. Activation of DNA methyltransferase 3a by Epstein-Barr nuclear antigen 1 in gastric carcinoma. Dig. Liver Dis. 54, 973\u2013983 (2022).","journal-title":"Dig. Liver Dis."},{"key":"2197_CR338","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.84","volume":"47","author":"MS Kang","year":"2015","unstructured":"Kang, M. S. & Kieff, E. Epstein-Barr virus latent genes. Exp. Mol. Med. 47, e131 (2015).","journal-title":"Exp. Mol. Med."},{"key":"2197_CR339","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1111\/cas.14978","volume":"112","author":"W Li","year":"2021","unstructured":"Li, W. et al. Activation of EHF via STAT3 phosphorylation by LMP2A in Epstein-Barr virus-positive gastric cancer. Cancer Sci. 112, 3349\u20133362 (2021).","journal-title":"Cancer Sci."},{"key":"2197_CR340","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1158\/0008-5472.CAN-08-3070","volume":"69","author":"R Hino","year":"2009","unstructured":"Hino, R. et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69, 2766\u20132774 (2009).","journal-title":"Cancer Res."},{"key":"2197_CR341","doi-asserted-by":"publisher","first-page":"e02481","DOI":"10.1128\/JVI.02481-20","volume":"95","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Epstein-Barr Virus-encoded latent membrane protein 2A downregulates GCNT3 via the TGF-beta1\/Smad-mTORC1 signaling axis. J. Virol. 95, e02481\u201302420 (2021).","journal-title":"J. Virol."},{"key":"2197_CR342","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198510","volume":"304","author":"H Xiao","year":"2021","unstructured":"Xiao, H. et al. EBV downregulates the m(6)A \u201cwriter\u201d WTAP in EBV-associated gastric carcinoma. Virus Res. 304, 198510 (2021).","journal-title":"Virus Res."},{"key":"2197_CR343","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1128\/JVI.03639-14","volume":"89","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku, A. et al. Profiling of virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma and their roles in gastric carcinogenesis. J. Virol. 89, 5581\u20135591 (2015).","journal-title":"J. Virol."},{"key":"2197_CR344","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/carcin\/bgaa123","volume":"42","author":"K Kase","year":"2021","unstructured":"Kase, K. et al. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation. Carcinogenesis 42, 21\u201330 (2021).","journal-title":"Carcinogenesis"},{"key":"2197_CR345","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10120-021-01215-3","volume":"24","author":"M Saito","year":"2021","unstructured":"Saito, M. & Kono, K. Landscape of EBV-positive gastric cancer. Gastric Cancer 24, 983\u2013989 (2021).","journal-title":"Gastric Cancer"},{"key":"2197_CR346","doi-asserted-by":"publisher","first-page":"694","DOI":"10.7150\/ijbs.36595","volume":"16","author":"K Min","year":"2020","unstructured":"Min, K., Kim, J. Y. & Lee, S. K. Epstein-Barr virus miR-BART1-3p suppresses apoptosis and promotes migration of gastric carcinoma cells by targeting DAB2. Int. J. Biol. Sci. 16, 694\u2013707 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR347","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1096\/fj.202000039RR","volume":"34","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell proliferation through the LOC553103-STMN1 axis. FASEB J. 34, 8012\u20138027 (2020).","journal-title":"FASEB J."},{"key":"2197_CR348","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.canlet.2014.10.023","volume":"356","author":"H Kim","year":"2015","unstructured":"Kim, H., Choi, H. & Lee, S. K. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 356, 733\u2013742 (2015).","journal-title":"Cancer Lett."},{"key":"2197_CR349","doi-asserted-by":"publisher","first-page":"629780","DOI":"10.3389\/fonc.2021.629780","volume":"11","author":"MML Leong","year":"2021","unstructured":"Leong, M. M. L. & Lung, M. L. The impact of epstein-barr virus infection on epigenetic regulation of host cell gene expression in epithelial and lymphocytic malignancies. Front. Oncol. 11, 629780 (2021).","journal-title":"Front. Oncol."},{"key":"2197_CR350","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.200302085","volume":"162","author":"N Ohtani","year":"2003","unstructured":"Ohtani, N. et al. Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4\/5. J. Cell Biol. 162, 173\u2013183 (2003).","journal-title":"J. Cell Biol."},{"key":"2197_CR351","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1359766","volume":"14","author":"W Dong","year":"2024","unstructured":"Dong, W. et al. Virus-induced host genomic remodeling dysregulates gene expression, triggering tumorigenesis. Front. Cell Infect. Microbiol. 14, 1359766 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2197_CR352","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/v4091537","volume":"4","author":"L Frappier","year":"2012","unstructured":"Frappier, L. Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses 4, 1537\u20131547 (2012).","journal-title":"Viruses"},{"key":"2197_CR353","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1128\/JVI.78.4.1697-1705.2004","volume":"78","author":"M Fukuda","year":"2004","unstructured":"Fukuda, M. & Longnecker, R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase\/Akt pathway. J. Virol. 78, 1697\u20131705 (2004).","journal-title":"J. Virol."},{"key":"2197_CR354","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/0008-5472.CAN-07-3027","volume":"68","author":"R Hino","year":"2008","unstructured":"Hino, R. et al. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res. 68, 1427\u20131435 (2008).","journal-title":"Cancer Res."},{"key":"2197_CR355","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1084\/jem.20072581","volume":"205","author":"EY Choy","year":"2008","unstructured":"Choy, E. Y. et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 205, 2551\u20132560 (2008).","journal-title":"J. Exp. Med."},{"key":"2197_CR356","doi-asserted-by":"publisher","first-page":"e1005344","DOI":"10.1371\/journal.ppat.1005344","volume":"11","author":"X Lin","year":"2015","unstructured":"Lin, X. et al. The Epstein-Barr virus BART miRNA cluster of the M81 strain modulates multiple functions in primary B cells. PLoS Pathog. 11, e1005344 (2015).","journal-title":"PLoS Pathog."},{"key":"2197_CR357","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-21-2292","volume":"82","author":"X Duan","year":"2022","unstructured":"Duan, X. et al. EBV infection in epithelial malignancies induces resistance to antitumor natural killer cells via F3-mediated platelet aggregation. Cancer Res. 82, 1070\u20131083 (2022).","journal-title":"Cancer Res."},{"key":"2197_CR358","doi-asserted-by":"publisher","first-page":"e1008778","DOI":"10.1371\/journal.ppat.1008778","volume":"16","author":"GN Fiches","year":"2020","unstructured":"Fiches, G. N. et al. Profiling of immune related genes silenced in EBV-positive gastric carcinoma identified novel restriction factors of human gammaherpesviruses. PLoS Pathog. 16, e1008778 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR359","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.ctrv.2024.102737","volume":"127","author":"J Bos","year":"2024","unstructured":"Bos, J. et al. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: a systematic review. Cancer Treat. Rev. 127, 102737 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"2197_CR360","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.humpath.2018.11.002","volume":"85","author":"LP Gong","year":"2019","unstructured":"Gong, L. P. et al. The implication of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric carcinoma. Hum. Pathol. 85, 82\u201391 (2019).","journal-title":"Hum. Pathol."},{"key":"2197_CR361","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.3390\/cancers15123178","volume":"15","author":"MY Salnikov","year":"2023","unstructured":"Salnikov, M. Y., Fonseca, G. J. & Mymryk, J. S. Differences in the tumor microenvironment of EBV-associated gastric cancers revealed using single-cell transcriptome analysis. Cancers 15, 3178 (2023).","journal-title":"Cancers"},{"key":"2197_CR362","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"MZ Qiu","year":"2023","unstructured":"Qiu, M. Z. et al. Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct. Target Ther. 8, 370 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2197_CR363","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/modpathol.2016.202","volume":"30","author":"R Saito","year":"2017","unstructured":"Saito, R. et al. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod. Pathol. 30, 427\u2013439 (2017).","journal-title":"Mod. Pathol."},{"key":"2197_CR364","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003341","volume":"9","author":"MJ Strong","year":"2013","unstructured":"Strong, M. J. et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog. 9, e1003341 (2013).","journal-title":"PLoS Pathog."},{"key":"2197_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat. Commun. 13, 866 (2022).","journal-title":"Nat. Commun."},{"key":"2197_CR366","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","volume":"182","author":"D Horst","year":"2009","unstructured":"Horst, D. et al. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J. Immunol. 182, 2313\u20132324 (2009).","journal-title":"J. Immunol."},{"key":"2197_CR367","doi-asserted-by":"crossref","unstructured":"Mathebela, P. et al. Influence of the microbiome metagenomics and epigenomics on gastric cancer. Int. J. Mol. Sci. 23, 13750 (2022).","DOI":"10.3390\/ijms232213750"},{"key":"2197_CR368","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","volume":"65","author":"K Mima","year":"2016","unstructured":"Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973\u20131980 (2016).","journal-title":"Gut"},{"key":"2197_CR369","doi-asserted-by":"publisher","first-page":"e1009023","DOI":"10.1371\/journal.ppat.1009023","volume":"16","author":"D Nkosi","year":"2020","unstructured":"Nkosi, D., Sun, L., Duke, L. C. & Meckes, D. G. Jr. Epstein-Barr virus LMP1 manipulates the content and functions of extracellular vesicles to enhance metastatic potential of recipient cells. PLoS Pathog. 16, e1009023 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR370","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/0008-5472.CAN-09-4620","volume":"70","author":"A Shinozaki","year":"2010","unstructured":"Shinozaki, A. et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 70, 4719\u20134727 (2010).","journal-title":"Cancer Res."},{"key":"2197_CR371","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/jgh.13432","volume":"32","author":"CY Tsai","year":"2017","unstructured":"Tsai, C. Y. et al. Comprehensive profiling of virus microRNAs of Epstein-Barr virus-associated gastric carcinoma: highlighting the interactions of ebv-Bart9 and host tumor cells. J. Gastroenterol. Hepatol. 32, 82\u201391 (2017).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2197_CR372","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13304","volume":"55","author":"L Che","year":"2022","unstructured":"Che, L. et al. Intracellular antibody targeting HBx suppresses invasion and metastasis in hepatitis B virus-related hepatocarcinogenesis via protein phosphatase 2A-B56gamma-mediated dephosphorylation of protein kinase B. Cell Prolif. 55, e13304 (2022).","journal-title":"Cell Prolif."},{"key":"2197_CR373","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.canlet.2021.11.031","volume":"526","author":"Y Du","year":"2022","unstructured":"Du, Y. et al. Hypoxia-induced EBV-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP\/VHL\/HIF1alpha\/VEGFA pathway. Cancer Lett. 526, 259\u2013272 (2022).","journal-title":"Cancer Lett."},{"key":"2197_CR374","doi-asserted-by":"publisher","first-page":"16205","DOI":"10.1096\/fj.202001508R","volume":"34","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. EBV-miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1. FASEB J. 34, 16205\u201316223 (2020).","journal-title":"FASEB J."},{"key":"2197_CR375","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-015-0331-y","volume":"16","author":"Y Sunakawa","year":"2015","unstructured":"Sunakawa, Y. & Lenz, H. J. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr. Treat. Options Oncol. 16, 17 (2015).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2197_CR376","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07308-5","volume":"9","author":"T Xiang","year":"2018","unstructured":"Xiang, T. et al. Vasculogenic mimicry formation in EBV-associated epithelial malignancies. Nat. Commun. 9, 5009 (2018).","journal-title":"Nat. Commun."},{"key":"2197_CR377","doi-asserted-by":"publisher","first-page":"e29236","DOI":"10.1002\/jmv.29236","volume":"95","author":"E Akbari","year":"2023","unstructured":"Akbari, E., Milani, A., Seyedinkhorasani, M. & Bolhassani, A. HPV co-infections with other pathogens in cancer development: a comprehensive review. J. Med. Virol. 95, e29236 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR378","doi-asserted-by":"publisher","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"17","author":"KA Szymonowicz","year":"2020","unstructured":"Szymonowicz, K. A. & Chen, J. Biological and clinical aspects of HPV-related cancers. Cancer Biol. Med. 17, 864\u2013878 (2020).","journal-title":"Cancer Biol. Med."},{"key":"2197_CR379","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1541-7786.MCR-20-0491","volume":"19","author":"L Gutierrez-Xicotencatl","year":"2021","unstructured":"Gutierrez-Xicotencatl, L. et al. Cellular Functions of HPV16 E5 oncoprotein during oncogenic transformation. Mol. Cancer Res. 19, 167\u2013179 (2021).","journal-title":"Mol. Cancer Res."},{"key":"2197_CR380","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/med.21697","volume":"40","author":"A Kumar","year":"2020","unstructured":"Kumar, A., Rathi, E., Hariharapura, R. C. & Kini, S. G. Is viral E6 oncoprotein a viable target? A critical analysis in the context of cervical cancer. Med. Res. Rev. 40, 2019\u20132048 (2020).","journal-title":"Med. Res. Rev."},{"key":"2197_CR381","doi-asserted-by":"publisher","first-page":"200213","DOI":"10.1016\/j.tvr.2021.200213","volume":"11","author":"A Vats","year":"2021","unstructured":"Vats, A., Trejo-Cerro, O., Thomas, M. & Banks, L. Human papillomavirus E6 and E7: what remains? Tumour Virus Res. 11, 200213 (2021).","journal-title":"Tumour Virus Res."},{"key":"2197_CR382","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1038\/s41388-020-01431-8","volume":"39","author":"S Ren","year":"2020","unstructured":"Ren, S. et al. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers. Oncogene 39, 6327\u20136339 (2020).","journal-title":"Oncogene"},{"key":"2197_CR383","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12985-022-01899-8","volume":"19","author":"SO Wendel","year":"2022","unstructured":"Wendel, S. O. et al. HPV 16 E7 alters translesion synthesis signaling. Virol. J. 19, 165 (2022).","journal-title":"Virol. J."},{"key":"2197_CR384","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2021.200221","volume":"12","author":"S Lagstrom","year":"2021","unstructured":"Lagstrom, S. et al. HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples. Tumour Virus Res. 12, 200221 (2021).","journal-title":"Tumour Virus Res."},{"key":"2197_CR385","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41588-020-0673-7","volume":"52","author":"A Gagliardi","year":"2020","unstructured":"Gagliardi, A. et al. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat. Genet. 52, 800\u2013810 (2020).","journal-title":"Nat. Genet."},{"key":"2197_CR386","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler, K. & Banday, A. R. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J. Hematol. Oncol. 16, 31 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2197_CR387","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2020.10.004","volume":"496","author":"S Revathidevi","year":"2021","unstructured":"Revathidevi, S. et al. APOBEC: a molecular driver in cervical cancer pathogenesis. Cancer Lett. 496, 104\u2013116 (2021).","journal-title":"Cancer Lett."},{"key":"2197_CR388","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-17-2118","volume":"78","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. E6 protein expressed by high-risk HPV activates super-enhancers of the EGFR and c-MET oncogenes by destabilizing the histone demethylase KDM5C. Cancer Res. 78, 1418\u20131430 (2018).","journal-title":"Cancer Res."},{"key":"2197_CR389","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.semcancer.2021.05.031","volume":"86","author":"A Khan","year":"2022","unstructured":"Khan, A. et al. Insights into the role of complement regulatory proteins in HPV-mediated cervical carcinogenesis. Semin. Cancer Biol. 86, 583\u2013589 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2197_CR390","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45920-w","volume":"15","author":"JCK Wang","year":"2024","unstructured":"Wang, J. C. K. et al. Structure of the p53 degradation complex from HPV16. Nat. Commun. 15, 1842 (2024).","journal-title":"Nat. Commun."},{"key":"2197_CR391","doi-asserted-by":"publisher","first-page":"e1008295","DOI":"10.1371\/journal.ppat.1008295","volume":"16","author":"CM Drews","year":"2020","unstructured":"Drews, C. M., Brimer, N. & Vande Pol, S. B. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity. PLoS Pathog. 16, e1008295 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR392","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/s41418-020-0520-5","volume":"27","author":"SA Yi","year":"2020","unstructured":"Yi, S. A. et al. HPV-mediated nuclear export of HP1gamma drives cervical tumorigenesis by downregulation of p53. Cell Death Differ. 27, 2537\u20132551 (2020).","journal-title":"Cell Death Differ."},{"key":"2197_CR393","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.aab3291","volume":"350","author":"L Lau","year":"2015","unstructured":"Lau, L., Gray, E. E., Brunette, R. L. & Stetson, D. B. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 350, 568\u2013571 (2015).","journal-title":"Science"},{"key":"2197_CR394","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41588-023-01357-3","volume":"55","author":"SV Puram","year":"2023","unstructured":"Puram, S. V. et al. Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma. Nat. Genet. 55, 640\u2013650 (2023).","journal-title":"Nat. Genet."},{"key":"2197_CR395","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-23-0964","volume":"30","author":"PM Pifer","year":"2024","unstructured":"Pifer, P. M. et al. FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner. Clin. Cancer Res. 30, 187\u2013197 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR396","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.7150\/thno.78091","volume":"13","author":"D Bruyere","year":"2023","unstructured":"Bruyere, D. et al. Human papillomavirus E6\/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics 13, 1130\u20131149 (2023).","journal-title":"Theranostics"},{"key":"2197_CR397","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12985-018-1086-4","volume":"15","author":"DF Squarzanti","year":"2018","unstructured":"Squarzanti, D. F. et al. Human papillomavirus type 16 E6 and E7 oncoproteins interact with the nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium: new insights for the virus-induced DNA damage response. Virol. J. 15, 176 (2018).","journal-title":"Virol. J."},{"key":"2197_CR398","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41580-019-0206-3","volume":"21","author":"C Niehrs","year":"2020","unstructured":"Niehrs, C. & Luke, B. Regulatory R-loops as facilitators of gene expression and genome stability. Nat. Rev. Mol. Cell Biol. 21, 167\u2013178 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2197_CR399","doi-asserted-by":"publisher","first-page":"e2305907120","DOI":"10.1073\/pnas.2305907120","volume":"120","author":"CW Templeton","year":"2023","unstructured":"Templeton, C. W. & Laimins, L. A. p53-dependent R-loop formation and HPV pathogenesis. Proc. Natl. Acad. Sci. USA 120, e2305907120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR400","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.3390\/cancers14194623","volume":"14","author":"VL Porter","year":"2022","unstructured":"Porter, V. L. & Marra, M. A. The drivers, mechanisms, and consequences of genome instability in HPV-driven cancers. Cancers 14, 4623 (2022).","journal-title":"Cancers"},{"key":"2197_CR401","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00018-019-03070-z","volume":"76","author":"S Gao","year":"2019","unstructured":"Gao, S. et al. E2F1 mediates the downregulation of POLD1 in replicative senescence. Cell Mol. Life Sci. 76, 2833\u20132850 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"2197_CR402","doi-asserted-by":"publisher","first-page":"10115","DOI":"10.3390\/ijms221810115","volume":"22","author":"R Marima","year":"2021","unstructured":"Marima, R. et al. The catastrophic HPV\/HIV dual viral oncogenomics in concert with dysregulated alternative splicing in cervical cancer. Int. J. Mol. Sci. 22, 10115 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR403","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41568-022-00490-1","volume":"22","author":"J Gao","year":"2022","unstructured":"Gao, J. & Pickett, H. A. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies. Nat. Rev. Cancer. 22, 515\u2013532 (2022).","journal-title":"Nat. Rev. Cancer."},{"key":"2197_CR404","doi-asserted-by":"publisher","first-page":"216459","DOI":"10.1016\/j.canlet.2023.216459","volume":"578","author":"N Kumar","year":"2023","unstructured":"Kumar, N. & Sethi, G. Telomerase and hallmarks of cancer: An intricate interplay governing cancer cell evolution. Cancer Lett. 578, 216459 (2023).","journal-title":"Cancer Lett."},{"key":"2197_CR405","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00018-021-04113-0","volume":"79","author":"LN Wang","year":"2022","unstructured":"Wang, L. N. et al. The association of telomere maintenance and TERT expression with susceptibility to human papillomavirus infection in cervical epithelium. Cell Mol. Life Sci. 79, 110 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"2197_CR406","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01244-8","volume":"21","author":"R Yang","year":"2023","unstructured":"Yang, R. et al. Regulation and clinical potential of telomerase reverse transcriptase (TERT\/hTERT) in breast cancer. Cell Commun. Signal 21, 218 (2023).","journal-title":"Cell Commun. Signal"},{"key":"2197_CR407","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2019.02.024","volume":"449","author":"PA Vliet-Gregg","year":"2019","unstructured":"Vliet-Gregg, P. A. et al. NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells. Cancer Lett. 449, 106\u2013113 (2019).","journal-title":"Cancer Lett."},{"key":"2197_CR408","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.3390\/cancers14215257","volume":"14","author":"ML Tornesello","year":"2022","unstructured":"Tornesello, M. L. et al. The molecular interplay between human oncoviruses and telomerase in cancer development. Cancers 14, 5257 (2022).","journal-title":"Cancers"},{"key":"2197_CR409","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1038\/sj.onc.1207388","volume":"23","author":"AW Plug-DeMaggio","year":"2004","unstructured":"Plug-DeMaggio, A. W. et al. Telomere erosion and chromosomal instability in cells expressing the HPV oncogene 16E6. Oncogene 23, 3561\u20133571 (2004).","journal-title":"Oncogene"},{"key":"2197_CR410","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev-virology-111821-103452","volume":"10","author":"CJ Studstill","year":"2023","unstructured":"Studstill, C. J. & Moody, C. A. For better or worse: modulation of the host DNA damage response by human papillomavirus. Annu. Rev. Virol. 10, 325\u2013345 (2023).","journal-title":"Annu. Rev. Virol."},{"key":"2197_CR411","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/pathogens11091027","volume":"11","author":"J Skelin","year":"2022","unstructured":"Skelin, J., Sabol, I. & Tomaic, V. Do or Die: HPV E5, E6 and E7 in cell death evasion. Pathogens 11, 1027 (2022).","journal-title":"Pathogens"},{"key":"2197_CR412","doi-asserted-by":"publisher","first-page":"109716","DOI":"10.1016\/j.abb.2023.109716","volume":"745","author":"B Chen","year":"2023","unstructured":"Chen, B., Zhao, L., Yang, R. & Xu, T. Advances in molecular mechanism of HPV16 E5 oncoprotein carcinogenesis. Arch. Biochem. Biophys. 745, 109716 (2023).","journal-title":"Arch. Biochem. Biophys."},{"key":"2197_CR413","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112508","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi, S. et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 42, 112508 (2023).","journal-title":"Cell Rep."},{"key":"2197_CR414","doi-asserted-by":"publisher","first-page":"103923","DOI":"10.1016\/j.micpath.2019.103923","volume":"139","author":"NE Ilahi","year":"2020","unstructured":"Ilahi, N. E. & Bhatti, A. Impact of HPV E5 on viral life cycle via EGFR signaling. Microb. Pathog. 139, 103923 (2020).","journal-title":"Microb. Pathog."},{"key":"2197_CR415","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.micpath.2012.11.002","volume":"58","author":"CL Pang","year":"2013","unstructured":"Pang, C. L. & Thierry, F. Human papillomavirus proteins as prospective therapeutic targets. Microb. Pathog. 58, 55\u201365 (2013).","journal-title":"Microb. Pathog."},{"key":"2197_CR416","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-2-16","volume":"2","author":"C Perez-Plasencia","year":"2007","unstructured":"Perez-Plasencia, C. et al. Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways. Infect. Agent. Cancer. 2, 16 (2007).","journal-title":"Infect. Agent. Cancer."},{"key":"2197_CR417","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29132","volume":"95","author":"H Zhao","year":"2023","unstructured":"Zhao, H. et al. HPV16 infection promotes the malignant transformation of the esophagus and progression of esophageal squamous cell carcinoma. J. Med. Virol. 95, e29132 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR418","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1093\/nar\/gkz635","volume":"47","author":"S Uxa","year":"2019","unstructured":"Uxa, S. et al. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. Nucleic Acids Res. 47, 9087\u20139103 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2197_CR419","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/cancers13030489","volume":"13","author":"CD James","year":"2021","unstructured":"James, C. D. et al. Restoring the DREAM complex inhibits the proliferation of high-risk HPV-positive human cells. Cancers 13, 489 (2021).","journal-title":"Cancers"},{"key":"2197_CR420","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1038\/onc.2013.426","volume":"33","author":"CL Pang","year":"2014","unstructured":"Pang, C. L. et al. A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c). Oncogene 33, 4039\u20134049 (2014).","journal-title":"Oncogene"},{"key":"2197_CR421","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02831-9","volume":"7","author":"M Fischer","year":"2017","unstructured":"Fischer, M. et al. Human papillomavirus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci. Rep. 7, 2603 (2017).","journal-title":"Sci. Rep."},{"key":"2197_CR422","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/microorganisms10051047","volume":"10","author":"A Perez-Gonzalez","year":"2022","unstructured":"Perez-Gonzalez, A., Cachay, E., Ocampo, A. & Poveda, E. Update on the epidemiological features and clinical implications of human papillomavirus infection (HPV) and human immunodeficiency virus (HIV) coinfection. Microorganisms 10, 1047 (2022).","journal-title":"Microorganisms"},{"key":"2197_CR423","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-020-00295-7","volume":"15","author":"S Tavakolian","year":"2020","unstructured":"Tavakolian, S., Goudarzi, H. & Faghihloo, E. Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers. Infect. Agent. Cancer. 15, 27 (2020).","journal-title":"Infect. Agent. Cancer."},{"key":"2197_CR424","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29, 946\u2013960 (2022).","journal-title":"Cell Death Differ."},{"key":"2197_CR425","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.3390\/ijms23105623","volume":"23","author":"AY Kwon","year":"2022","unstructured":"Kwon, A. Y. et al. miR-22-3p and miR-30e-5p are associated with prognosis in cervical squamous cell carcinoma. Int. J. Mol. Sci. 23, 5623 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR426","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01872-22","volume":"97","author":"S Li","year":"2023","unstructured":"Li, S. et al. E6-encoded by cancer-causing human papillomavirus interacts with aurora kinase a to promote HPV-mediated carcinogenesis. J. Virol. 97, e0187222 (2023).","journal-title":"J. Virol."},{"key":"2197_CR427","doi-asserted-by":"publisher","first-page":"e1011171","DOI":"10.1371\/journal.ppat.1011171","volume":"19","author":"MI Khalil","year":"2023","unstructured":"Khalil, M. I. et al. HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer. PLoS Pathog. 19, e1011171 (2023).","journal-title":"PLoS Pathog."},{"key":"2197_CR428","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03476-3","volume":"12","author":"E Cararo-Lopes","year":"2021","unstructured":"Cararo-Lopes, E. et al. Autophagy buffers Ras-induced genotoxic stress enabling malignant transformation in keratinocytes primed by human papillomavirus. Cell Death Dis 12, 194 (2021).","journal-title":"Cell Death Dis"},{"key":"2197_CR429","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21249-5","volume":"8","author":"VM Dan","year":"2018","unstructured":"Dan, V. M. et al. Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines. Sci. Rep. 8, 2810 (2018).","journal-title":"Sci. Rep."},{"key":"2197_CR430","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2463-7","volume":"11","author":"S Iyer","year":"2020","unstructured":"Iyer, S. et al. Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target. Cell Death Dis. 11, 268 (2020).","journal-title":"Cell Death Dis."},{"key":"2197_CR431","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1080\/15548627.2020.1847444","volume":"17","author":"M Antonioli","year":"2021","unstructured":"Antonioli, M. et al. HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. Autophagy 17, 2842\u20132855 (2021).","journal-title":"Autophagy"},{"key":"2197_CR432","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/v16020193","volume":"16","author":"A Zhitkevich","year":"2024","unstructured":"Zhitkevich, A. et al. HIV-1 reverse transcriptase expression in HPV16-infected epidermoid carcinoma cells alters E6 expression and cellular metabolism, and induces a hybrid epithelial\/mesenchymal cell phenotype. Viruses 16, 193 (2024).","journal-title":"Viruses"},{"key":"2197_CR433","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","volume":"10","author":"C Ding","year":"2020","unstructured":"Ding, C. et al. Small molecules targeting the innate immune cGAS\u2012STING\u2012TBK1 signaling pathway. Acta Pharm. Sin B 10, 2272\u20132298 (2020).","journal-title":"Acta Pharm. Sin B"},{"key":"2197_CR434","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1172\/JCI129497","volume":"130","author":"X Luo","year":"2020","unstructured":"Luo, X. et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J. Clin. Invest. 130, 1635\u20131652 (2020).","journal-title":"J. Clin. Invest."},{"key":"2197_CR435","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01875-21","volume":"96","author":"J Poirson","year":"2022","unstructured":"Poirson, J. et al. High-risk mucosal human papillomavirus 16 (HPV16) E6 protein and cutaneous HPV5 and HPV8 E6 proteins employ distinct strategies to interfere with interferon regulatory factor 3-mediated beta interferon expression. J. Virol. 96, e0187521 (2022).","journal-title":"J. Virol."},{"key":"2197_CR436","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","volume":"11","author":"AA Shamseddine","year":"2021","unstructured":"Shamseddine, A. A. et al. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 11, 1896\u20131912 (2021).","journal-title":"Cancer Discov."},{"key":"2197_CR437","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semcancer.2022.11.010","volume":"87","author":"M Israr","year":"2022","unstructured":"Israr, M., DeVoti, J. A., Papayannakos, C. J. & Bonagura, V. R. Role of chemokines in HPV-induced cancers. Semin. Cancer Biol. 87, 170\u2013183 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2197_CR438","doi-asserted-by":"publisher","first-page":"e1008206","DOI":"10.1371\/journal.ppat.1008206","volume":"16","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment. PLoS Pathog. 16, e1008206 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR439","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel, T. R., Lill, J. K. & Altenburger, L. M. How chemokines organize the tumour microenvironment. Nat. Rev. Cancer 24, 28\u201350 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2197_CR440","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/v9090245","volume":"9","author":"SV Graham","year":"2017","unstructured":"Graham, S. V. Keratinocyte differentiation-dependent human papillomavirus gene regulation. Viruses 9, 245 (2017).","journal-title":"Viruses"},{"key":"2197_CR441","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41388-023-02912-2","volume":"43","author":"X Luo","year":"2024","unstructured":"Luo, X. et al. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway. Oncogene 43, 388\u2013394 (2024).","journal-title":"Oncogene"},{"key":"2197_CR442","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/biology13020077","volume":"13","author":"P Rosendo-Chalma","year":"2024","unstructured":"Rosendo-Chalma, P. et al. The hallmarks of cervical cancer: molecular mechanisms induced by human papillomavirus. Biology 13, 77 (2024).","journal-title":"Biology"},{"key":"2197_CR443","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2022.03.005","volume":"86","author":"M Kyrgiou","year":"2022","unstructured":"Kyrgiou, M. & Moscicki, A. B. Vaginal microbiome and cervical cancer. Semin Cancer Biol. 86, 189\u2013198 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2197_CR444","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70027","volume":"96","author":"M Logel","year":"2024","unstructured":"Logel, M. et al. A narrative review of the putative etiologic role and diagnostic utility of the cervicovaginal microbiome in human papillomavirus-associated cervical carcinogenesis. J. Med. Virol. 96, e70027 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR445","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1002\/jmv.28001","volume":"94","author":"B Dong","year":"2022","unstructured":"Dong, B. et al. Prevotella as the hub of the cervicovaginal microbiota affects the occurrence of persistent human papillomavirus infection and cervical lesions in women of childbearing age via host NF-\u03baB\/C-myc. J. Med. Virol. 94, 5519\u20135534 (2022).","journal-title":"J. Med. Virol."},{"key":"2197_CR446","doi-asserted-by":"crossref","unstructured":"Nicol\u00f2, S. et al. Bacterial species from vaginal microbiota differently affect the production of the E6 and E7 oncoproteins and of p53 and p-Rb oncosuppressors in HPV16-infected cells. Int. J. Mol. Sci. 24, (2023).","DOI":"10.3390\/ijms24087173"},{"key":"2197_CR447","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0126-x","volume":"4","author":"P \u0141aniewski","year":"2020","unstructured":"\u0141aniewski, P. et al. Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. NPJ. Precis. Oncol. 4, 22 (2020).","journal-title":"NPJ. Precis. Oncol."},{"key":"2197_CR448","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.CAN-19-1771","volume":"80","author":"S Miyauchi","year":"2020","unstructured":"Miyauchi, S. et al. HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res. 80, 732\u2013746 (2020).","journal-title":"Cancer Res."},{"key":"2197_CR449","doi-asserted-by":"crossref","unstructured":"Santegoets, S. J. et al. CD163(+) cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J. Immunother Cancer 8, (2020).","DOI":"10.1136\/jitc-2020-001053"},{"key":"2197_CR450","doi-asserted-by":"publisher","first-page":"101262","DOI":"10.1016\/j.xcrm.2023.101262","volume":"4","author":"SJ Santegoets","year":"2023","unstructured":"Santegoets, S. J., Stolk, A., Welters, M. J. P. & van der Burg, S. H. The combined HPV16-E2\/E6\/E7 T cell response in oropharyngeal cancer predicts superior survival. Cell Rep. Med. 4, 101262 (2023).","journal-title":"Cell Rep. Med."},{"key":"2197_CR451","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41423-021-00756-y","volume":"19","author":"M Karin","year":"2022","unstructured":"Karin, M. & Shalapour, S. Regulation of antitumor immunity by inflammation-induced epigenetic alterations. Cell. Mol. Immunol. 19, 59\u201366 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"2197_CR452","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.apsb.2022.01.002","volume":"12","author":"Z Ju","year":"2022","unstructured":"Ju, Z. et al. Recent development on COX-2 inhibitors as promising anti-inflammatory agents: the past 10 years. Acta Pharm Sin B 12, 2790\u20132807 (2022).","journal-title":"Acta Pharm Sin B"},{"key":"2197_CR453","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.3390\/cells11162528","volume":"11","author":"J Garcia-Quiroz","year":"2022","unstructured":"Garcia-Quiroz, J. et al. The interaction of human papillomavirus infection and prostaglandin E(2) signaling in carcinogenesis: a focus on cervical cancer therapeutics. Cells 11, 2528 (2022).","journal-title":"Cells"},{"key":"2197_CR454","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cytogfr.2016.03.007","volume":"30","author":"G Mangino","year":"2016","unstructured":"Mangino, G. et al. Inflammatory microenvironment and human papillomavirus-induced carcinogenesis. Cytokine Growth Factor Rev. 30, 103\u2013111 (2016).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2197_CR455","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/ijms20010198","volume":"20","author":"TK Cabeca","year":"2019","unstructured":"Cabeca, T. K. et al. HPV-mediated resistance to TNF and TRAIL is characterized by global alterations in apoptosis regulatory factors, dysregulation of death receptors, and induction of ROS\/RNS. Int. J. Mol. Sci. 20, 198 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR456","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7150\/ijbs.21547","volume":"14","author":"A Cruz-Gregorio","year":"2018","unstructured":"Cruz-Gregorio, A. et al. Human papillomavirus types 16 and 18 early-expressed proteins differentially modulate the cellular redox state and DNA damage. Int. J. Biol. Sci. 14, 21\u201335 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR457","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.7150\/ijbs.38146","volume":"15","author":"H Li","year":"2019","unstructured":"Li, H. et al. HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. Int. J. Biol. Sci. 15, 2438\u20132447 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR458","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0980-8","volume":"18","author":"L Han","year":"2019","unstructured":"Han, L., Lam, E. W. & Sun, Y. Extracellular vesicles in the tumor microenvironment: old stories, but new tales. Mol. Cancer 18, 59 (2019).","journal-title":"Mol. Cancer"},{"key":"2197_CR459","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-020-01745-1","volume":"39","author":"JJ Qiu","year":"2020","unstructured":"Qiu, J. J. et al. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the beta-catenin signaling pathway. J. Exp. Clin. Cancer Res. 39, 260 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR460","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01494-0","volume":"22","author":"E Heydarnia","year":"2024","unstructured":"Heydarnia, E. et al. Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms. Cell Commun. Signal 22, 107 (2024).","journal-title":"Cell Commun. Signal"},{"key":"2197_CR461","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.3390\/ijms241310729","volume":"24","author":"A Sirico","year":"2023","unstructured":"Sirico, A. et al. BDNF and NGF expression in preneoplastic cervical disease according to HIV Status. Int. J. Mol. Sci. 24, 10729 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR462","doi-asserted-by":"publisher","first-page":"117519","DOI":"10.1016\/j.biopha.2024.117519","volume":"180","author":"Y Tian","year":"2024","unstructured":"Tian, Y., Zhang, S. & Ni, F. Targeting glucose metabolism for HPV-associated cervical cancer: a sweet poison. Biomed. Pharmacother. 180, 117519 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"2197_CR463","doi-asserted-by":"crossref","unstructured":"Priego-Hernandez, V. D. et al. Expression of HIF-1alpha and genes involved in glucose metabolism is increased in cervical cancer and HPV-16-positive cell lines. Pathogens. 12, 33 (2022).","DOI":"10.3390\/pathogens12010033"},{"key":"2197_CR464","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1073\/pnas.96.4.1291","volume":"96","author":"W Zwerschke","year":"1999","unstructured":"Zwerschke, W. et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 96, 1291\u20131296 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR465","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/ijbs.67770","volume":"18","author":"C Hu","year":"2022","unstructured":"Hu, C. et al. HPV E6\/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m(6)A-MYC expression. Int. J. Biol. Sci. 18, 507\u2013521 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR466","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118236","volume":"258","author":"V Chandel","year":"2020","unstructured":"Chandel, V. et al. Metabolic regulation in HPV-associated head and neck squamous cell carcinoma. Life Sci. 258, 118236 (2020).","journal-title":"Life Sci."},{"key":"2197_CR467","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/microorganisms12010014","volume":"12","author":"T Yoshizaki","year":"2023","unstructured":"Yoshizaki, T. et al. Recent advances in assessing the clinical implications of Epstein-Barr virus infection and their application to the diagnosis and treatment of nasopharyngeal carcinoma. Microorganisms 12, 14 (2023).","journal-title":"Microorganisms"},{"key":"2197_CR468","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1202117","volume":"13","author":"YH Low","year":"2023","unstructured":"Low, Y. H. et al. Pathogenesis and therapeutic implications of EBV-associated epithelial cancers. Front. Oncol. 13, 1202117 (2023).","journal-title":"Front. Oncol."},{"key":"2197_CR469","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","volume":"22","author":"CW Dawson","year":"2012","unstructured":"Dawson, C. W., Port, R. J. & Young, L. S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin. Cancer Biol. 22, 144\u2013153 (2012).","journal-title":"Semin. Cancer Biol."},{"key":"2197_CR470","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein-Barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"2197_CR471","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2445","volume":"8","author":"JK Tay","year":"2022","unstructured":"Tay, J. K. et al. The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-kappaB signaling. Sci. Adv. 8, eabh2445 (2022).","journal-title":"Sci. Adv."},{"key":"2197_CR472","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2016.05.032","volume":"380","author":"J Lu","year":"2016","unstructured":"Lu, J. et al. EBV-LMP1 suppresses the DNA damage response through DNA-PK\/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. Cancer Lett. 380, 191\u2013200 (2016).","journal-title":"Cancer Lett."},{"key":"2197_CR473","doi-asserted-by":"publisher","first-page":"14144","DOI":"10.1073\/pnas.1821752116","volume":"116","author":"MML Leong","year":"2019","unstructured":"Leong, M. M. L. et al. EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells. Proc. Natl. Acad. Sci. USA 116, 14144\u201314153 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR474","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41586-023-05923-x","volume":"616","author":"JSZ Li","year":"2023","unstructured":"Li, J. S. Z. et al. Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. Nature 616, 504\u2013509 (2023).","journal-title":"Nature"},{"key":"2197_CR475","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/JVI.05648-11","volume":"86","author":"JY Cao","year":"2012","unstructured":"Cao, J. Y., Mansouri, S. & Frappier, L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. J. Virol. 86, 382\u2013394 (2012).","journal-title":"J. Virol."},{"key":"2197_CR476","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03156-3","volume":"7","author":"K Wang","year":"2017","unstructured":"Wang, K. et al. Epstein-Barr virus-induced up-regulation of TCAB1 is involved in the DNA damage response in nasopharyngeal carcinoma. Sci. Rep. 7, 3218 (2017).","journal-title":"Sci. Rep."},{"key":"2197_CR477","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12929-020-00699-y","volume":"28","author":"SH Chen","year":"2021","unstructured":"Chen, S. H. et al. O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma. J. Biomed. Sci. 28, 2 (2021).","journal-title":"J. Biomed. Sci."},{"key":"2197_CR478","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/path.4239","volume":"231","author":"GT Chung","year":"2013","unstructured":"Chung, G. T. et al. Constitutive activation of distinct NF-kappaB signals in EBV-associated nasopharyngeal carcinoma. J. Pathol. 231, 311\u2013322 (2013).","journal-title":"J. Pathol."},{"key":"2197_CR479","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24348-6","volume":"12","author":"JP Bruce","year":"2021","unstructured":"Bruce, J. P. et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-kappaB activation and immune escape. Nat. Commun. 12, 4193 (2021).","journal-title":"Nat. Commun."},{"key":"2197_CR480","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1128\/JVI.00125-08","volume":"82","author":"CP Kung","year":"2008","unstructured":"Kung, C. P. & Raab-Traub, N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J. Virol. 82, 5486\u20135493 (2008).","journal-title":"J. Virol."},{"key":"2197_CR481","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.4245","volume":"231","author":"RJ Port","year":"2013","unstructured":"Port, R. J. et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J. Pathol. 231, 367\u2013377 (2013).","journal-title":"J. Pathol."},{"key":"2197_CR482","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2019.01.022","volume":"447","author":"YJ Xu","year":"2019","unstructured":"Xu, Y. J. et al. Epstein-Barr virus-coded miR-BART13 promotes nasopharyngeal carcinoma cell growth and metastasis via targeting of the NKIRAS2\/NF-kappaB pathway. Cancer Lett. 447, 33\u201340 (2019).","journal-title":"Cancer Lett."},{"key":"2197_CR483","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2060-9","volume":"10","author":"S Mai","year":"2019","unstructured":"Mai, S. et al. MicroRNA-18a promotes cancer progression through SMG1 suppression and mTOR pathway activation in nasopharyngeal carcinoma. Cell Death Dis. 10, 819 (2019).","journal-title":"Cell Death Dis."},{"key":"2197_CR484","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00430-018-0570-1","volume":"208","author":"H Yin","year":"2019","unstructured":"Yin, H., Qu, J., Peng, Q. & Gan, R. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med. Microbiol. Immunol. 208, 573\u2013583 (2019).","journal-title":"Med. Microbiol. Immunol."},{"key":"2197_CR485","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/bab.1856","volume":"67","author":"Y Ren","year":"2020","unstructured":"Ren, Y. et al. Viral IL-10 promotes cell proliferation and cell cycle progression via JAK2\/STAT3 signaling pathway in nasopharyngeal carcinoma cells. Biotechnol. Appl. Biochem. 67, 929\u2013938 (2020).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"2197_CR486","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.omtn.2020.09.021","volume":"22","author":"Z Tang","year":"2020","unstructured":"Tang, Z. et al. miR-4721, induced by EBV-miR-BART22, targets GSK3beta to enhance the tumorigenic capacity of NPC through the WNT\/beta-catenin pathway. Mol. Ther. Nucleic Acids 22, 557\u2013571 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2197_CR487","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00153-8","volume":"5","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. NPJ Precis. Oncol. 5, 14 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"2197_CR488","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1128\/JVI.02662-13","volume":"88","author":"AR Marquitz","year":"2014","unstructured":"Marquitz, A. R. et al. Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J. Virol. 88, 1389\u20131393 (2014).","journal-title":"J. Virol."},{"key":"2197_CR489","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1044579X02000901","volume":"12","author":"SW Tsao","year":"2002","unstructured":"Tsao, S. W. et al. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 473\u2013487 (2002).","journal-title":"Semin. Cancer Biol."},{"key":"2197_CR490","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.7150\/thno.30941","volume":"9","author":"F Shi","year":"2019","unstructured":"Shi, F. et al. EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. Theranostics 9, 2424\u20132438 (2019).","journal-title":"Theranostics"},{"key":"2197_CR491","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41418-022-00939-8","volume":"29","author":"L Yuan","year":"2022","unstructured":"Yuan, L. et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 29, 1513\u20131527 (2022).","journal-title":"Cell Death Differ."},{"key":"2197_CR492","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02995-7","volume":"23","author":"G Feng","year":"2023","unstructured":"Feng, G. et al. Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K\/Akt\/mTOR pathway. Cancer Cell Int. 23, 185 (2023).","journal-title":"Cancer Cell Int."},{"key":"2197_CR493","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.bbadis.2019.01.015","volume":"1865","author":"S Cheng","year":"2019","unstructured":"Cheng, S. et al. Epstein-Barr virus noncoding RNAs from the extracellular vesicles of nasopharyngeal carcinoma (NPC) cells promote angiogenesis via TLR3\/RIG-I-mediated VCAM-1 expression. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1201\u20131213 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2197_CR494","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13046-023-02835-6","volume":"42","author":"C Liao","year":"2023","unstructured":"Liao, C. et al. Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1alpha promotes invasion and metastasis of nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 42, 261 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR495","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-20-4321","volume":"81","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Cancer Res. 81, 5074\u20135088 (2021).","journal-title":"Cancer Res."},{"key":"2197_CR496","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104357","volume":"86","author":"L Ka-Yue Chow","year":"2022","unstructured":"Ka-Yue Chow, L. et al. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma. EBioMedicine 86, 104357 (2022).","journal-title":"EBioMedicine"},{"key":"2197_CR497","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04112-8","volume":"21","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma. J. Transl. Med. 21, 278 (2023).","journal-title":"J. Transl. Med."},{"key":"2197_CR498","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/2326-6066.CIR-22-0374","volume":"11","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. EBV-upregulated B7-H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. Cancer Immunol. Res. 11, 830\u2013846 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2197_CR499","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/thno.29622","volume":"9","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus-associated malignancies. Theranostics 9, 1115\u20131124 (2019).","journal-title":"Theranostics"},{"key":"2197_CR500","doi-asserted-by":"publisher","first-page":"e1011934","DOI":"10.1371\/journal.ppat.1011934","volume":"20","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation. PLoS Pathog. 20, e1011934 (2024).","journal-title":"PLoS Pathog."},{"key":"2197_CR501","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02925-9","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization. Cell Death Dis. 11, 742 (2020).","journal-title":"Cell Death Dis."},{"key":"2197_CR502","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/cells9051158","volume":"9","author":"S Song","year":"2020","unstructured":"Song, S. et al. BHRF1 Enhances EBV-mediated nasopharyngeal carcinoma tumorigenesis through modulating mitophagy associated with mitochondrial membrane permeabilization transition. Cells 9, 1158 (2020).","journal-title":"Cells"},{"key":"2197_CR503","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01288-1","volume":"20","author":"X Wei","year":"2021","unstructured":"Wei, X. et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol. Cancer 20, 7 (2021).","journal-title":"Mol. Cancer"},{"key":"2197_CR504","doi-asserted-by":"publisher","first-page":"e1009873","DOI":"10.1371\/journal.ppat.1009873","volume":"17","author":"N Zhu","year":"2021","unstructured":"Zhu, N. et al. EBV latent membrane proteins promote hybrid epithelial-mesenchymal and extreme mesenchymal states of nasopharyngeal carcinoma cells for tumorigenicity. PLoS Pathog. 17, e1009873 (2021).","journal-title":"PLoS Pathog."},{"key":"2197_CR505","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/path.6036","volume":"259","author":"WC Tang","year":"2023","unstructured":"Tang, W. C. et al. Latent membrane protein 1 and macrophage-derived TNFalpha synergistically activate and mobilize invadopodia to drive invasion of nasopharyngeal carcinoma. J. Pathol. 259, 163\u2013179 (2023).","journal-title":"J. Pathol."},{"key":"2197_CR506","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41417-022-00453-6","volume":"29","author":"DK Li","year":"2022","unstructured":"Li, D. K. et al. Exosomal HMGA2 protein from EBV-positive NPC cells destroys vascular endothelial barriers and induces endothelial-to-mesenchymal transition to promote metastasis. Cancer Gene. Ther. 29, 1439\u20131451 (2022).","journal-title":"Cancer Gene. Ther."},{"key":"2197_CR507","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yexcr.2017.08.005","volume":"359","author":"WW Sung","year":"2017","unstructured":"Sung, W. W., Chen, P. R., Liao, M. H. & Lee, J. W. Enhanced aerobic glycolysis of nasopharyngeal carcinoma cells by Epstein-Barr virus latent membrane protein 1. Exp. Cell Res. 359, 94\u2013100 (2017).","journal-title":"Exp. Cell Res."},{"key":"2197_CR508","doi-asserted-by":"publisher","first-page":"e02168","DOI":"10.1128\/JVI.02168-16","volume":"91","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. Epstein-Barr virus-encoded latent membrane protein 1 upregulates glucose transporter 1 transcription via the mTORC1\/NF-kappaB signaling pathways. J. Virol. 91, e02168\u201302116 (2017).","journal-title":"J. Virol."},{"key":"2197_CR509","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/onc.2014.32","volume":"33","author":"L Xiao","year":"2014","unstructured":"Xiao, L. et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene 33, 4568\u20134578 (2014).","journal-title":"Oncogene"},{"key":"2197_CR510","doi-asserted-by":"publisher","first-page":"e1007484","DOI":"10.1371\/journal.ppat.1007484","volume":"14","author":"X Lyu","year":"2018","unstructured":"Lyu, X. et al. EBV-miR-BART1-5P activates AMPK\/mTOR\/HIF1 pathway via a PTEN-independent manner to promote glycolysis and angiogenesis in nasopharyngeal carcinoma. PLoS Pathog. 14, e1007484 (2018).","journal-title":"PLoS Pathog."},{"key":"2197_CR511","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/path.4575","volume":"237","author":"AK Lo","year":"2015","unstructured":"Lo, A. K. et al. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. J. Pathol. 237, 238\u2013248 (2015).","journal-title":"J. Pathol."},{"key":"2197_CR512","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/v12080811","volume":"12","author":"G Krishna","year":"2020","unstructured":"Krishna, G., Soman Pillai, V. & Valiya Veettil, M. Upregulation of GLS1 isoforms KGA and GAC facilitates mitochondrial metabolism and cell proliferation in Epstein-Barr virus-infected cells. Viruses 12, 811 (2020).","journal-title":"Viruses"},{"key":"2197_CR513","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1158\/0008-5472.CAN-20-3121","volume":"81","author":"SC Liu","year":"2021","unstructured":"Liu, S. C. et al. Epstein-Barr virus induces adipocyte dedifferentiation to modulate the tumor microenvironment. Cancer Res. 81, 3283\u20133294 (2021).","journal-title":"Cancer Res."},{"key":"2197_CR514","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.molmed.2022.12.003","volume":"29","author":"J Naipauer","year":"2023","unstructured":"Naipauer, J. & Mesri, E. A. The Kaposi\u2019s sarcoma progenitor enigma: KSHV-induced MEndT-EndMT axis. Trends Mol. Med. 29, 188\u2013200 (2023).","journal-title":"Trends Mol. Med."},{"key":"2197_CR515","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12250-019-00114-3","volume":"34","author":"L Yan","year":"2019","unstructured":"Yan, L., Majerciak, V., Zheng, Z. M. & Lan, K. Towards better understanding of KSHV life cycle: from transcription and posttranscriptional regulations to pathogenesis. Virol. Sin. 34, 135\u2013161 (2019).","journal-title":"Virol. Sin."},{"key":"2197_CR516","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1038\/s41388-019-0726-5","volume":"38","author":"R Nakayama","year":"2019","unstructured":"Nakayama, R., Ueno, Y., Ueda, K. & Honda, T. Latent infection with Kaposi\u2019s sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1. Oncogene 38, 4340\u20134351 (2019).","journal-title":"Oncogene"},{"key":"2197_CR517","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29534","volume":"96","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response. J. Med. Virol. 96, e29534 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR518","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00281-020-00787-z","volume":"42","author":"J Frohlich","year":"2020","unstructured":"Frohlich, J. & Grundhoff, A. Epigenetic control in Kaposi sarcoma-associated herpesvirus infection and associated disease. Semin. Immunopathol. 42, 143\u2013157 (2020).","journal-title":"Semin. Immunopathol."},{"key":"2197_CR519","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41580-020-0234-z","volume":"21","author":"CM Roake","year":"2020","unstructured":"Roake, C. M. & Artandi, S. E. Regulation of human telomerase in homeostasis and disease. Nat. Rev. Mol. Cell Biol. 21, 384\u2013397 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2197_CR520","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20819-4","volume":"12","author":"TP Lippert","year":"2021","unstructured":"Lippert, T. P. et al. Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeres. Nat. Commun. 12, 512 (2021).","journal-title":"Nat. Commun."},{"key":"2197_CR521","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1172\/JCI127166","volume":"129","author":"T Li","year":"2019","unstructured":"Li, T., Ju, E. & Gao, S. J. Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis. J. Clin. Invest. 129, 3310\u20133323 (2019).","journal-title":"J. Clin. Invest."},{"key":"2197_CR522","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28676","volume":"95","author":"T Li","year":"2023","unstructured":"Li, T. & Gao, S. J. KSHV hijacks FoxO1 to promote cell proliferation and cellular transformation by antagonizing oxidative stress. J. Med. Virol. 95, e28676 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR523","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06193-1","volume":"14","author":"XJ Wu","year":"2023","unstructured":"Wu, X. J. et al. Kaposi\u2019s sarcoma-associated herpesvirus viral protein kinase augments cell survival. Cell Death Dis. 14, 688 (2023).","journal-title":"Cell Death Dis."},{"key":"2197_CR524","doi-asserted-by":"publisher","first-page":"e1008730","DOI":"10.1371\/journal.ppat.1008730","volume":"16","author":"W Li","year":"2020","unstructured":"Li, W. et al. Sperm associated antigen 9 promotes oncogenic KSHV-encoded interferon regulatory factor-induced cellular transformation and angiogenesis by activating the JNK\/VEGFA pathway. PLoS Pathog. 16, e1008730 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR525","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011385","volume":"19","author":"LN Moore","year":"2023","unstructured":"Moore, L. N. et al. Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus-induced intrinsic apoptosis. PLoS Pathog. 19, e1011385 (2023).","journal-title":"PLoS Pathog."},{"key":"2197_CR526","doi-asserted-by":"publisher","first-page":"e1006639","DOI":"10.1371\/journal.ppat.1006639","volume":"13","author":"B Abere","year":"2017","unstructured":"Abere, B. et al. The Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target. PLoS Pathog. 13, e1006639 (2017).","journal-title":"PLoS Pathog."},{"key":"2197_CR527","doi-asserted-by":"publisher","first-page":"9389","DOI":"10.1093\/nar\/gkab689","volume":"49","author":"D Bhowmik","year":"2021","unstructured":"Bhowmik, D. et al. Cooperative DNA binding mediated by KicGAS\/ORF52 oligomerization allows inhibition of DNA-induced phase separation and activation of cGAS. Nucleic Acids Res. 49, 9389\u20139403 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2197_CR528","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101652","volume":"60","author":"C Munz","year":"2022","unstructured":"Munz, C. Natural killer cell responses to human oncogenic gamma-herpesvirus infections. Semin. Immunol. 60, 101652 (2022).","journal-title":"Semin. Immunol."},{"key":"2197_CR529","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108249","volume":"33","author":"I Gabaev","year":"2020","unstructured":"Gabaev, I. et al. Quantitative proteomics analysis of lytic KSHV infection in human endothelial cells reveals targets of viral immune modulation. Cell Rep. 33, 108249 (2020).","journal-title":"Cell Rep."},{"key":"2197_CR530","doi-asserted-by":"publisher","first-page":"102230","DOI":"10.1016\/j.coi.2022.102230","volume":"77","author":"A Nalwoga","year":"2022","unstructured":"Nalwoga, A. & Whitby, D. Adaptive immune responses to Kaposi\u2019s sarcoma-associated herpesvirus. Curr. Opin. Immunol. 77, 102230 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"2197_CR531","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41416-020-0872-0","volume":"123","author":"MS Gilardini Montani","year":"2020","unstructured":"Gilardini Montani, M. S. et al. KSHV infection skews macrophage polarisation towards M2-like\/TAM and activates Ire1 alpha-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression. Br. J. Cancer 123, 298\u2013306 (2020).","journal-title":"Br. J. Cancer"},{"key":"2197_CR532","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00022-23","volume":"37","author":"KA Lurain","year":"2024","unstructured":"Lurain, K. A. et al. HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus. Clin. Microbiol. Rev. 37, e0002223 (2024).","journal-title":"Clin. Microbiol. Rev."},{"key":"2197_CR533","doi-asserted-by":"crossref","unstructured":"Lucena Lage, S. et al. Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders. Blood. 144, 1496\u20131507 (2024).","DOI":"10.1182\/blood.2024024144"},{"key":"2197_CR534","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1158\/0008-5472.CAN-17-2321","volume":"77","author":"M Gruffaz","year":"2017","unstructured":"Gruffaz, M. et al. TLR4-mediated inflammation promotes KSHV-induced cellular transformation and tumorigenesis by activating the STAT3 pathway. Cancer Res. 77, 7094\u20137108 (2017).","journal-title":"Cancer Res."},{"key":"2197_CR535","doi-asserted-by":"publisher","first-page":"e1011771","DOI":"10.1371\/journal.ppat.1011771","volume":"19","author":"T Inagaki","year":"2023","unstructured":"Inagaki, T. et al. KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming. PLoS Pathog. 19, e1011771 (2023).","journal-title":"PLoS Pathog."},{"key":"2197_CR536","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41590-022-01199-x","volume":"23","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. KSHV-encoded ORF45 activates human NLRP1 inflammasome. Nat. Immunol. 23, 916\u2013926 (2022).","journal-title":"Nat. Immunol."},{"key":"2197_CR537","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04517-5","volume":"21","author":"R Ramaswami","year":"2023","unstructured":"Ramaswami, R. et al. Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis. J. Transl. Med. 21, 653 (2023).","journal-title":"J. Transl. Med."},{"key":"2197_CR538","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.freeradbiomed.2022.05.016","volume":"187","author":"MT Bayo Jimenez","year":"2022","unstructured":"Bayo Jimenez, M. T. et al. Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. Free Radic. Biol. Med. 187, 72\u201391 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"2197_CR539","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2493","volume":"34","author":"S Tavakolian","year":"2024","unstructured":"Tavakolian, S. et al. Role of the VEGF in virus-associated cancers. Rev. Med. Virol. 34, e2493 (2024).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR540","doi-asserted-by":"publisher","first-page":"e29071","DOI":"10.1002\/jmv.29071","volume":"95","author":"DA Davis","year":"2023","unstructured":"Davis, D. A., Shrestha, P. & Yarchoan, R. Hypoxia and hypoxia-inducible factors in Kaposi sarcoma-associated herpesvirus infection and disease pathogenesis. J. Med. Virol. 95, e29071 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR541","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chom.2024.03.012","volume":"32","author":"SH Sin","year":"2024","unstructured":"Sin, S. H. et al. The complete Kaposi sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice. Cell Host Microbe 32, 755\u2013767.e754 (2024).","journal-title":"Cell Host Microbe"},{"key":"2197_CR542","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1038\/s41418-020-0578-0","volume":"27","author":"W Li","year":"2020","unstructured":"Li, W. et al. An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82. Cell Death Differ. 27, 3289\u20133306 (2020).","journal-title":"Cell Death Differ."},{"key":"2197_CR543","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1038\/s41388-020-1317-1","volume":"39","author":"W Li","year":"2020","unstructured":"Li, W. et al. Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1. Oncogene 39, 4603\u20134618 (2020).","journal-title":"Oncogene"},{"key":"2197_CR544","doi-asserted-by":"publisher","first-page":"e1009006","DOI":"10.1371\/journal.ppat.1009006","volume":"16","author":"MV Medina","year":"2020","unstructured":"Medina, M. V. et al. KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi\u2019s sarcoma. PLoS Pathog. 16, e1009006 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR545","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2530","volume":"34","author":"MJ Kamali","year":"2024","unstructured":"Kamali, M. J. et al. Hijacking and rewiring of host CircRNA\/miRNA\/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers. Rev. Med. Virol. 34, e2530 (2024).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR546","doi-asserted-by":"crossref","unstructured":"Markazi, A., Bracci, P. M., McGrath, M. & Gao, S. J. Pseudomonas aeruginosa stimulates inflammation and enhances Kaposi\u2019s sarcoma herpesvirus-induced cell proliferation and cellular transformation through both lipopolysaccharide and flagellin. mBio. 11, e02843 (2020).","DOI":"10.1128\/mBio.02843-20"},{"key":"2197_CR547","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00003-21","volume":"95","author":"X Kong","year":"2021","unstructured":"Kong, X. et al. Bone marrow-derived SH-SY5Y neuroblastoma cells infected with Kaposi\u2019s sarcoma-associated herpesvirus display unique infection phenotypes and growth properties. J. Virol. 95, e0000321 (2021).","journal-title":"J. Virol."},{"key":"2197_CR548","doi-asserted-by":"crossref","unstructured":"Valiya Veettil, M. et al. Kaposi\u2019s sarcoma-associated herpesvirus infection induces the expression of neuroendocrine genes in endothelial cells. J. Virol. 94, e01692 (2020).","DOI":"10.1128\/JVI.01692-19"},{"key":"2197_CR549","doi-asserted-by":"publisher","first-page":"9362","DOI":"10.1093\/nar\/gkv988","volume":"43","author":"S Yao","year":"2015","unstructured":"Yao, S. et al. MiRNA-891a-5p mediates HIV-1 Tat and KSHV Orf-K1 synergistic induction of angiogenesis by activating NF-kappaB signaling. Nucleic Acids Res. 43, 9362\u20139378 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2197_CR550","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13578-021-00688-0","volume":"11","author":"T Li","year":"2021","unstructured":"Li, T. & Gao, S. J. Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection. Cell Biosci. 11, 176 (2021).","journal-title":"Cell Biosci."},{"key":"2197_CR551","doi-asserted-by":"publisher","first-page":"e1007062","DOI":"10.1371\/journal.ppat.1007062","volume":"14","author":"RK Singh","year":"2018","unstructured":"Singh, R. K. et al. Metabolic reprogramming of Kaposi\u2019s sarcoma-associated herpes virus infected B-cells in hypoxia. PLoS Pathog. 14, e1007062 (2018).","journal-title":"PLoS Pathog."},{"key":"2197_CR552","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45852-5","volume":"15","author":"Q Wan","year":"2024","unstructured":"Wan, Q. et al. Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nat. Commun. 15, 1442 (2024).","journal-title":"Nat. Commun."},{"key":"2197_CR553","doi-asserted-by":"publisher","first-page":"8083","DOI":"10.1073\/pnas.1918607117","volume":"117","author":"UY Choi","year":"2020","unstructured":"Choi, U. Y. et al. Oncogenic human herpesvirus hijacks proline metabolism for tumorigenesis. Proc. Natl. Acad. Sci. USA 117, 8083\u20138093 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR554","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40170-023-00316-0","volume":"11","author":"SR Privatt","year":"2023","unstructured":"Privatt, S. R. et al. Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states. Cancer Metab. 11, 13 (2023).","journal-title":"Cancer Metab."},{"key":"2197_CR555","doi-asserted-by":"publisher","first-page":"e1008114","DOI":"10.1371\/journal.ppat.1008114","volume":"16","author":"M Gruffaz","year":"2020","unstructured":"Gruffaz, M. et al. Signatures of oral microbiome in HIV-infected individuals with oral Kaposi\u2019s sarcoma and cell-associated KSHV DNA. PLoS Pathog. 16, e1008114 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR556","first-page":"1331","volume":"221","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. Kaposi sarcoma-associated herpesvirus and staphylococcus aureus coinfection in oral cavities of HIV-positive patients: a unique niche for oncogenic virus lytic reactivation. J. Infect. Dis. 221, 1331\u20131341 (2020).","journal-title":"J. Infect. Dis."},{"key":"2197_CR557","first-page":"1226","volume":"221","author":"RF Little","year":"2020","unstructured":"Little, R. F. & Uldrick, T. S. Are there clues to oral Kaposi sarcoma-associated herpesvirus shedding and Kaposi sarcoma oncogenesis in the oral microbiome? J. Infect. Dis. 221, 1226\u20131228 (2020).","journal-title":"J. Infect. Dis."},{"key":"2197_CR558","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.7150\/thno.42494","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics 10, 5704\u20135718 (2020).","journal-title":"Theranostics"},{"key":"2197_CR559","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cancers13061414","volume":"13","author":"IA Montes-Mojarro","year":"2021","unstructured":"Montes-Mojarro, I. A., Fend, F. & Quintanilla-Martinez, L. EBV and the pathogenesis of NK\/T cell lymphoma. Cancers 13, 1414 (2021).","journal-title":"Cancers"},{"key":"2197_CR560","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","volume":"107","author":"CMM Wai","year":"2022","unstructured":"Wai, C. M. M. et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 107, 1864\u20131879 (2022).","journal-title":"Haematologica"},{"key":"2197_CR561","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3390\/v15020423","volume":"15","author":"JWY Ho","year":"2023","unstructured":"Ho, J. W. Y. et al. Comprehensive profiling of EBV gene expression and promoter methylation reveals latency II viral infection and sporadic abortive lytic activation in peripheral T-cell lymphomas. Viruses 15, 423 (2023).","journal-title":"Viruses"},{"key":"2197_CR562","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bjh.17922","volume":"196","author":"L Leoncini","year":"2022","unstructured":"Leoncini, L. Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes. Br. J. Haematol. 196, 468\u2013470 (2022).","journal-title":"Br. J. Haematol."},{"key":"2197_CR563","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","volume":"156","author":"I Magrath","year":"2012","unstructured":"Magrath, I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br. J. Haematol. 156, 744\u2013756 (2012).","journal-title":"Br. J. Haematol."},{"key":"2197_CR564","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","volume":"23","author":"ST Lim","year":"2005","unstructured":"Lim, S. T. et al. AIDS-related Burkitt\u2019s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J. Clin. Oncol. 23, 4430\u20134438 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR565","doi-asserted-by":"crossref","unstructured":"Campo, E. et al. Lymphoma classifications, how to develop a future unified taxonomy. J. Clin. Oncol. 27, 3177\u20133182 (2024).","DOI":"10.1200\/JCO.24.00070"},{"key":"2197_CR566","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","volume":"4","author":"J Nagasaki","year":"2020","unstructured":"Nagasaki, J. et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 4, 4069\u20134082 (2020).","journal-title":"Blood Adv."},{"key":"2197_CR567","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","volume":"132","author":"FZ Cader","year":"2018","unstructured":"Cader, F. Z. et al. Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment. Blood 132, 825\u2013836 (2018).","journal-title":"Blood"},{"key":"2197_CR568","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer, M. G. M. et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J. Clin. Oncol. 36, 942\u2013950 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR569","doi-asserted-by":"publisher","first-page":"e1008590","DOI":"10.1371\/journal.ppat.1008590","volume":"16","author":"C Li","year":"2020","unstructured":"Li, C. et al. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. PLoS Pathog. 16, e1008590 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR570","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bjh.14339","volume":"175","author":"AJ Worth","year":"2016","unstructured":"Worth, A. J., Houldcroft, C. J. & Booth, C. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host. Br. J. Haematol. 175, 559\u2013576 (2016).","journal-title":"Br. J. Haematol."},{"key":"2197_CR571","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","volume":"13","author":"A Carbone","year":"2008","unstructured":"Carbone, A., Gloghini, A. & Dotti, G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13, 577\u2013585 (2008).","journal-title":"Oncologist"},{"key":"2197_CR572","first-page":"315","volume":"390","author":"JA Healy","year":"2015","unstructured":"Healy, J. A. & Dave, S. S. The Role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr. Top. Microbiol. Immunol. 390, 315\u2013337 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2197_CR573","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.26579","volume":"97","author":"L Malpica","year":"2022","unstructured":"Malpica, L. et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 97, 951\u2013965 (2022).","journal-title":"Am. J. Hematol."},{"key":"2197_CR574","doi-asserted-by":"crossref","unstructured":"Munz, C. Redirecting T cells against Epstein-Barr virus infection and associated oncogenesis. Cells 9, 1400 (2020).","DOI":"10.3390\/cells9061400"},{"key":"2197_CR575","first-page":"1256","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. Hepatitis virus-associated non-Hodgkin lymphoma: pathogenesis and treatment strategies. J. Clin. Transl. Hepatol. 11, 1256\u20131266 (2023).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"2197_CR576","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-024-00530-6","volume":"13","author":"C Wang","year":"2024","unstructured":"Wang, C., Xiao, Q., Zhang, X. & Liu, Y. HIV associated lymphoma: latest updates from 2023 ASH annual meeting. Exp. Hematol. Oncol. 13, 65 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2197_CR577","doi-asserted-by":"publisher","first-page":"102370","DOI":"10.1016\/j.eclinm.2023.102370","volume":"67","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Estimates of the global burden of non-Hodgkin lymphoma attributable to HIV: a population attributable modeling study. EClinicalMedicine 67, 102370 (2024).","journal-title":"EClinicalMedicine"},{"key":"2197_CR578","doi-asserted-by":"publisher","first-page":"e00513","DOI":"10.1128\/JVI.00513-19","volume":"93","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. TAF family proteins and MEF2C are essential for Epstein-Barr virus super-enhancer activity. J. Virol. 93, e00513\u2013e00519 (2019).","journal-title":"J. Virol."},{"key":"2197_CR579","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1038\/s41388-023-02846-9","volume":"42","author":"E Molina","year":"2023","unstructured":"Molina, E. et al. MYC directly transactivates CR2\/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells. Oncogene 42, 3358\u20133370 (2023).","journal-title":"Oncogene"},{"key":"2197_CR580","doi-asserted-by":"publisher","first-page":"e1012132","DOI":"10.1371\/journal.ppat.1012132","volume":"20","author":"JA Bristol","year":"2024","unstructured":"Bristol, J. A. et al. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice. PLoS Pathog. 20, e1012132 (2024).","journal-title":"PLoS Pathog."},{"key":"2197_CR581","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/bloodadvances.2022007695","volume":"6","author":"M Ikeda","year":"2022","unstructured":"Ikeda, M., Hayes, C. K., Schaller, S. J. & Longnecker, R. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis. Blood Adv. 6, 4283\u20134296 (2022).","journal-title":"Blood Adv."},{"key":"2197_CR582","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2021.10.006","volume":"523","author":"W Dang","year":"2021","unstructured":"Dang, W. et al. IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis. Cancer Lett. 523, 135\u2013147 (2021).","journal-title":"Cancer Lett."},{"key":"2197_CR583","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44455-w","volume":"15","author":"F Giehler","year":"2024","unstructured":"Giehler, F. et al. Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex. Nat. Commun. 15, 414 (2024).","journal-title":"Nat. Commun."},{"key":"2197_CR584","doi-asserted-by":"publisher","first-page":"166838","DOI":"10.1016\/j.bbadis.2023.166838","volume":"1869","author":"G Shareena","year":"2023","unstructured":"Shareena, G. & Kumar, D. Epigenetics of Epstein Barr virus - a review. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166838 (2023).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2197_CR585","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/ng.3413","volume":"47","author":"H Kretzmer","year":"2015","unstructured":"Kretzmer, H. et al. DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat. Genet. 47, 1316\u20131325 (2015).","journal-title":"Nat. Genet."},{"key":"2197_CR586","doi-asserted-by":"publisher","first-page":"e2561","DOI":"10.1002\/rmv.2561","volume":"34","author":"LOD Oliveira","year":"2024","unstructured":"Oliveira, L. O. D., Costa, I. B. & Quaresma, J. A. S. Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development. Rev. Med. Virol. 34, e2561 (2024).","journal-title":"Rev. Med. Virol."},{"key":"2197_CR587","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/PAS.0000000000001324","volume":"43","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. Chronic active Epstein-Barr virus infection of T\/NK-cell type mimicking classic Hodgkin lymphoma: clinicopathologic and genetic features of 8 cases supporting a variant with \u201cHodgkin\/Reed-Sternberg-like\u201d cells of NK phenotype. Am. J. Surg. Pathol. 43, 1611\u20131621 (2019).","journal-title":"Am. J. Surg. Pathol."},{"key":"2197_CR588","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci, E. et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 131, 2454\u20132465 (2018).","journal-title":"Blood"},{"key":"2197_CR589","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.prp.2016.11.001","volume":"213","author":"BM Etzel","year":"2017","unstructured":"Etzel, B. M. et al. Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma. Pathol. Res. Pract. 213, 256\u2013260 (2017).","journal-title":"Pathol. Res. Pract."},{"key":"2197_CR590","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/ijms21041501","volume":"21","author":"A Saleem","year":"2020","unstructured":"Saleem, A. & Natkunam, Y. Extranodal NK\/T-cell lymphomas: the role of natural killer cells and EBV in lymphomagenesis. Int. J. Mol. Sci. 21, 1501 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR591","doi-asserted-by":"publisher","first-page":"14421","DOI":"10.1073\/pnas.1921139117","volume":"117","author":"T Sommermann","year":"2020","unstructured":"Sommermann, T. et al. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. Proc. Natl. Acad. Sci. USA 117, 14421\u201314432 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR592","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1331730","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells. Front. Immunol. 14, 1331730 (2023).","journal-title":"Front. Immunol."},{"key":"2197_CR593","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01097-21","volume":"12","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. The ubiquitin sensor and adaptor protein p62 mediates signal transduction of a viral oncogenic pathway. mBio 12, e0109721 (2021).","journal-title":"mBio"},{"key":"2197_CR594","doi-asserted-by":"publisher","first-page":"26318","DOI":"10.1073\/pnas.2007946117","volume":"117","author":"K Fish","year":"2020","unstructured":"Fish, K. et al. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. Proc. Natl. Acad. Sci. USA 117, 26318\u201326327 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR595","doi-asserted-by":"publisher","first-page":"EAAU5612","DOI":"10.1126\/scitranslmed.aau5612","volume":"11","author":"TE Messick","year":"2019","unstructured":"Messick, T. E. et al. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Sci. Transl. Med. 11, EAAU5612 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2197_CR596","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29834","volume":"96","author":"M Zeng","year":"2024","unstructured":"Zeng, M., Jia, Q. & Chen, J. Enhanced prognostic evaluation of diffuse large B-cell lymphoma: A comprehensive surveillance study incorporating Epstein-Barr virus infection status and immunohistochemical markers. J. Med. Virol. 96, e29834 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR597","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","volume":"52","author":"MA Piris","year":"2020","unstructured":"Piris, M. A., Medeiros, L. J. & Chang, K. C. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology 52, 154\u2013165 (2020).","journal-title":"Pathology"},{"key":"2197_CR598","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/ijms19041168","volume":"19","author":"M Navari","year":"2018","unstructured":"Navari, M. et al. Pathobiologic roles of Epstein-Barr virus-encoded MicroRNAs in human lymphomas. Int. J. Mol. Sci. 19, 1168 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2197_CR599","first-page":"e01941","volume":"10","author":"A Murer","year":"2019","unstructured":"Murer, A. et al. MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. mBio 10, e01941\u201301918 (2019).","journal-title":"mBio"},{"key":"2197_CR600","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00836-22","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. A polymorphism in the Epstein-Barr virus EBER2 noncoding RNA drives in vivo expansion of latently infected B cells. mBio 13, e0083622 (2022).","journal-title":"mBio"},{"key":"2197_CR601","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115508118","volume":"118","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth. Proc. Natl. Acad. Sci. USA 118, e2115508118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR602","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.1128\/JVI.01492-15","volume":"89","author":"AR Marquitz","year":"2015","unstructured":"Marquitz, A. R., Mathur, A., Edwards, R. H. & Raab-Traub, N. Host gene expression Is regulated by two types of noncoding RNAs transcribed from the Epstein-Barr virus BamHI A rightward transcript region. J. Virol. 89, 11256\u201311268 (2015).","journal-title":"J. Virol."},{"key":"2197_CR603","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12985-016-0602-7","volume":"13","author":"C Harold","year":"2016","unstructured":"Harold, C., Cox, D. & Riley, K. J. Epstein-Barr viral microRNAs target caspase 3. Virol. J. 13, 145 (2016).","journal-title":"Virol. J."},{"key":"2197_CR604","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/onc.2013.71","volume":"33","author":"DT Vereide","year":"2014","unstructured":"Vereide, D. T. et al. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 33, 1258\u20131264 (2014).","journal-title":"Oncogene"},{"key":"2197_CR605","doi-asserted-by":"crossref","unstructured":"Baron, M. et al. Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments. Haematologica 109, 3615\u20133630 (2024).","DOI":"10.3324\/haematol.2023.284332"},{"key":"2197_CR606","doi-asserted-by":"crossref","unstructured":"Chantziou, A. et al. HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma. Blood Adv. 8, 6215\u20136231 (2024).","DOI":"10.1182\/bloodadvances.2023012116"},{"key":"2197_CR607","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303913","volume":"10","author":"YQ Li","year":"2023","unstructured":"Li, Y. Q. et al. Single-cell analysis reveals malignant cells reshape the cellular landscape and foster an immunosuppressive microenvironment of extranodal NK\/T-cell lymphoma. Adv. Sci. 10, e2303913 (2023).","journal-title":"Adv. Sci."},{"key":"2197_CR608","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/v13122523","volume":"13","author":"A Santisteban-Espejo","year":"2021","unstructured":"Santisteban-Espejo, A. et al. Prognostic role of the expression of latent-membrane protein 1 of Epstein-Barr virus in classical Hodgkin lymphoma. Viruses 13, 2523 (2021).","journal-title":"Viruses"},{"key":"2197_CR609","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314426121","volume":"121","author":"MA Maroui","year":"2024","unstructured":"Maroui, M. A. et al. Aflatoxin B1 and Epstein-Barr virus-induced CCL22 expression stimulates B cell infection. Proc. Natl. Acad. Sci. USA 121, e2314426121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR610","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12985-020-01308-y","volume":"17","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis. Virol. J. 17, 51 (2020).","journal-title":"Virol. J."},{"key":"2197_CR611","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fimmu.2020.00367","volume":"11","author":"H Iizasa","year":"2020","unstructured":"Iizasa, H. et al. Role of viral and host microRNAs in immune regulation of Epstein-Barr virus-associated diseases. Front. Immunol. 11, 367 (2020).","journal-title":"Front. Immunol."},{"key":"2197_CR612","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-020-00307-6","volume":"15","author":"V De Re","year":"2020","unstructured":"De Re, V. et al. Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infect. Agent. Cancer. 15, 42 (2020).","journal-title":"Infect. Agent. Cancer."},{"key":"2197_CR613","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690\u20132697 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR614","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","volume":"130","author":"WR Liu","year":"2017","unstructured":"Liu, W. R. & Shipp, M. A. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130, 2265\u20132270 (2017).","journal-title":"Blood"},{"key":"2197_CR615","doi-asserted-by":"publisher","first-page":"e1005642","DOI":"10.1371\/journal.ppat.1005642","volume":"12","author":"SD Ma","year":"2016","unstructured":"Ma, S. D. et al. PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog. 12, e1005642 (2016).","journal-title":"PLoS Pathog."},{"key":"2197_CR616","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi, X. W. et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J. Hematol. Oncol. 9, 109 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2197_CR617","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-024-02266-y","volume":"38","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma. Leukemia 38, 1553\u20131563 (2024).","journal-title":"Leukemia"},{"key":"2197_CR618","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1016\/S2542-5196(21)00149-2","volume":"5","author":"I Rana","year":"2021","unstructured":"Rana, I., Dahlberg, S., Steinmaus, C. & Zhang, L. Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies. Lancet Planet Health 5, e633\u2013e643 (2021).","journal-title":"Lancet Planet Health"},{"key":"2197_CR619","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","volume":"84","author":"AM Muller","year":"2005","unstructured":"Muller, A. M., Ihorst, G., Mertelsmann, R. & Engelhardt, M. Epidemiology of non-Hodgkin\u2019s lymphoma (NHL): trends, geographic distribution, and etiology. Ann. Hematol. 84, 1\u201312 (2005).","journal-title":"Ann. Hematol."},{"key":"2197_CR620","doi-asserted-by":"publisher","first-page":"e000208","DOI":"10.1136\/jitc-2019-000208","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vdelta2(+) T cells activities after hematopoietic transplantation for blood malignancies. J. Immunother Cancer 8, e000208 (2020).","journal-title":"J. Immunother Cancer"},{"key":"2197_CR621","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2015-11-681411","volume":"127","author":"R Dolcetti","year":"2016","unstructured":"Dolcetti, R., Gloghini, A., Caruso, A. & Carbone, A. A lymphomagenic role for HIV beyond immune suppression? Blood 127, 1403\u20131409 (2016).","journal-title":"Blood"},{"key":"2197_CR622","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.20050068","volume":"201","author":"RJ Bende","year":"2005","unstructured":"Bende, R. J. et al. Among B cell non-Hodgkin\u2019s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, 1229\u20131241 (2005).","journal-title":"J. Exp. Med."},{"key":"2197_CR623","doi-asserted-by":"publisher","first-page":"G191","DOI":"10.1152\/ajpgi.2000.278.2.G191","volume":"278","author":"F Shanahan","year":"2000","unstructured":"Shanahan, F. Nutrient tasting and signaling mechanisms in the gut V. mechanisms of immunologic sensation of intestinal contents. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G191\u2013196 (2000).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2197_CR624","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s12015-020-10112-8","volume":"17","author":"J Feng","year":"2021","unstructured":"Feng, J. et al. Latent membrane protein 1 promotes tumorigenesis through upregulation of PGC1beta signaling pathway. Stem Cell Rev. Rep. 17, 1486\u20131499 (2021).","journal-title":"Stem Cell Rev. Rep."},{"key":"2197_CR625","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200512119","volume":"119","author":"S Beer","year":"2022","unstructured":"Beer, S. et al. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. USA 119, e2200512119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR626","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2011-02-335448","volume":"118","author":"YC Chou","year":"2011","unstructured":"Chou, Y. C. et al. Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation. Blood 118, 1340\u20131349 (2011).","journal-title":"Blood"},{"key":"2197_CR627","doi-asserted-by":"crossref","unstructured":"Bonglack, E. N. et al. Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas. Proc. Natl. Acad. Sci USA. 118, e2022495118 (2021).","DOI":"10.1073\/pnas.2022495118"},{"key":"2197_CR628","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.2019004126","volume":"135","author":"T Dalton","year":"2020","unstructured":"Dalton, T. et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood 135, 1870\u20131881 (2020).","journal-title":"Blood"},{"key":"2197_CR629","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1182\/bloodadvances.2020001675","volume":"4","author":"H Gazon","year":"2020","unstructured":"Gazon, H. et al. Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery. Blood Adv. 4, 5574\u20135579 (2020).","journal-title":"Blood Adv."},{"key":"2197_CR630","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/jmv.26510","volume":"93","author":"H Atabati","year":"2021","unstructured":"Atabati, H. et al. Evaluating mRNA expression of tax, B chain of PDGF and PDGF-beta receptors as well as HTLV-I proviral load in ATL patients and healthy carriers. J. Med. Virol. 93, 3865\u20133870 (2021).","journal-title":"J. Med. Virol."},{"key":"2197_CR631","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","volume":"116","author":"M Iwanaga","year":"2010","unstructured":"Iwanaga, M. et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116, 1211\u20131219 (2010).","journal-title":"Blood"},{"key":"2197_CR632","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41379-020-00654-0","volume":"34","author":"K Yamada","year":"2021","unstructured":"Yamada, K. et al. Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia\/lymphoma. Mod. Pathol. 34, 314\u2013326 (2021).","journal-title":"Mod. Pathol."},{"key":"2197_CR633","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3324\/haematol.2020.272468","volume":"106","author":"G Forlani","year":"2021","unstructured":"Forlani, G. et al. Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia. Haematologica 106, 2076\u20132085 (2021).","journal-title":"Haematologica"},{"key":"2197_CR634","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115316119","volume":"119","author":"T Zhao","year":"2022","unstructured":"Zhao, T. et al. HTLV-1 activates YAP via NF-kappaB\/p65 to promote oncogenesis. Proc. Natl. Acad. Sci. USA. 119, e2115316119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2197_CR635","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28424","volume":"95","author":"X Zuo","year":"2023","unstructured":"Zuo, X., Zhou, R., Yang, S. & Ma, G. HTLV-1 persistent infection and ATLL oncogenesis. J. Med. Virol. 95, e28424 (2023).","journal-title":"J. Med. Virol."},{"key":"2197_CR636","doi-asserted-by":"publisher","first-page":"E1269","DOI":"10.1073\/pnas.1715724115","volume":"115","author":"M Mahgoub","year":"2018","unstructured":"Mahgoub, M. et al. Sporadic on\/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc. Natl. Acad. Sci. USA 115, E1269\u2013E1278 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR637","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15264","volume":"8","author":"N Rosewick","year":"2017","unstructured":"Rosewick, N. et al. Cis-perturbation of cancer drivers by the HTLV-1\/BLV proviruses is an early determinant of leukemogenesis. Nat. Commun. 8, 15264 (2017).","journal-title":"Nat. Commun."},{"key":"2197_CR638","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30029-9","volume":"13","author":"M Matsuo","year":"2022","unstructured":"Matsuo, M. et al. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nat. Commun. 13, 2405 (2022).","journal-title":"Nat. Commun."},{"key":"2197_CR639","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2019002665","volume":"135","author":"AG Rowan","year":"2020","unstructured":"Rowan, A. G. et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis. Blood 135, 2023\u20132032 (2020).","journal-title":"Blood"},{"key":"2197_CR640","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01254-x","volume":"19","author":"CH Yeh","year":"2020","unstructured":"Yeh, C. H. et al. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol. Cancer. 19, 139 (2020).","journal-title":"Mol. Cancer."},{"key":"2197_CR641","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00841-7","volume":"13","author":"R Hleihel","year":"2023","unstructured":"Hleihel, R. et al. Primary cells from patients with adult T cell leukemia\/lymphoma depend on HTLV-1 Tax expression for NF-kappaB activation and survival. Blood Cancer J. 13, 67 (2023).","journal-title":"Blood Cancer J."},{"key":"2197_CR642","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10408363.2022.2157791","volume":"60","author":"S Ahmadi Ghezeldasht","year":"2023","unstructured":"Ahmadi Ghezeldasht, S., Blackbourn, D. J., Mosavat, A. & Rezaee, S. A. Pathogenicity and virulence of human T lymphotropic virus type-1 (HTLV-1) in oncogenesis: adult T-cell leukemia\/lymphoma (ATLL). Crit. Rev. Clin. Lab. Sci. 60, 189\u2013211 (2023).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"2197_CR643","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia, J. et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature 626, 626\u2013634 (2024).","journal-title":"Nature"},{"key":"2197_CR644","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s42003-022-04284-x","volume":"5","author":"T Kameda","year":"2022","unstructured":"Kameda, T. et al. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia\/lymphoma. Commun. Biol. 5, 1309 (2022).","journal-title":"Commun. Biol."},{"key":"2197_CR645","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe, T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood 129, 1071\u20131081 (2017).","journal-title":"Blood"},{"key":"2197_CR646","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","volume":"132","author":"UA Shah","year":"2018","unstructured":"Shah, U. A. et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood 132, 1507\u20131518 (2018).","journal-title":"Blood"},{"key":"2197_CR647","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005568118","volume":"118","author":"Y He","year":"2021","unstructured":"He, Y. et al. NF-kappaB-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. Proc. Natl. Acad. Sci. USA 118, e2005568118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR648","doi-asserted-by":"publisher","first-page":"e1008618","DOI":"10.1371\/journal.ppat.1008618","volume":"16","author":"H Zhi","year":"2020","unstructured":"Zhi, H. et al. RNF8 dysregulation and down-regulation during HTLV-1 infection promote genomic instability in adult T-cell leukemia. PLoS Pathog. 16, e1008618 (2020).","journal-title":"PLoS Pathog."},{"key":"2197_CR649","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/nar\/gkae015","volume":"52","author":"P Marie","year":"2024","unstructured":"Marie, P. et al. Gene-to-gene coordinated regulation of transcription and alternative splicing by 3D chromatin remodeling upon NF-kappaB activation. Nucleic Acids Res. 52, 1527\u20131543 (2024).","journal-title":"Nucleic Acids Res."},{"key":"2197_CR650","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16853-x","volume":"11","author":"LB Ameur","year":"2020","unstructured":"Ameur, L. B. et al. Intragenic recruitment of NF-kappaB drives splicing modifications upon activation by the oncogene Tax of HTLV-1. Nat. Commun. 11, 3045 (2020).","journal-title":"Nat. Commun."},{"key":"2197_CR651","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1182\/blood.2021013579","volume":"139","author":"W Zhong","year":"2022","unstructured":"Zhong, W. et al. ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood 139, 1052\u20131065 (2022).","journal-title":"Blood"},{"key":"2197_CR652","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32104-7","volume":"13","author":"W Zhong","year":"2022","unstructured":"Zhong, W. et al. An acquired phosphatidylinositol 4-phosphate transport initiates T-cell deterioration and leukemogenesis. Nat. Commun. 13, 4390 (2022).","journal-title":"Nat. Commun."},{"key":"2197_CR653","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","volume":"36","author":"CRM Bangham","year":"2018","unstructured":"Bangham, C. R. M. Human T cell leukemia virus type 1: persistence and pathogenesis. Annu. Rev. Immunol. 36, 43\u201371 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"2197_CR654","doi-asserted-by":"publisher","first-page":"e1009219","DOI":"10.1371\/journal.ppat.1009219","volume":"17","author":"A Akkouche","year":"2021","unstructured":"Akkouche, A. et al. In vivo antagonistic role of the human T-cell leukemia virus type 1 regulatory proteins tax and HBZ. PLoS Pathog. 17, e1009219 (2021).","journal-title":"PLoS Pathog."},{"key":"2197_CR655","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2309925121","volume":"121","author":"T Shichijo","year":"2024","unstructured":"Shichijo, T. et al. Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses. Proc. Natl. Acad. Sci. USA 121, e2309925121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR656","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.1516208112","volume":"112","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc. Natl. Acad. Sci. USA 112, 12480\u201312485 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR657","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ijc.29726","volume":"138","author":"M Witzens-Harig","year":"2016","unstructured":"Witzens-Harig, M. et al. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced bax expression. Int. J. Cancer. 138, 507\u2013514 (2016).","journal-title":"Int. J. Cancer."},{"key":"2197_CR658","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1002\/jcp.30044","volume":"236","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y., Mukai, R. & Ohshima, T. HTLV-1 viral oncoprotein HBZ contributes to the enhancement of HAX-1 stability by impairing the ubiquitination pathway. J. Cell. Physiol. 236, 2756\u20132766 (2021).","journal-title":"J. Cell. Physiol."},{"key":"2197_CR659","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/0008-5472.CAN-13-0436","volume":"74","author":"A Tanaka-Nakanishi","year":"2014","unstructured":"Tanaka-Nakanishi, A., Yasunaga, J., Takai, K. & Matsuoka, M. HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res. 74, 188\u2013200 (2014).","journal-title":"Cancer Res."},{"key":"2197_CR660","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.celrep.2019.09.016","volume":"29","author":"H Katsuya","year":"2019","unstructured":"Katsuya, H. et al. The nature of the HTLV-1 provirus in naturally infected individuals analyzed by the viral DNA-capture-seq approach. Cell Rep. 29, 724\u2013735.e724 (2019).","journal-title":"Cell Rep."},{"key":"2197_CR661","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1073\/pnas.1423199113","volume":"113","author":"Y Satou","year":"2016","unstructured":"Satou, Y. et al. The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proc. Natl. Acad. Sci. USA 113, 3054\u20133059 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2197_CR662","doi-asserted-by":"publisher","first-page":"e1011202","DOI":"10.1371\/journal.ppat.1011202","volume":"19","author":"N Polakowski","year":"2023","unstructured":"Polakowski, N. et al. HBZ upregulates myoferlin expression to facilitate HTLV-1 infection. PLoS Pathog. 19, e1011202 (2023).","journal-title":"PLoS Pathog."},{"key":"2197_CR663","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1182\/blood-2011-05-357459","volume":"119","author":"K Sugata","year":"2012","unstructured":"Sugata, K. et al. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood 119, 434\u2013444 (2012).","journal-title":"Blood"},{"key":"2197_CR664","doi-asserted-by":"publisher","first-page":"991928","DOI":"10.3389\/fimmu.2022.991928","volume":"13","author":"BJY Tan","year":"2022","unstructured":"Tan, B. J. Y., Sugata, K., Ono, M. & Satou, Y. HTLV-1 persistence and leukemogenesis: a game of hide-and-seek with the host immune system. Front. Immunol. 13, 991928 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR665","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4049\/jimmunol.0903846","volume":"185","author":"F Toulza","year":"2010","unstructured":"Toulza, F. et al. Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J. Immunol. 185, 183\u2013189 (2010).","journal-title":"J. Immunol."},{"key":"2197_CR666","doi-asserted-by":"publisher","first-page":"e1005372","DOI":"10.1371\/journal.ppat.1005372","volume":"12","author":"K Yasuma","year":"2016","unstructured":"Yasuma, K. et al. HTLV-1 bZIP factor impairs anti-viral immunity by inducing co-inhibitory molecule, T cell immunoglobulin and ITIM domain (TIGIT). PLoS Pathog. 12, e1005372 (2016).","journal-title":"PLoS Pathog."},{"key":"2197_CR667","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.1235214","volume":"340","author":"JR Teijaro","year":"2013","unstructured":"Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207\u2013211 (2013).","journal-title":"Science"},{"key":"2197_CR668","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1235208","volume":"340","author":"EB Wilson","year":"2013","unstructured":"Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202\u2013207 (2013).","journal-title":"Science"},{"key":"2197_CR669","doi-asserted-by":"publisher","first-page":"e1006597","DOI":"10.1371\/journal.ppat.1006597","volume":"13","author":"L Sawada","year":"2017","unstructured":"Sawada, L. et al. IL-10-mediated signals act as a switch for lymphoproliferation in human t-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 13, e1006597 (2017).","journal-title":"PLoS Pathog."},{"key":"2197_CR670","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/ijc.33901","volume":"150","author":"N Yoshida-Sakai","year":"2022","unstructured":"Yoshida-Sakai, N. et al. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. Int. J. Cancer. 150, 1184\u20131197 (2022).","journal-title":"Int. J. Cancer."},{"key":"2197_CR671","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/bloodadvances.2023011131","volume":"8","author":"T Watanabe","year":"2024","unstructured":"Watanabe, T. et al. Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood Adv. 8, 1345\u20131358 (2024).","journal-title":"Blood Adv."},{"key":"2197_CR672","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 20, 864\u2013884 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2197_CR673","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070115","volume":"379","author":"L Rahangdale","year":"2022","unstructured":"Rahangdale, L. et al. Human papillomavirus vaccination and cervical cancer risk. BMJ 379, e070115 (2022).","journal-title":"BMJ"},{"key":"2197_CR674","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.23.00757","volume":"42","author":"DQ Huang","year":"2024","unstructured":"Huang, D. Q. et al. Antiviral therapy utilization and 10-year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J. Clin. Oncol. 42, 790\u2013799 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR675","doi-asserted-by":"publisher","first-page":"m2200","DOI":"10.1136\/bmj.m2200","volume":"370","author":"Y Shi","year":"2020","unstructured":"Shi, Y. & Zheng, M. Hepatitis B virus persistence and reactivation. BMJ 370, m2200 (2020).","journal-title":"BMJ"},{"key":"2197_CR676","doi-asserted-by":"crossref","unstructured":"Bertoletti, A. & Tan, A. T. Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future. Clin. Mol. Hepatol. 30, 728\u2013734 (2024).","DOI":"10.3350\/cmh.2024.0469"},{"key":"2197_CR677","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2023.09.019","volume":"80","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers. J. Hepatol. 80, 31\u201340 (2024).","journal-title":"J. Hepatol."},{"key":"2197_CR678","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-019-0743-4","volume":"12","author":"P Gao","year":"2019","unstructured":"Gao, P. et al. Immune checkpoint inhibitors in the treatment of virus-associated cancers. J Hematol. Oncol. 12, 58 (2019).","journal-title":"J Hematol. Oncol."},{"key":"2197_CR679","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology 73, 4\u201313 (2021).","journal-title":"Hepatology"},{"key":"2197_CR680","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jconrel.2020.02.045","volume":"321","author":"X Gao","year":"2020","unstructured":"Gao, X. et al. Hyperbranched poly(beta-amino ester) based polyplex nanopaticles for delivery of CRISPR\/Cas9 system and treatment of HPV infection associated cervical cancer. J. Control. Rel. 321, 654\u2013668 (2020).","journal-title":"J. Control. Rel."},{"key":"2197_CR681","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.7150\/ijbs.64630","volume":"17","author":"B Cao","year":"2021","unstructured":"Cao, B. et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int. J. Biol. Sci. 17, 3850\u20133861 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2197_CR682","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","volume":"28","author":"P Hillemanns","year":"2022","unstructured":"Hillemanns, P. et al. A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa Trial. Clin. Cancer Res. 28, 4885\u20134892 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR683","doi-asserted-by":"crossref","unstructured":"Argenziano, M. E. et al. Epidemiology, pathophysiology and clinical aspects of hepatocellular carcinoma in MAFLD patients. Hepatol. Int. 18, 922\u2013940 (2024).","DOI":"10.1007\/s12072-024-10692-4"},{"key":"2197_CR684","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown, Z. J. et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 158, 410\u2013420 (2023).","journal-title":"JAMA Surg."},{"key":"2197_CR685","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns, S. et al. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 10, 395\u2013404 (2024).","journal-title":"JAMA Oncol."},{"key":"2197_CR686","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"C Polaris Observatory","year":"2023","unstructured":"Polaris Observatory, C. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol. Hepatol. 8, 879\u2013907 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2197_CR687","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","volume":"149","author":"E Serti","year":"2015","unstructured":"Serti, E. et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149, 190\u2013200.e192 (2015).","journal-title":"Gastroenterology"},{"key":"2197_CR688","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/apt.12344","volume":"38","author":"AK Singal","year":"2013","unstructured":"Singal, A. K., Salameh, H., Kuo, Y. F. & Fontana, R. J. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol. Ther. 38, 98\u2013106 (2013).","journal-title":"Aliment Pharmacol. Ther."},{"key":"2197_CR689","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"Global Burden of Disease Liver Cancer, C.","year":"2017","unstructured":"Global Burden of Disease Liver Cancer, C. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 3, 1683\u20131691 (2017).","journal-title":"JAMA Oncol."},{"key":"2197_CR690","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","volume":"76","author":"S Fung","year":"2022","unstructured":"Fung, S., Choi, H. S. J., Gehring, A. & Janssen, H. L. A. Getting to HBV cure: the promising paths forward. Hepatology 76, 233\u2013250 (2022).","journal-title":"Hepatology"},{"key":"2197_CR691","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni, C. et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 157, 227\u2013241 (2019).","journal-title":"Gastroenterology"},{"key":"2197_CR692","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/hep.32109","volume":"75","author":"L Wei","year":"2022","unstructured":"Wei, L. et al. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: a randomized clinical trial. Hepatology 75, 182\u2013195 (2022).","journal-title":"Hepatology"},{"key":"2197_CR693","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/hepr.13851","volume":"53","author":"O Yoshida","year":"2023","unstructured":"Yoshida, O. et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study. Hepatol. Res. 53, 196\u2013207 (2023).","journal-title":"Hepatol. Res."},{"key":"2197_CR694","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12929-020-00662-x","volume":"27","author":"JH Horng","year":"2020","unstructured":"Horng, J. H. et al. HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J. Biomed. Sci. 27, 70 (2020).","journal-title":"J. Biomed. Sci."},{"key":"2197_CR695","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 15, 406\u2013416 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2197_CR696","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines 9, 22 (2024).","journal-title":"NPJ Vaccines"},{"key":"2197_CR697","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S307962","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y., Han, Q., Zhao, H. & Zhang, J. The mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatocell Carcinoma 8, 435\u2013450 (2021).","journal-title":"J. Hepatocell Carcinoma"},{"key":"2197_CR698","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1365-2036.2011.04634.x","volume":"33","author":"JS Wong","year":"2011","unstructured":"Wong, J. S. et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol. Ther. 33, 1104\u20131112 (2011).","journal-title":"Aliment Pharmacol. Ther."},{"key":"2197_CR699","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12072-023-10618-6","volume":"18","author":"JX Luo","year":"2024","unstructured":"Luo, J. X., Zhang, Y., Hu, X. Y. & Xiang, N. Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis. Hepatol. Int. 18, 63\u201372 (2024).","journal-title":"Hepatol. Int."},{"key":"2197_CR700","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"2197_CR701","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3350\/cmh.2016.0040","volume":"23","author":"KS Lee","year":"2017","unstructured":"Lee, K. S. et al. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin. Mol. Hepatol. 23, 331\u2013339 (2017).","journal-title":"Clin. Mol. Hepatol."},{"key":"2197_CR702","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3350\/cmh.2019.0044n","volume":"26","author":"HY Woo","year":"2020","unstructured":"Woo, H. Y. et al. Entecavir+tenofovir vs. lamivudine\/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clin. Mol. Hepatol. 26, 352\u2013363 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"2197_CR703","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.31289","volume":"73","author":"J Choi","year":"2021","unstructured":"Choi, J., Jo, C. & Lim, Y. S. Tenofovir versus entecavir on recurrence of hepatitis b virus-related hepatocellular carcinoma after surgical resection. Hepatology 73, 661\u2013673 (2021).","journal-title":"Hepatology"},{"key":"2197_CR704","doi-asserted-by":"crossref","unstructured":"Chung, S. W. et al. Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol., 23, 300\u2013309 (2024).","DOI":"10.1016\/j.cgh.2024.07.013"},{"key":"2197_CR705","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","volume":"73","author":"I Tout","year":"2020","unstructured":"Tout, I. et al. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J. Hepatol. 73, 409\u2013422 (2020).","journal-title":"J. Hepatol."},{"key":"2197_CR706","doi-asserted-by":"crossref","unstructured":"Mon, H. C. et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J. Hepatol. 82, 51\u201361 (2024).","DOI":"10.1016\/j.jhep.2024.07.018"},{"key":"2197_CR707","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N. Engl. J. Med. 387, 1957\u20131968 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR708","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jvh.13236","volume":"27","author":"W Qi","year":"2020","unstructured":"Qi, W. et al. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy\/ablation. J. Viral Hepat. 27, 387\u2013396 (2020).","journal-title":"J. Viral Hepat."},{"key":"2197_CR709","doi-asserted-by":"publisher","first-page":"105892","DOI":"10.1016\/j.antiviral.2024.105892","volume":"226","author":"S Jiang","year":"2024","unstructured":"Jiang, S. et al. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-alpha in NA-treated patients with CHB. Antiviral Res. 226, 105892 (2024).","journal-title":"Antiviral Res."},{"key":"2197_CR710","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2018.12.019","volume":"162","author":"C Li","year":"2019","unstructured":"Li, C. et al. An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Res. 162, 118\u2013129 (2019).","journal-title":"Antiviral Res."},{"key":"2197_CR711","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28196-w","volume":"13","author":"P Lanzoni-Mangutchi","year":"2022","unstructured":"Lanzoni-Mangutchi, P. et al. Structure and assembly of the S-layer in C. difficile. Nat. Commun. 13, 970 (2022).","journal-title":"Nat. Commun."},{"key":"2197_CR712","first-page":"668","volume":"73","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion. Gut 73, 668\u2013681 (2024).","journal-title":"Gut"},{"key":"2197_CR713","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR714","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"2197_CR715","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.2147\/OTT.S312748","volume":"14","author":"S De Matteis","year":"2021","unstructured":"De Matteis, S. et al. Sorafenib in the treatment of virus-related HCC: differences between HCV and HBV. Onco. Targets Ther. 14, 4305\u20134308 (2021).","journal-title":"Onco. Targets Ther."},{"key":"2197_CR716","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.dld.2017.04.022","volume":"49","author":"A Casadei Gardini","year":"2017","unstructured":"Casadei Gardini, A. et al. Sorafenib and regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: analysis of RESORCE and SHARP trials. Dig. Liver Dis. 49, 943\u2013944 (2017).","journal-title":"Dig. Liver Dis."},{"key":"2197_CR717","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1002\/cam4.3880","volume":"10","author":"JJ Harding","year":"2021","unstructured":"Harding, J. J. et al. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 10, 3059\u20133067 (2021).","journal-title":"Cancer Med."},{"key":"2197_CR718","doi-asserted-by":"publisher","first-page":"e00056","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"RK Kelley","year":"2019","unstructured":"Kelley, R. K. et al. A phase 2 study of galunisertib (TGF-beta1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl. Gastroenterol. 10, e00056 (2019).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"2197_CR719","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cas.14251","volume":"111","author":"Y Shimizu","year":"2020","unstructured":"Shimizu, Y. et al. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 111, 334\u2013342 (2020).","journal-title":"Cancer Sci."},{"key":"2197_CR720","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","volume":"18","author":"Y Sawada","year":"2012","unstructured":"Sawada, Y. et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 18, 3686\u20133696 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR721","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley, R. K. et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J. Clin. Oncol. 39, 2991\u20133001 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR722","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"2197_CR723","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/hepr.13798","volume":"52","author":"S Hagiwara","year":"2022","unstructured":"Hagiwara, S. et al. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. Hepatol. Res. 52, 754\u2013761 (2022).","journal-title":"Hepatol. Res."},{"key":"2197_CR724","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition. J. Immunother Cancer 7, 322 (2019).","journal-title":"J. Immunother Cancer"},{"key":"2197_CR725","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.21037\/atm-21-3020","volume":"9","author":"G Yuan","year":"2021","unstructured":"Yuan, G. et al. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann. Transl. Med. 9, 1412 (2021).","journal-title":"Ann. Transl. Med."},{"key":"2197_CR726","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu, B. et al. IFNalpha potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 12, 1718\u20131741 (2022).","journal-title":"Cancer Discov."},{"key":"2197_CR727","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg, S. M. & Hinrichs, C. S. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41, 58\u201369 (2023).","journal-title":"Cancer Cell"},{"key":"2197_CR728","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","volume":"29","author":"F Zou","year":"2021","unstructured":"Zou, F. et al. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol. Ther. 29, 1794\u20131807 (2021).","journal-title":"Mol. Ther."},{"key":"2197_CR729","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","volume":"15","author":"F Meng","year":"2021","unstructured":"Meng, F. et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol. Int. 15, 1402\u20131412 (2021).","journal-title":"Hepatol. Int."},{"key":"2197_CR730","doi-asserted-by":"crossref","unstructured":"Wan, X. et al. Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC. Clin. Mol. Hepatol. 30, 735\u2013755 (2024).","DOI":"10.3350\/cmh.2024.0058"},{"key":"2197_CR731","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct. Target Ther. 9, 101 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2197_CR732","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0304-3959(87)90178-3","volume":"29","author":"RP Smith","year":"1987","unstructured":"Smith, R. P. Objective changes in intrauterine pressure during placebo treatment of dysmenorrhea. Pain 29, 59\u201366 (1987).","journal-title":"Pain"},{"key":"2197_CR733","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","volume":"156","author":"GN Ioannou","year":"2019","unstructured":"Ioannou, G. N. & Feld, J. J. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 156, 446\u2013460 e442 (2019).","journal-title":"Gastroenterology"},{"key":"2197_CR734","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1126\/science.adf2226","volume":"380","author":"A Offersgaard","year":"2023","unstructured":"Offersgaard, A., Bukh, J. & Gottwein, J. M. Toward a vaccine against hepatitis C virus. Science 380, 37\u201338 (2023).","journal-title":"Science"},{"key":"2197_CR735","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","volume":"156","author":"JR Bailey","year":"2019","unstructured":"Bailey, J. R., Barnes, E. & Cox, A. L. Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology 156, 418\u2013430 (2019).","journal-title":"Gastroenterology"},{"key":"2197_CR736","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.32470","volume":"76","author":"T Donnison","year":"2022","unstructured":"Donnison, T. et al. A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. Hepatology 76, 1190\u20131202 (2022).","journal-title":"Hepatology"},{"key":"2197_CR737","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1136\/gutjnl-2020-321190","volume":"70","author":"D Bankwitz","year":"2021","unstructured":"Bankwitz, D. et al. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. Gut 70, 1734\u20131745 (2021).","journal-title":"Gut"},{"key":"2197_CR738","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541\u2013549 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR739","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal, J., Kanwal, F., Roberts, M. S. & Dunn, M. A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 162, 397\u2013406 (2015).","journal-title":"Ann. Intern. Med."},{"key":"2197_CR740","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/fon-2019-0845","volume":"16","author":"L Ma","year":"2020","unstructured":"Ma, L. et al. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 16, 675\u2013686 (2020).","journal-title":"Future Oncol."},{"key":"2197_CR741","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","volume":"13","author":"T Kanda","year":"2019","unstructured":"Kanda, T. et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol. Int. 13, 649\u2013661 (2019).","journal-title":"Hepatol. Int."},{"key":"2197_CR742","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.eclinm.2024.102671","volume":"73","author":"W Sohn","year":"2024","unstructured":"Sohn, W. et al. Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study. EClinicalMedicine 73, 102671 (2024).","journal-title":"EClinicalMedicine"},{"key":"2197_CR743","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere, M. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N. Engl. J. Med. 376, 2134\u20132146 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR744","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jhep.2021.05.015","volume":"75","author":"R Kolamunnage-Dona","year":"2021","unstructured":"Kolamunnage-Dona, R. et al. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J. Hepatol. 75, 879\u2013887 (2021).","journal-title":"J. Hepatol."},{"key":"2197_CR745","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix, J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57, 821\u2013829 (2012).","journal-title":"J. Hepatol."},{"key":"2197_CR746","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","volume":"67","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J. Hepatol. 67, 999\u20131008 (2017).","journal-title":"J. Hepatol."},{"key":"2197_CR747","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42\u201352 (2007).","journal-title":"Hepatology"},{"key":"2197_CR748","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1136\/gut.2009.182212","volume":"58","author":"K Himmelsbach","year":"2009","unstructured":"Himmelsbach, K. et al. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 58, 1644\u20131653 (2009).","journal-title":"Gut"},{"key":"2197_CR749","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1172\/JCI126277","volume":"130","author":"DY Chen","year":"2020","unstructured":"Chen, D. Y. et al. Hepatitis C virus-specific CD4+ T cell phenotype and function in different infection outcomes. J. Clin. Investig. 130, 768\u2013773 (2020).","journal-title":"J. Clin. Investig."},{"key":"2197_CR750","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro, B. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59, 81\u201388 (2013).","journal-title":"J. Hepatol."},{"key":"2197_CR751","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"2197_CR752","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","volume":"65","author":"GA Sautto","year":"2016","unstructured":"Sautto, G. A. et al. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65, 512\u2013523 (2016).","journal-title":"Gut"},{"key":"2197_CR753","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3389\/fimmu.2019.02711","volume":"10","author":"M Seif","year":"2019","unstructured":"Seif, M., Einsele, H., Loffler, J. & CAR, T. Cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front. Immunol. 10, 2711 (2019).","journal-title":"Front. Immunol."},{"key":"2197_CR754","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani, J. A. et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20, 167\u2013192 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2197_CR755","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F. et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022).","journal-title":"Ann. Oncol."},{"key":"2197_CR756","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.gie.2023.03.030","volume":"98","author":"MA Al-Haddad","year":"2023","unstructured":"Al-Haddad, M. A. et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: methodology and review of evidence. Gastrointest. Endosc. 98, 285\u2013305 (2023).","journal-title":"Gastrointest. Endosc."},{"key":"2197_CR757","doi-asserted-by":"crossref","unstructured":"Shechter, O. et al. Epstein-Barr virus (EBV) epithelial associated malignancies: exploring pathologies and current treatments. Int. J. Mol. Sci. 23, 14389 (2022).","DOI":"10.3390\/ijms232214389"},{"key":"2197_CR758","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun, C. et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 31, 1882\u20131897 (2023).","journal-title":"Cell Host Microbe"},{"key":"2197_CR759","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang, F. H. et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond) 41, 747\u2013795 (2021).","journal-title":"Cancer Commun. (Lond)"},{"key":"2197_CR760","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41571-023-00767-w","volume":"20","author":"Y Hirata","year":"2023","unstructured":"Hirata, Y. et al. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat. Rev. Clin. Oncol. 20, 453\u2013469 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2197_CR761","first-page":"3169","volume":"13","author":"Y Nie","year":"2023","unstructured":"Nie, Y., Zhao, W., Lu, L. & Zhou, F. Predictive biomarkers and new developments of immunotherapy in gastric cancer: a 2023 update. Am. J. Cancer Res. 13, 3169\u20133184 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"2197_CR762","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi, P. et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann. Oncol. 32, 452\u2013465 (2021).","journal-title":"Ann. Oncol."},{"key":"2197_CR763","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.701611","volume":"12","author":"V Jean-Pierre","year":"2021","unstructured":"Jean-Pierre, V. et al. Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine. Front. Microbiol. 12, 701611 (2021).","journal-title":"Front. Microbiol."},{"key":"2197_CR764","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen, M. et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25, 4697\u20134705 (2007).","journal-title":"Vaccine"},{"key":"2197_CR765","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"2197_CR766","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virol.2010.12.006","volume":"413","author":"AE Plate","year":"2011","unstructured":"Plate, A. E., Reimer, J. J., Jardetzky, T. S. & Longnecker, R. Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH\/gL. Virology 413, 26\u201338 (2011).","journal-title":"Virology"},{"key":"2197_CR767","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui, X. et al. Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34, 4050\u20134055 (2016).","journal-title":"Vaccine"},{"key":"2197_CR768","doi-asserted-by":"crossref","unstructured":"Cui, X. et al. Immunization with Epstein-Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge. Vaccines 9, 285 (2021).","DOI":"10.3390\/vaccines9030285"},{"key":"2197_CR769","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 5, 67\u201373 (2019).","journal-title":"JAMA Oncol."},{"key":"2197_CR770","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-023-00489-9","volume":"18","author":"G Li","year":"2023","unstructured":"Li, G., Zhou, Z., Wang, Z. & Wang, Z. Assessing Epstein-Barr virus in gastric cancer: clinicopathological features and prognostic implications. Infect. Agent Cancer 18, 11 (2023).","journal-title":"Infect. Agent Cancer"},{"key":"2197_CR771","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"2197_CR772","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571\u20131580 (2020).","journal-title":"JAMA Oncol."},{"key":"2197_CR773","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"2197_CR774","doi-asserted-by":"publisher","first-page":"103237","DOI":"10.1016\/j.critrevonc.2021.103237","volume":"159","author":"C Sanchez-Romero","year":"2021","unstructured":"Sanchez-Romero, C. et al. Extranodal NK\/T cell lymphoma, nasal type: An updated overview. Crit. Rev. Oncol. Hematol. 159, 103237 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2197_CR775","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00705-024-06033-3","volume":"169","author":"LL Li","year":"2024","unstructured":"Li, L. L. et al. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer. Arch. Virol. 169, 114 (2024).","journal-title":"Arch. Virol."},{"key":"2197_CR776","doi-asserted-by":"publisher","first-page":"1003859","DOI":"10.3389\/fimmu.2022.1003859","volume":"13","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer. Front. Immunol. 13, 1003859 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR777","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djx213","volume":"110","author":"A Panda","year":"2018","unstructured":"Panda, A. et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. J. Natl. Cancer Inst. 110, 316\u2013320 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"2197_CR778","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449\u20131458 (2018).","journal-title":"Nat. Med."},{"key":"2197_CR779","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann. Oncol. 30, 1479\u20131486 (2019).","journal-title":"Ann. Oncol."},{"key":"2197_CR780","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima, S. et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J. Immunother Cancer 7, 24 (2019).","journal-title":"J. Immunother Cancer"},{"key":"2197_CR781","first-page":"5006","volume":"11","author":"YT Sun","year":"2021","unstructured":"Sun, Y. T. et al. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am. J. Cancer Res. 11, 5006\u20135015 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"2197_CR782","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"2197_CR783","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III checkmate 649 trial. J. Clin. Oncol. 42, 2012\u20132020 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR784","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"2197_CR785","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392, 123\u2013133 (2018).","journal-title":"Lancet"},{"key":"2197_CR786","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR787","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013 (2018).","journal-title":"JAMA Oncol."},{"key":"2197_CR788","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152881","volume":"216","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res. Pract. 216, 152881 (2020).","journal-title":"Pathol Res. Pract."},{"key":"2197_CR789","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","volume":"23","author":"LT Chen","year":"2020","unstructured":"Chen, L. T. et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 23, 510\u2013519 (2020).","journal-title":"Gastric Cancer"},{"key":"2197_CR790","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"2197_CR791","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","volume":"24","author":"N Boku","year":"2021","unstructured":"Boku, N. et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 24, 946\u2013958 (2021).","journal-title":"Gastric Cancer"},{"key":"2197_CR792","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1271857","volume":"8","author":"HG Caruso","year":"2019","unstructured":"Caruso, H. G., Heimberger, A. B. & Cooper, L. J. N. Steering CAR T cells to distinguish friend from foe. Oncoimmunology 8, e1271857 (2019).","journal-title":"Oncoimmunology"},{"key":"2197_CR793","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/cer-2019-0065","volume":"9","author":"JR Baumgardner","year":"2020","unstructured":"Baumgardner, J. R. et al. CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments. J. Comp. Eff. Res. 9, 327\u2013340 (2020).","journal-title":"J. Comp. Eff. Res."},{"key":"2197_CR794","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 32, 609\u2013619 (2021).","journal-title":"Ann. Oncol."},{"key":"2197_CR795","doi-asserted-by":"crossref","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 28, 1189\u20131198 (2024).","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2197_CR796","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0632-8","volume":"13","author":"N Sakamoto","year":"2015","unstructured":"Sakamoto, N. et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med. 13, 277 (2015).","journal-title":"J. Transl. Med."},{"key":"2197_CR797","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1002\/ijc.31285","volume":"142","author":"T Ishikawa","year":"2018","unstructured":"Ishikawa, T. et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int. J. Cancer 142, 2599\u20132609 (2018).","journal-title":"Int. J. Cancer"},{"key":"2197_CR798","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02055-2","volume":"23","author":"M Yu","year":"2024","unstructured":"Yu, M. et al. NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer. Mol. Cancer 23, 139 (2024).","journal-title":"Mol. Cancer"},{"key":"2197_CR799","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17460441.2018.1443074","volume":"13","author":"JE Wolford","year":"2018","unstructured":"Wolford, J. E. & Tewari, K. S. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Exp.Opin. Drug Discov. 13, 445\u2013457 (2018).","journal-title":"Exp.Opin. Drug Discov."},{"key":"2197_CR800","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote, I. et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N. Engl. J. Med. 391, 44\u201355 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR801","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1470-2045(24)00274-2","volume":"25","author":"SS Murthy","year":"2024","unstructured":"Murthy, S. S. et al. Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study. Lancet Oncol. 25, 969\u2013978 (2024).","journal-title":"Lancet Oncol."},{"key":"2197_CR802","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07740-1","volume":"21","author":"O Del Moral-Hernandez","year":"2021","unstructured":"Del Moral-Hernandez, O. et al. TOP2A\/MCM2, p16(INK4a), and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions. BMC Cancer 21, 39 (2021).","journal-title":"BMC Cancer"},{"key":"2197_CR803","doi-asserted-by":"publisher","first-page":"e1336","DOI":"10.1016\/S2214-109X(22)00271-6","volume":"10","author":"AJB Vallely","year":"2022","unstructured":"Vallely, A. J. B. et al. Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT). Lancet Glob. Health 10, e1336\u2013e1346 (2022).","journal-title":"Lancet Glob. Health"},{"key":"2197_CR804","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-23-3941","volume":"30","author":"L Sivars","year":"2024","unstructured":"Sivars, L. et al. Cell-free human papillomavirus DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer. Clin. Cancer Res. 30, 2764\u20132771 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR805","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijbiomac.2022.03.103","volume":"206","author":"S Najafi","year":"2022","unstructured":"Najafi, S. Circular RNAs as emerging players in cervical cancer tumorigenesis; a review to roles and biomarker potentials. Int. J. Biol. Macromol. 206, 939\u2013953 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"2197_CR806","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12985-022-01822-1","volume":"19","author":"MT Bruno","year":"2022","unstructured":"Bruno, M. T. et al. Possible role of negative human papillomavirus E6\/E7 mRNA as a predictor of regression of cervical intraepithelial neoplasia 2 lesions in hr-HPV positive women. Virol. J. 19, 95 (2022).","journal-title":"Virol. J."},{"key":"2197_CR807","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.drudis.2019.07.011","volume":"24","author":"AM Almeida","year":"2019","unstructured":"Almeida, A. M., Queiroz, J. A., Sousa, F. & Sousa, A. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov. Today 24, 2044\u20132057 (2019).","journal-title":"Drug Discov. Today"},{"key":"2197_CR808","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41401-021-00616-5","volume":"42","author":"M Ghanaat","year":"2021","unstructured":"Ghanaat, M. et al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol. Sin. 42, 1981\u20131990 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"2197_CR809","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1093\/cid\/ciaa1162","volume":"72","author":"E Clark","year":"2021","unstructured":"Clark, E. et al. Veteran women living with human immunodeficiency virus have increased risk of human papillomavirus (HPV)-associated genital tract cancers. Clin. Infect. Dis. 72, e359\u2013e366 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2197_CR810","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ijc.31826","volume":"144","author":"S Joshi","year":"2019","unstructured":"Joshi, S. et al. Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: Results of a prospective cohort study with up to 6.4 years of follow-up from India. Int. J. Cancer 144, 1082\u20131091 (2019).","journal-title":"Int. J. Cancer"},{"key":"2197_CR811","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742861","volume":"12","author":"W Mbuya","year":"2021","unstructured":"Mbuya, W. et al. Depletion of human papilloma virus E6- and E7-oncoprotein-specific T-cell responses in women living with HIV. Front. Immunol. 12, 742861 (2021).","journal-title":"Front. Immunol."},{"key":"2197_CR812","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1126\/science.365.6453.530","volume":"365","author":"J Cohen","year":"2019","unstructured":"Cohen, J. Cancer therapy returns to original target: HIV. Science 365, 530 (2019).","journal-title":"Science"},{"key":"2197_CR813","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00914-z","volume":"9","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. NPJ Vaccines 9, 119 (2024).","journal-title":"NPJ Vaccines"},{"key":"2197_CR814","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","volume":"107","author":"Y Hasan","year":"2020","unstructured":"Hasan, Y. et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer. Int J. Radiat. Oncol. Biol. Phys. 107, 487\u2013498 (2020).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"2197_CR815","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ymthe.2020.11.002","volume":"29","author":"FL Komdeur","year":"2021","unstructured":"Komdeur, F. L. et al. First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol. Ther. 29, 611\u2013625 (2021).","journal-title":"Mol. Ther."},{"key":"2197_CR816","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","volume":"26","author":"YJ Choi","year":"2020","unstructured":"Choi, Y. J. et al. A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin. Cancer Res. 26, 1616\u20131623 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR817","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","volume":"29","author":"RV Barnabas","year":"2023","unstructured":"Barnabas, R. V. et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat. Med. 29, 3224\u20133232 (2023).","journal-title":"Nat. Med."},{"key":"2197_CR818","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","volume":"21","author":"JW Youn","year":"2020","unstructured":"Youn, J. W. et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 21, 1653\u20131660 (2020).","journal-title":"Lancet Oncol."},{"key":"2197_CR819","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-23-3639","volume":"30","author":"SS Sheth","year":"2024","unstructured":"Sheth, S. S. et al. Randomized phase II trial of imiquimod with or without 9-valent HPV vaccine versus observation in patients with high-grade pre-neoplastic cervical lesions (NCT02864147). Clin. Cancer Res. 30, 1768\u20131777 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR820","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00970-w","volume":"19","author":"X Li","year":"2021","unstructured":"Li, X. et al. CRISPR\/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer. J. Nanobiotechnol. 19, 231 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"2197_CR821","doi-asserted-by":"crossref","unstructured":"Ehrke-Schulz, E. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Cancers 12, (2020).","DOI":"10.3390\/cancers12071934"},{"key":"2197_CR822","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13046-021-01841-w","volume":"40","author":"F Paolini","year":"2021","unstructured":"Paolini, F. et al. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors. J. Exp. Clin. Cancer Res. 40, 37 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR823","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s13046-019-1500-9","volume":"38","author":"JF Putri","year":"2019","unstructured":"Putri, J. F. et al. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers. J. Exp. Clin. Cancer Res. 38, 499 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR824","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","volume":"14","author":"E Sachdev","year":"2019","unstructured":"Sachdev, E. et al. PARP Inhibition In Cancer: An Update On Clinical Development. Target Oncol. 14, 657\u2013679 (2019).","journal-title":"Target Oncol."},{"key":"2197_CR825","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.gendis.2022.09.014","volume":"10","author":"M Mann","year":"2023","unstructured":"Mann, M., Singh, V. P. & Kumar, L. Cervical cancer: a tale from HPV infection to PARP inhibitors. Genes. Dis. 10, 1445\u20131456 (2023).","journal-title":"Genes. Dis."},{"key":"2197_CR826","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/annonc\/mdw635","volume":"28","author":"PH Thaker","year":"2017","unstructured":"Thaker, P. H. et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann. Oncol. 28, 505\u2013511 (2017).","journal-title":"Ann. Oncol."},{"key":"2197_CR827","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/1535-7163.MCT-20-0055","volume":"19","author":"Y Qiu","year":"2020","unstructured":"Qiu, Y. et al. HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma And Promote Vessel Normalization In Association With MMP-9 Inhibition and TIMP-3 induction. Mol. Cancer Ther. 19, 2476\u20132489 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2197_CR828","doi-asserted-by":"crossref","unstructured":"Park, S. et al. HIV-1 Protease inhibitors slow HPV16-driven cell proliferation through targeted depletion of viral E6 and E7 oncoproteins. Cancers 13, 949 (2021).","DOI":"10.3390\/cancers13050949"},{"key":"2197_CR829","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00577-1","volume":"20","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. HIV gp120\/Tat protein-induced epithelial-mesenchymal transition promotes the progression of cervical lesions. AIDS Res. Ther. 20, 82 (2023).","journal-title":"AIDS Res. Ther."},{"key":"2197_CR830","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1089\/hum.2022.165","volume":"34","author":"Q Xu","year":"2023","unstructured":"Xu, Q. et al. HIV Tat-conjugated histone H3 peptides induce tumor cell death via cellular stress responses. Hum. Gene. Ther. 34, 42\u201355 (2023).","journal-title":"Hum. Gene. Ther."},{"key":"2197_CR831","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173235","volume":"882","author":"F Hajizadeh","year":"2020","unstructured":"Hajizadeh, F. et al. Silencing of HIF-1alpha\/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. Eur. J. Pharmacol. 882, 173235 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"2197_CR832","doi-asserted-by":"crossref","unstructured":"Glinsky, G. V. et al. Effects of anticancer agent P-bi-TAT on gene expression link the integrin thyroid hormone receptor to expression of stemness and energy metabolism genes in cancer cells. Metabolites. 12, 325 (2022).","DOI":"10.3390\/metabo12040325"},{"key":"2197_CR833","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","volume":"27","author":"L Ferrall","year":"2021","unstructured":"Ferrall, L. et al. Cervical cancer immunotherapy: facts and hopes. Clin. Cancer Res. 27, 4953\u20134973 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR834","doi-asserted-by":"publisher","first-page":"175883592096300","DOI":"10.1177\/1758835920963001","volume":"12","author":"K Loharamtaweethong","year":"2020","unstructured":"Loharamtaweethong, K. et al. PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer. Ther. Adv. Med. Oncol. 12, 1758835920963001 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2197_CR835","doi-asserted-by":"crossref","unstructured":"Fujinaga, K. P-TEFb as a promising therapeutic target. Molecules. 25, 838 (2020).","DOI":"10.3390\/molecules25040838"},{"key":"2197_CR836","doi-asserted-by":"publisher","first-page":"eabl3836","DOI":"10.1126\/scitranslmed.abl3836","volume":"14","author":"TS Uldrick","year":"2022","unstructured":"Uldrick, T. S. et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci. Transl. Med. 14, eabl3836 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2197_CR837","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08798-7","volume":"10","author":"R Fromentin","year":"2019","unstructured":"Fromentin, R. et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals. Nat. Commun. 10, 814 (2019).","journal-title":"Nat. Commun."},{"key":"2197_CR838","doi-asserted-by":"publisher","first-page":"e1973","DOI":"10.1093\/cid\/ciaa1530","volume":"73","author":"TA Rasmussen","year":"2021","unstructured":"Rasmussen, T. A. et al. Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study. Clin. Infect. Dis. 73, e1973\u2013e1981 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2197_CR839","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1158\/1078-0432.CCR-20-0776","volume":"26","author":"DM Da Silva","year":"2020","unstructured":"Da Silva, D. M. et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). Clin. Cancer Res. 26, 5621\u20135630 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR840","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","volume":"30","author":"H Lou","year":"2024","unstructured":"Lou, H. et al. Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study. Clin. Cancer Res. 30, 1501\u20131508 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR841","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(22)00624-9","volume":"399","author":"FO Voss","year":"2022","unstructured":"Voss, F. O., van Beurden, M. & Jordanova, E. S. Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia. Lancet 399, 1755\u20131757 (2022).","journal-title":"Lancet"},{"key":"2197_CR842","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cncr.35063","volume":"130","author":"A Knisely","year":"2024","unstructured":"Knisely, A. et al. Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130, 400\u2013409 (2024).","journal-title":"Cancer"},{"key":"2197_CR843","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","volume":"41","author":"N Porciello","year":"2022","unstructured":"Porciello, N. et al. T-cell repertoire diversity: friend or foe for protective antitumor response? J. Exp. Clin. Cancer Res. 41, 356 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR844","doi-asserted-by":"publisher","first-page":"658753","DOI":"10.3389\/fimmu.2021.658753","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao, Q. et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front. Immunol. 12, 658753 (2021).","journal-title":"Front. Immunol."},{"key":"2197_CR845","doi-asserted-by":"crossref","unstructured":"Shevyrev, D. V., Tereshchenko, V. P. & Sennikov, S. V. The enigmatic nature of the TCR-pMHC interaction: implications for CAR-T and TCR-T engineering. Int. J. Mol. Sci. 23, 14728 (2022).","DOI":"10.3390\/ijms232314728"},{"key":"2197_CR846","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"2197_CR847","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216242","volume":"566","author":"M Poorebrahim","year":"2023","unstructured":"Poorebrahim, M. et al. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. Cancer Lett. 566, 216242 (2023).","journal-title":"Cancer Lett."},{"key":"2197_CR848","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29630","volume":"96","author":"I Quiros-Fernandez","year":"2024","unstructured":"Quiros-Fernandez, I. et al. Dual T cell receptor\/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. J. Med. Virol. 96, e29630 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR849","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet. 51, 1131\u20131136 (2019).","journal-title":"Nat. Genet."},{"key":"2197_CR850","doi-asserted-by":"publisher","first-page":"vii308","DOI":"10.1093\/annonc\/mdq277","volume":"21","author":"AT Chan","year":"2010","unstructured":"Chan, A. T. Nasopharyngeal carcinoma. Ann. Oncol. 21, vii308\u2013312 (2010).","journal-title":"Ann. Oncol."},{"key":"2197_CR851","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan, K. C. A. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513\u2013522 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR852","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1200\/JCO.2015.60.7846","volume":"33","author":"JP Bruce","year":"2015","unstructured":"Bruce, J. P. et al. Nasopharyngeal cancer: molecular landscape. J. Clin. Oncol. 33, 3346\u20133355 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR853","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"2197_CR854","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","volume":"387","author":"MLK Chua","year":"2016","unstructured":"Chua, M. L. K., Wee, J. T. S., Hui, E. P. & Chan, A. T. C. Nasopharyngeal carcinoma. Lancet 387, 1012\u20131024 (2016).","journal-title":"Lancet"},{"key":"2197_CR855","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1200\/JCO.22.02328","volume":"41","author":"E Yilmaz","year":"2023","unstructured":"Yilmaz, E. et al. Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. J. Clin. Oncol. 41, 1132\u20131146 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR856","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen, Y. P. et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J. Clin. Oncol. 39, 840\u2013859 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR857","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","volume":"33","author":"DCT Chan","year":"2022","unstructured":"Chan, D. C. T. et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Ann. Oncol. 33, 794\u2013803 (2022).","journal-title":"Ann. Oncol."},{"key":"2197_CR858","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1200\/JCO.22.01979","volume":"41","author":"PJ Lou","year":"2023","unstructured":"Lou, P. J. et al. Performance and operational feasibility of Epstein-Barr virus-based screening for detection of nasopharyngeal carcinoma: direct comparison of two alternative approaches. J. Clin. Oncol. 41, 4257\u20134266 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR859","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41591-021-01482-8","volume":"27","author":"BBY Ma","year":"2021","unstructured":"Ma, B. B. Y., Hui, E. P. & Chan, A. T. C. The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nat. Med. 27, 1512\u20131513 (2021).","journal-title":"Nat. Med."},{"key":"2197_CR860","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1586\/14787210.5.3.403","volume":"5","author":"M Okano","year":"2007","unstructured":"Okano, M. & Gross, T. G. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert. Rev. Anti. Infect. Ther. 5, 403\u2013413 (2007).","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"2197_CR861","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1079515","volume":"13","author":"W Li","year":"2022","unstructured":"Li, W. et al. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front. Immunol. 13, 1079515 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR862","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong, K. C. W. et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat. Rev. Clin. Oncol. 18, 679\u2013695 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2197_CR863","first-page":"300","volume":"64","author":"E Petrosky","year":"2015","unstructured":"Petrosky, E. et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Morb Mortal Wkly. Rep. 64, 300\u2013304 (2015).","journal-title":"Morb Mortal Wkly. Rep."},{"key":"2197_CR864","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"RBS Roden","year":"2018","unstructured":"Roden, R. B. S. & Stern, P. L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 18, 240\u2013254 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2197_CR865","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin. Immunol. 34, 123\u2013132 (2017).","journal-title":"Semin. Immunol."},{"key":"2197_CR866","first-page":"6952","volume":"62","author":"CL Lin","year":"2002","unstructured":"Lin, C. L. et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62, 6952\u20136958 (2002).","journal-title":"Cancer Res."},{"key":"2197_CR867","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia, W. K. et al. A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann. Oncol. 23, 997\u20131005 (2012).","journal-title":"Ann. Oncol."},{"key":"2197_CR868","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s00262-022-03183-8","volume":"71","author":"M Prasad","year":"2022","unstructured":"Prasad, M. et al. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors. Cancer Immunol. Immunother 71, 2583\u20132596 (2022).","journal-title":"Cancer Immunol. Immunother"},{"key":"2197_CR869","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3389\/fimmu.2019.02216","volume":"10","author":"Q Zeng","year":"2019","unstructured":"Zeng, Q., Zhou, Y. & Schwarz, H. CD137L-DCs, potent immune-stimulators-history, characteristics, and perspectives. Front. Immunol. 10, 2216 (2019).","journal-title":"Front. Immunol."},{"key":"2197_CR870","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1172\/JCI125364","volume":"129","author":"J Ruhl","year":"2019","unstructured":"Ruhl, J. et al. Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas. J. Clin. Invest. 129, 2071\u20132087 (2019).","journal-title":"J. Clin. Invest."},{"key":"2197_CR871","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1172\/JCI128370","volume":"129","author":"S Sharma","year":"2019","unstructured":"Sharma, S. & Rouce, R. H. Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine. J. Clin. Invest. 129, 1836\u20131838 (2019).","journal-title":"J. Clin. Invest."},{"key":"2197_CR872","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","volume":"78","author":"GS Taylor","year":"2004","unstructured":"Taylor, G. S. et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+\u2212 and CD8+\u2212T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 78, 768\u2013778 (2004).","journal-title":"J. Virol."},{"key":"2197_CR873","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor, G. S. et al. A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin. Cancer Res. 20, 5009\u20135022 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR874","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","volume":"5","author":"Y Kang","year":"2020","unstructured":"Kang, Y. et al. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct. Target Ther. 5, 245 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2197_CR875","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3006","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin, D. C. et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 46, 866\u2013871 (2014).","journal-title":"Nat. Genet."},{"key":"2197_CR876","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ccell.2022.08.010","volume":"40","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell 40, 1044\u20131059 (2022).","journal-title":"Cancer Cell"},{"key":"2197_CR877","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","volume":"108","author":"MK Gandhi","year":"2006","unstructured":"Gandhi, M. K. et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108, 2280\u20132289 (2006).","journal-title":"Blood"},{"key":"2197_CR878","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.1430","volume":"94","author":"D Chua","year":"2001","unstructured":"Chua, D. et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer 94, 73\u201380 (2001).","journal-title":"Int. J. Cancer"},{"key":"2197_CR879","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdh027","volume":"15","author":"P Comoli","year":"2004","unstructured":"Comoli, P. et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. 15, 113\u2013117 (2004).","journal-title":"Ann. Oncol."},{"key":"2197_CR880","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof, K. C. et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898\u20131904 (2005).","journal-title":"Blood"},{"key":"2197_CR881","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia, W. K. et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol. Ther. 22, 132\u2013139 (2014).","journal-title":"Mol. Ther."},{"key":"2197_CR882","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0501-6","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med. Oncol. 32, 86 (2015).","journal-title":"Med. Oncol."},{"key":"2197_CR883","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","volume":"33","author":"E Anastasiadou","year":"2019","unstructured":"Anastasiadou, E. et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33, 132\u2013147 (2019).","journal-title":"Leukemia"},{"key":"2197_CR884","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma, B. B. Y. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J. Clin. Oncol. 36, 1412\u20131418 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR885","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","volume":"36","author":"T Doi","year":"2018","unstructured":"Doi, T. et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J. Clin. Oncol. 36, 61\u201367 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR886","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"key":"2197_CR887","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J. Clin. Oncol. 35, 4050\u20134056 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR888","first-page":"100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield, A. S. et al. Outcomes With pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin. Res. Rep. 2, 100205 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"2197_CR889","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/cas.13932","volume":"110","author":"M Nishio","year":"2019","unstructured":"Nishio, M. et al. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 110, 1012\u20131020 (2019).","journal-title":"Cancer Sci."},{"key":"2197_CR890","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00162-7","volume":"5","author":"C Smith","year":"2021","unstructured":"Smith, C. et al. Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma. NPJ Precis. Oncol. 5, 24 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"2197_CR891","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22, 1162\u20131174 (2021).","journal-title":"Lancet Oncol."},{"key":"2197_CR892","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38407-7","volume":"14","author":"DW Lim","year":"2023","unstructured":"Lim, D. W. et al. Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma. Nat. Commun. 14, 2781 (2023).","journal-title":"Nat. Commun."},{"key":"2197_CR893","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12564-4","volume":"24","author":"S Lin","year":"2024","unstructured":"Lin, S. et al. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer 24, 797 (2024).","journal-title":"BMC Cancer"},{"key":"2197_CR894","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li, D. et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci. Adv. 9, eadg9721 (2023).","journal-title":"Sci. Adv."},{"key":"2197_CR895","doi-asserted-by":"publisher","first-page":"9341","DOI":"10.2147\/OTT.S221040","volume":"12","author":"X Tang","year":"2019","unstructured":"Tang, X. et al. CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo. Onco. Targets Ther. 12, 9341\u20139350 (2019).","journal-title":"Onco. Targets Ther."},{"key":"2197_CR896","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/bjc.2017.475","volume":"118","author":"HI Cho","year":"2018","unstructured":"Cho, H. I. et al. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. Br. J. Cancer 118, 534\u2013545 (2018).","journal-title":"Br. J. Cancer"},{"key":"2197_CR897","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJM200004063421407","volume":"342","author":"K Antman","year":"2000","unstructured":"Antman, K. & Chang, Y. Kaposi\u2019s sarcoma. N. Engl. J. Med. 342, 1027\u20131038 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR898","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/jdv.12349","volume":"28","author":"XJ Wu","year":"2014","unstructured":"Wu, X. J. et al. One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China. J. Eur. Acad. Dermatol. Venereol. 28, 1545\u20131552 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2197_CR899","doi-asserted-by":"publisher","first-page":"797","DOI":"10.6004\/jnccn.2018.7018","volume":"16","author":"J Saller","year":"2018","unstructured":"Saller, J. et al. Response to checkpoint inhibitor therapy in advanced classic Kaposi sarcoma: a case report and immunogenomic study. J. Natl. Compr. Canc. Netw. 16, 797\u2013800 (2018).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2197_CR900","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood.2023022364","volume":"142","author":"M Tashakori","year":"2023","unstructured":"Tashakori, M. & Beckman, A. K. Circulating plasmablastic cells in a patient with HHV-8-associated multicentric Castleman disease and Kaposi sarcoma. Blood 142, 2124 (2023).","journal-title":"Blood"},{"key":"2197_CR901","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-021-00364-5","volume":"16","author":"SE Krown","year":"2021","unstructured":"Krown, S. E. & Borok, M. Z. Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa. Infect. Agent Cancer 16, 25 (2021).","journal-title":"Infect. Agent Cancer"},{"key":"2197_CR902","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2023.4273","volume":"9","author":"KD Volesky-Avellaneda","year":"2023","unstructured":"Volesky-Avellaneda, K. D. et al. Cancers attributable to infections in the US in 2017: a meta-analysis. JAMA Oncol. 9, 1678\u20131687 (2023).","journal-title":"JAMA Oncol."},{"key":"2197_CR903","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00535-4","volume":"7","author":"C Casper","year":"2022","unstructured":"Casper, C. et al. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines 7, 108 (2022).","journal-title":"NPJ Vaccines"},{"key":"2197_CR904","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/cei\/uxad115","volume":"215","author":"LA Ramon-Luing","year":"2024","unstructured":"Ramon-Luing, L. A. et al. Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi sarcoma patients. Clin. Expert. Immunol. 215, 190\u2013201 (2024).","journal-title":"Clin. Expert. Immunol."},{"key":"2197_CR905","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280209","volume":"18","author":"P Volkow","year":"2023","unstructured":"Volkow, P. et al. Impact of valganciclovir therapy on severe IRIS-Kaposi sarcoma mortality: an open-label, parallel, randomized controlled trial. PLoS One 18, e0280209 (2023).","journal-title":"PLoS One"},{"key":"2197_CR906","doi-asserted-by":"crossref","unstructured":"Gothland, A. et al. Primaquine as a candidate for HHV-8-associated primary effusion lymphoma and Kaposi\u2019s sarcoma treatment. Cancers 14, 543 (2022).","DOI":"10.3390\/cancers14030543"},{"key":"2197_CR907","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/blood.2021011649","volume":"137","author":"E Vaccher","year":"2021","unstructured":"Vaccher, E. & Carbone, A. Simultaneous occurrence of KSHV-associated malignancies in a patient affected by HIV. Blood 137, 3149 (2021).","journal-title":"Blood"},{"key":"2197_CR908","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-023-01441-5","volume":"16","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Echinomycin as a promising therapeutic agent against KSHV-related malignancies. J. Hematol. Oncol. 16, 48 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2197_CR909","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4103\/jcrt.jcrt_2587_22","volume":"19","author":"W Li","year":"2023","unstructured":"Li, W. et al. A SEER data-based nomogram for the prognostic analysis of survival of patients with Kaposi\u2019s sarcoma. J. Cancer Res. Ther. 19, 917\u2013923 (2023).","journal-title":"J. Cancer Res. Ther."},{"key":"2197_CR910","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.idc.2024.06.001","volume":"38","author":"DM Margolis","year":"2024","unstructured":"Margolis, D. M. Advancing toward a human immunodeficiency virus cure: initial progress on a difficult path. Infect. Dis. Clin. North Am. 38, 487\u2013497 (2024).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"2197_CR911","doi-asserted-by":"crossref","unstructured":"Sun, Y. & Wang, L. Development of anti-HIV therapeutics: from conventional drug discovery to cutting-edge technology. Pharmaceuticals 17, 887 (2024).","DOI":"10.3390\/ph17070887"},{"key":"2197_CR912","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(19)33222-2","volume":"395","author":"SE Krown","year":"2020","unstructured":"Krown, S. E. et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet 395, 1195\u20131207 (2020).","journal-title":"Lancet"},{"key":"2197_CR913","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/QAI.0000000000002361","volume":"84","author":"M Nyirenda","year":"2020","unstructured":"Nyirenda, M. et al. Early progression and immune reconstitution inflammatory syndrome during treatment of mild-to-moderate Kaposi sarcoma in sub-Saharan Africa and South America: incidence, long-term outcomes, and effects of early chemotherapy. J. Acquir. Immune Defic. Syndr. 84, 422\u2013429 (2020).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2197_CR914","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1346-8138.15031","volume":"46","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Yang, K., Chen, S. & Ji, Y. Tacrolimus ointment for the treatment of superficial Kaposiform hemangioendothelioma and tufted angioma. J. Dermatol. 46, 898\u2013901 (2019).","journal-title":"J. Dermatol."},{"key":"2197_CR915","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110144","volume":"37","author":"O Mendez-Solis","year":"2021","unstructured":"Mendez-Solis, O. et al. Kaposi\u2019s sarcoma herpesvirus activates the hypoxia response to usurp HIF2alpha-dependent translation initiation for replication and oncogenesis. Cell Rep. 37, 110144 (2021).","journal-title":"Cell Rep."},{"key":"2197_CR916","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1570162X18666200603145640","volume":"18","author":"P Cornejo-Juarez","year":"2020","unstructured":"Cornejo-Juarez, P. et al. Bone marrow culture yield for the diagnosis of opportunistic diseases in patients with AIDS and disseminated Kaposi sarcoma. Curr. HIV Res. 18, 277\u2013282 (2020).","journal-title":"Curr. HIV Res."},{"key":"2197_CR917","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1158\/1078-0432.CCR-18-3528","volume":"25","author":"R Ramaswami","year":"2019","unstructured":"Ramaswami, R. et al. A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi sarcoma. Clin. Cancer Res. 25, 4238\u20134247 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2197_CR918","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1078-0432.CCR-19-1044","volume":"26","author":"EG Reid","year":"2020","unstructured":"Reid, E. G. et al. Pilot trial AMC-063: safety and efficacy of bortezomib in AIDS-associated Kaposi sarcoma. Cli. Cancer Res. 26, 558\u2013565 (2020).","journal-title":"Cli. Cancer Res."},{"key":"2197_CR919","doi-asserted-by":"crossref","unstructured":"Host, K. M. et al. Kaposi\u2019s Sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes. mBio. 8, e00917 (2017).","DOI":"10.1128\/mBio.00917-17"},{"key":"2197_CR920","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","volume":"23","author":"J Delyon","year":"2022","unstructured":"Delyon, J. et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 23, 491\u2013500 (2022).","journal-title":"Lancet Oncol."},{"key":"2197_CR921","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.annonc.2022.03.012","volume":"33","author":"A Zer","year":"2022","unstructured":"Zer, A. et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann. Oncol. 33, 720\u2013727 (2022).","journal-title":"Ann. Oncol."},{"key":"2197_CR922","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2217\/imt-2019-0183","volume":"12","author":"T Gambichler","year":"2020","unstructured":"Gambichler, T. & Susok, L. PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia. Immunotherapy 12, 451\u2013457 (2020).","journal-title":"Immunotherapy"},{"key":"2197_CR923","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick, T. S. et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study. JAMA Oncol. 5, 1332\u20131339 (2019).","journal-title":"JAMA Oncol."},{"key":"2197_CR924","volume":"5","author":"N Skoetz","year":"2017","unstructured":"Skoetz, N. et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst. Rev. 5, CD007941 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2197_CR925","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2352-3026(20)30126-5","volume":"7","author":"SA Atallah-Yunes","year":"2020","unstructured":"Atallah-Yunes, S. A., Murphy, D. J. & Noy, A. HIV-associated Burkitt lymphoma. Lancet Haematol. 7, e594\u2013e600 (2020).","journal-title":"Lancet Haematol."},{"key":"2197_CR926","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/bjh.19425","volume":"204","author":"SA Atallah-Yunes","year":"2024","unstructured":"Atallah-Yunes, S. A., Habermann, T. M. & Khurana, A. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation. Br. J. Haematol. 204, 2165\u20132172 (2024).","journal-title":"Br. J. Haematol."},{"key":"2197_CR927","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","volume":"10","author":"GD Cao","year":"2020","unstructured":"Cao, G. D. et al. The oncolytic virus in cancer diagnosis and treatment. Front. Oncol. 10, 1786 (2020).","journal-title":"Front. Oncol."},{"key":"2197_CR928","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.23.02366","volume":"42","author":"JK McGee-Avila","year":"2024","unstructured":"McGee-Avila, J. K. et al. Cancer treatment disparities in people with HIV in the United States, 2001-2019. J. Clin. Oncol. 42, 1810\u20131820 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR929","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hon.2575","volume":"37","author":"S Rattotti","year":"2019","unstructured":"Rattotti, S. et al. Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the rete ematologica lombarda (REL) clinical network. Hematol. Oncol. 37, 160\u2013167 (2019).","journal-title":"Hematol. Oncol."},{"key":"2197_CR930","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00277-017-3129-0","volume":"96","author":"Y Tsutsumi","year":"2017","unstructured":"Tsutsumi, Y. et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann. Hematol. 96, 2057\u20132061 (2017).","journal-title":"Ann. Hematol."},{"key":"2197_CR931","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1080\/10428194.2017.1403597","volume":"59","author":"CRC Tan","year":"2018","unstructured":"Tan, C. R. C. et al. Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leuk. Lymphoma 59, 1851\u20131860 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"2197_CR932","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini, E. et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 98, e81\u201382 (2013).","journal-title":"Haematologica"},{"key":"2197_CR933","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","volume":"106","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica 106, 2277\u20132280 (2021).","journal-title":"Haematologica"},{"key":"2197_CR934","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4143\/crt.2019.198","volume":"52","author":"SJ Kim","year":"2020","unstructured":"Kim, S. J. et al. Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial. Cancer Res. Treat. 52, 374\u2013387 (2020).","journal-title":"Cancer Res. Treat."},{"key":"2197_CR935","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/annonc\/mdw231","volume":"27","author":"D Tan","year":"2016","unstructured":"Tan, D., Diong, C. P., Loh, Y. & Goh, Y. T. Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer\/T-cell lymphoma (ENKTL). Ann. Oncol. 27, 1811\u20131812 (2016).","journal-title":"Ann. Oncol."},{"key":"2197_CR936","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdv596","volume":"27","author":"SJ Kim","year":"2016","unstructured":"Kim, S. J. et al. Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann. Oncol. 27, 508\u2013513 (2016).","journal-title":"Ann. Oncol."},{"key":"2197_CR937","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/JVI.01602-10","volume":"85","author":"PF Tsai","year":"2011","unstructured":"Tsai, P. F. et al. Interplay between PKCdelta and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. J. Virol. 85, 2373\u20132385 (2011).","journal-title":"J. Virol."},{"key":"2197_CR938","doi-asserted-by":"publisher","first-page":"1153790","DOI":"10.3389\/fimmu.2023.1153790","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: the central and western China AIDS lymphoma league 001 study (CALL-001 study). Front. Immunol. 14, 1153790 (2023).","journal-title":"Front. Immunol."},{"key":"2197_CR939","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2017.180893","volume":"103","author":"P Schommers","year":"2018","unstructured":"Schommers, P. et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica 103, 857\u2013864 (2018).","journal-title":"Haematologica"},{"key":"2197_CR940","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1600-0773.1989.tb01137.x","volume":"65","author":"A Kojo","year":"1989","unstructured":"Kojo, A. et al. Preferential inhibition of mouse hepatic coumarin 7-hydroxylase by inhibitors of steroid metabolizing monooxygenases. Pharmacol. Toxicol. 65, 104\u2013109 (1989).","journal-title":"Pharmacol. Toxicol."},{"key":"2197_CR941","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1182\/blood-2023-180522","volume":"142","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Selinexor in combination with R-EPOCH for patients with previously untreated HIV-associated diffuse large B cell lymphoma(DLBCL). Blood 142, 6292\u20136292 (2023).","journal-title":"Blood"},{"key":"2197_CR942","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y","volume":"68","author":"AK Chiang","year":"1996","unstructured":"Chiang, A. K., Tao, Q., Srivastava, G. & Ho, F. C. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin\u2019s disease. Int. J. Cancer 68, 285\u2013290 (1996).","journal-title":"Int. J. Cancer"},{"key":"2197_CR943","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.102","volume":"47","author":"E Tse","year":"2015","unstructured":"Tse, E. & Kwong, Y. L. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp. Mol. Med. 47, e136 (2015).","journal-title":"Exp. Mol. Med."},{"key":"2197_CR944","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","volume":"101","author":"S Gottschalk","year":"2003","unstructured":"Gottschalk, S. et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101, 1905\u20131912 (2003).","journal-title":"Blood"},{"key":"2197_CR945","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/mt.2015.91","volume":"23","author":"SG Cho","year":"2015","unstructured":"Cho, S. G. et al. Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs. Mol. Ther. 23, 1401\u20131409 (2015).","journal-title":"Mol. Ther."},{"key":"2197_CR946","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798\u2013808 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR947","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop, S. et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J. Clin. Investig. 130, 733\u2013747 (2020).","journal-title":"J. Clin. Investig."},{"key":"2197_CR948","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14712598.2023.2196366","volume":"23","author":"A Marjanska","year":"2023","unstructured":"Marjanska, A. & Styczynski, J. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation. Expert Opin. Biol. Ther. 23, 539\u2013552 (2023).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2197_CR949","doi-asserted-by":"publisher","first-page":"204062072091096","DOI":"10.1177\/2040620720910964","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu, L., Liu, Q. & Feng, S. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Ther. Adv. Hematol. 11, 2040620720910964 (2020).","journal-title":"Ther. Adv. Hematol."},{"key":"2197_CR950","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-024-00930-x","volume":"21","author":"K Toner","year":"2024","unstructured":"Toner, K., McCann, C. D. & Bollard, C. M. Applications of cell therapy in the treatment of virus-associated cancers. Nat. Rev. Clin. Oncol. 21, 709\u2013724 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2197_CR951","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"KM Mahadeo","year":"2024","unstructured":"Mahadeo, K. M. et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 25, 376\u2013387 (2024).","journal-title":"Lancet Oncol."},{"key":"2197_CR952","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","volume":"8","author":"S Nikiforow","year":"2024","unstructured":"Nikiforow, S. et al. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 8, 3001\u20133012 (2024).","journal-title":"Blood Adv."},{"key":"2197_CR953","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjh.13051","volume":"167","author":"MA Vickers","year":"2014","unstructured":"Vickers, M. A. et al. Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br. J. Haematol. 167, 402\u2013410 (2014).","journal-title":"Br. J. Haematol."},{"key":"2197_CR954","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02515-5","volume":"12","author":"Y Feng","year":"2022","unstructured":"Feng, Y. et al. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK\/T cell lymphoma. Sci. Rep. 12, 36 (2022).","journal-title":"Sci. Rep."},{"key":"2197_CR955","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3324\/haematol.2017.180430","volume":"103","author":"SB Ng","year":"2018","unstructured":"Ng, S. B. et al. Epstein-Barr virus-associated primary nodal T\/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica 103, 278\u2013287 (2018).","journal-title":"Haematologica"},{"key":"2197_CR956","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","volume":"66","author":"T Nagato","year":"2017","unstructured":"Nagato, T. et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol. Immunother. 66, 877\u2013890 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"2197_CR957","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-023-01483-9","volume":"16","author":"XP Tian","year":"2023","unstructured":"Tian, X. P. et al. Novel target and treatment agents for natural killer\/T-cell lymphoma. J Hematol. Oncol. 16, 78 (2023).","journal-title":"J Hematol. Oncol."},{"key":"2197_CR958","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao, R. et al. Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target. Ther. 6, 365 (2021).","journal-title":"Signal Transduct Target. Ther."},{"key":"2197_CR959","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang, H. et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): Results from a single-arm, multicenter, phase II study. J. Clin. Oncol. 41, 3032\u20133041 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR960","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong, Y. L. et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129, 2437\u20132442 (2017).","journal-title":"Blood"},{"key":"2197_CR961","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03040-0","volume":"21","author":"H Li","year":"2023","unstructured":"Li, H. et al. CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK\/T cell lymphoma. BMC Med. 21, 330 (2023).","journal-title":"BMC Med."},{"key":"2197_CR962","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Expanding anti-CD38 immunotherapy for lymphoid malignancies. J. Exp. Clin. Cancer Res. 41, 210 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2197_CR963","doi-asserted-by":"publisher","first-page":"229","DOI":"10.20892\/j.issn.2095-3941.2022.0759","volume":"20","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Facing challenges with hope: universal immune cells for hematologic malignancies. Cancer Biol. Med. 20, 229\u2013247 (2023).","journal-title":"Cancer Biol. Med."},{"key":"2197_CR964","first-page":"254","volume":"10","author":"AJ Krakowski","year":"1985","unstructured":"Krakowski, A. J. Patients who sign against medical advice. Psychiatr. J. Univ. Ott. 10, 254\u2013259 (1985).","journal-title":"Psychiatr. J. Univ. Ott."},{"key":"2197_CR965","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879983","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Chimeric antigen receptor-modified T cell immunotherapy for relapsed and refractory adult Burkitt lymphoma. Front. Immunol. 13, 879983 (2022).","journal-title":"Front. Immunol."},{"key":"2197_CR966","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","volume":"6","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma. Blood Adv. 6, 717\u2013730 (2022).","journal-title":"Blood Adv."},{"key":"2197_CR967","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/hiv.13514","volume":"24","author":"ST Hattenhauer","year":"2023","unstructured":"Hattenhauer, S. T. et al. Enabling CAR T-cell therapies for HIV-positive lymphoma patients\u2014a call for action. HIV Med. 24, 957\u2013964 (2023).","journal-title":"HIV Med."},{"key":"2197_CR968","first-page":"100902","volume":"40","author":"N Nakano","year":"2023","unstructured":"Nakano, N. et al. Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia\/lymphoma: a Japanese national survey. Lancet Reg. Health West Pac. 40, 100902 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"2197_CR969","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka, K. & Tamura, K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 15, e517\u2013e526 (2014).","journal-title":"Lancet Oncol."},{"key":"2197_CR970","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood.2022016765","volume":"140","author":"M Cheminant","year":"2022","unstructured":"Cheminant, M. et al. KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. Blood 140, 1522\u20131532 (2022).","journal-title":"Blood"},{"key":"2197_CR971","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","volume":"332","author":"PS Gill","year":"1995","unstructured":"Gill, P. S. et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332, 1744\u20131748 (1995).","journal-title":"N. Engl. J. Med."},{"key":"2197_CR972","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-6872-5_15","volume":"1582","author":"R Nasr","year":"2017","unstructured":"Nasr, R., Marcais, A., Hermine, O. & Bazarbachi, A. Overview of targeted therapies for adult T-cell leukemia\/lymphoma. Methods Mol. Biol. 1582, 197\u2013216 (2017).","journal-title":"Methods Mol. Biol."},{"key":"2197_CR973","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi, A. et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28, 4177\u20134183 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2197_CR974","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/QCO.0000000000000207","volume":"28","author":"LB Cook","year":"2015","unstructured":"Cook, L. B. & Taylor, G. P. Treatment of adult T-cell leukaemia\/lymphoma: is the virus a target? Curr. Opin. Infect. Dis. 28, 583\u2013588 (2015).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2197_CR975","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu, K. et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood 141, 1159\u20131168 (2023).","journal-title":"Blood"},{"key":"2197_CR976","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijpharm.2018.07.069","volume":"549","author":"M Kabiri","year":"2018","unstructured":"Kabiri, M., Sankian, M., Hosseinpour, M. & Tafaghodi, M. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1. Int. J. Pharm 549, 404\u2013414 (2018).","journal-title":"Int. J. Pharm"},{"key":"2197_CR977","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.13302","volume":"169","author":"Y Suehiro","year":"2015","unstructured":"Suehiro, Y. et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study. Br. J. Haematol. 169, 356\u2013367 (2015).","journal-title":"Br. J. Haematol."},{"key":"2197_CR978","doi-asserted-by":"crossref","unstructured":"Wang, T. T. et al. Current state of therapeutics for HTLV-1. Viruses 16, 1616 (2024).","DOI":"10.3390\/v16101616"},{"key":"2197_CR979","doi-asserted-by":"publisher","first-page":"580371","DOI":"10.3389\/fcimb.2020.580371","volume":"10","author":"AR Panfil","year":"2020","unstructured":"Panfil, A. R., Green, P. L. & Yoder, K. E. CRISPR genome editing applied to the pathogenic retrovirus HTLV-1. Front. Cell Infect. Microbiol. 10, 580371 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2197_CR980","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/leu.2013.46","volume":"27","author":"A Tanaka","year":"2013","unstructured":"Tanaka, A. et al. A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia 27, 1621\u20131627 (2013).","journal-title":"Leukemia"},{"key":"2197_CR981","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa, M. et al. Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma. Cancer Cell 34, 286\u2013297.e210 (2018).","journal-title":"Cancer Cell"},{"key":"2197_CR982","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/j.ymthe.2023.03.014","volume":"31","author":"T Rojo-Romanos","year":"2023","unstructured":"Rojo-Romanos, T. et al. Precise excision of HTLV-1 provirus with a designer-recombinase. Mol. Ther. 31, 2266\u20132285 (2023).","journal-title":"Mol. Ther."},{"key":"2197_CR983","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","volume":"61","author":"Y Hoshida","year":"2014","unstructured":"Hoshida, Y. et al. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol. 61, S79\u2013S90 (2014).","journal-title":"J. Hepatol."},{"key":"2197_CR984","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29685","volume":"96","author":"I Lo Cigno","year":"2024","unstructured":"Lo Cigno, I. et al. High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects. J. Med. Virol. 96, e29685 (2024).","journal-title":"J. Med. Virol."},{"key":"2197_CR985","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10456-015-9475-4","volume":"18","author":"T Ma","year":"2015","unstructured":"Ma, T. et al. KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi\u2019s sarcoma. Angiogenesis 18, 477\u2013488 (2015).","journal-title":"Angiogenesis"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02197-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T19:02:08Z","timestamp":1746990128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":985,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02197-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}